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CHAPTER 1
Background
“Health is a state of complete physical, mental and social well-being and not merely the absence
of disease or infirmity.”1

As an increasing number of people are living with chronic conditions in the United
States, advances in medical care are progressively focusing on quality of life for individuals with
these conditions.2 For example, a diagnosis of human immunodeficiency virus (HIV) is no
longer a death sentence, but can be managed as a chronic disease with current treatments.3
However, a number of chronic illnesses have complex treatment regimens, and the effectiveness
of these regimens is dependent on individuals strictly following instructions from their care
providers (i.e., adhere). For example, HIV pharmacological treatment involves complex
regimens of medications that need to be taken at specific times during the day, with exacting
regularity or the infection will adapt to those treatments.3, 4 Diabetes is another chronic illness
requiring complex routines including checking blood regularly, taking medication throughout the
day, monitoring insulin administration, and dietary restrictions.5
As treatment for these once acute illnesses has moved from an acute to chronic care
model, there has been increasing attention to the potential for adverse effects associated with
these medications. For example, early HIV treatments began to redistribute body fat (e.g.
lipodystrophy) towards the abdomen leading to chronic cardiometabolic conditions and facial fat
loss (e.g. lipoatrophy).6, 7 Adverse effects such as these were not only severe, but led to lower
quality of life and poor adherence. To counter these effects, researchers developed new
efficacious treatments with fewer of these adverse effects.8, 9 However, these newer treatments
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have increased the cost of care for chronic conditions not only due to the expense of the new
treatments, but also extending the lifespan of individuals receiving these treatments.10, 11
Included in this list of conditions that have moved from an acute care to chronic care
model are psychiatric illnesses.12, 13 Bipolar disorders (BD) are among the more costly of these
conditions to treat, due to inpatient care, the wide variety and complexity of psychotropic
medication treatment, and disability.14 BD often onsets in the early 20s and is a life-long
condition.15 Treatment for BD is generally divided into phases of acute symptom management
and maintenance of symptom remission.16 Maintenance (i.e., chronic) treatment for BD focuses
on maintaining symptom remission, often with the same treatments that were found to be
effective during the acute stage. Although adverse effects of these medications are an
acknowledged concern, the primary focus has been on treating these effects as they emerge,
rather than to change medication regimens to avoid such adverse effects due to valid concerns
that frequently changing medications can lead to instability of psychiatric symptoms.16
Person-centered approaches to identify quality of life experienced by individuals treated
for BD has seen increased importance to date as therapies have become more effective over
longer periods of time.17 BD involves a wide range of symptoms, including depression,
psychosis and manic symptoms.18, 19 This results in treatment with a broad range of medications
including antidepressants, mood stabilizers, antipsychotics, and sedatives/hypnotics in addition
to psychotherapy. This complexity makes it an ideal choice to study the quality of life and
benefit of long-term medication treatment for serious mental illness more generally.
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Diagnostic Criteria for Bipolar Disorder
According to the American Psychiatric Association Diagnostic and Statistical Manual of
Mental Disorders (DSM-5),20 BD is characterized by signature episodes of mania or hypomania
and episodes of depression often intermingled with euthymia (i.e., a stable mental state or mood
that is neither manic nor depressive). Briefly, manic episodes involve at least one week of
abnormally and persistently elevated, expansive or irritable mood with increased activity or
energy most of the day, nearly every day. This episode must also be severe enough to cause
marked impairment in social or occupational functioning, up to and including hospitalization,
and may involve psychosis. A hypo-manic episode is similar to a manic episode, but lasts a
shorter period of time and does not lead to marked impairment in social or occupational
functioning, and does not include psychosis. Depressive episodes involve two weeks of
depressed mood or loss of interest or pleasure, causing clinically significant distress to the
individual and may impair functioning. Diagnosis of a manic episode is necessary for a diagnosis
of bipolar I disorder, and a hypo-manic episode for bipolar II disorder, but a diagnosis of
depression is not needed for a diagnosis of bipolar I disorder (DSM-5 diagnostic criteria in
Appendix).
Individuals with BD experience high levels of disability and healthcare costs.12 Onset of
BD often presents as depression,15 often first detected in the emergency room, sometimes after a
person harms themselves.21, 22 It is not uncommon for individuals in a manic episode with
irritability to initially be detected by law enforcement, often by being arrested for belligerent
behavior.23 Left untreated, individuals with BD have difficulty acquiring and maintaining
employment,24 leading to poverty and use of Medicaid.25 As with other psychiatric illness,
comorbidity with other psychiatric illnesses is extremely common. Individuals with BD most
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commonly have comorbid anxiety disorders 26 or substance use disorders.27 Persons with BD
have excess premature mortality.16, 28, 29

Treatment options for BD
Treatment for BD is life-long and centers on psychotropic medications. Treatment is
generally divided into two main phases: acute symptom management and maintenance of
symptom remission. The acute phase entails treatment at the first onset of symptoms. The
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines recommend initial
treatment for mania with the mood stabilizer lithium, which has consistently been found to be the
most effective mood stabilizer.30 However, lithium has serious adverse effects that emerge
during long-term use, including weight gain, polyuria (i.e., excessive urination), and
hypothyroidism.31 If lithium adverse effects are intolerable, divalproex (an antiepileptic or mood
stabilizer) is among the other first-line treatments during the acute phase.16 Due to the episodic
nature of BD, achieving remission may take years, which has resulted in many individuals taking
two or more psychotropic medications concurrently (i.e., polypharmacy), and even up to five or
more different medications (i.e., complex polypharmacy) has been commonly identified.32 As
symptoms subside and euthymia is maintained, the maintenance phase begins. Clinical
guidelines recommend continuing whatever treatments were found to be effective from the acute
phase while in maintenance. Other medications with known efficacy during the maintenance
phase are lamotrigine (an antiepileptic or mood stabilizer),33, 34 and quetiapine (an
antipsychotic)35 among others. If symptoms recur or new symptoms arise, adjunct medications
can be added to treat those symptoms.16 Multiple adjunct medications are often needed to reach
stability and eventual remission.32
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Non-Adherence to Psychotropic Medication Treatment
For all medical conditions, individuals who do not consistently adhere to their medication
regimens often experience worse clinical outcomes, whether due to suboptimal management of
the underlying condition or adverse effects from the medications themselves, BD is no
exception. Unfortunately, adherence to medication is low in this population, ranging from 2070%.36, 37 Moreover, as individuals move into the maintenance phase of treatment they often
experience increasingly severe symptoms that are more difficult to treat when they do not adhere
to their medications.38
Numerous studies have attempted to understand the factors contributing to non-adherence
for individuals with BD from the perspective of the provider and the client. Health care providers
suggest non-adherence is due to symptoms of the illness itself such as “lack of insight” about the
condition 39, 40 or denial of the severity of the disorder.41 The complexity of medication regimens
themselves (i.e., it is more difficult to take multiple medications concurrently) has been
associated with non-adherence.42 However, as noted above, clinical guidelines indicate adding
adjunct medications to treat new symptoms experienced while in the maintenance phase, which
has the effect of increasing medication burden over time. Providers have also indicated that
adverse effects of the medications (i.e., weight gain, somnolence, sexual dysfunction) may lead
to non-adherence.43, 44 Studies that examine the determinants of non-adherence by surveying
individuals treated for BD suggest that concern about medications (i.e., “I sometimes worry
about long-term effects of this medicine”) versus perceived necessity of taking those medications
(i.e., “Without this medication I would be very ill”) is also associated with non-adherence.43
Individuals who perceived their illness as severe and that medication was beneficial were more
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likely to maintain adherence.40 Despite these studies, adherence remains suboptimal for persons
with BD.

Measuring Adherence
Undermining common limitations to these studies of medication treatment for BD are the
challenges stemming from (mis)measuring adherence. It is commonly understood that few
individuals are perfectly adherent to their medication regimens, regardless of the condition under
study.41 However, there is not a consistent definition of adherence or agreed upon gold standard
of how to measure it.45, 46 For example, non-adherence could be defined as individuals’
inconsistently taking their medications (e.g., “drug holidays”), missing doses as a result of
schedule changes (e.g., when traveling away from home), or taking too much of their
medications purposefully (i.e., abuse). Non-adherence may be a general behavior, or be tied to
specific medications. For example, individuals may be non-adherent to one type of medication,
but fully-adherent to others (i.e., antipsychotics versus antidepressants).46 In addition, although
self-report of medication adherence is one of the most common ways to measure this behavior,
and is encouraged due to the rapport building it instills between the practitioner and the
individual they treat,47 it is subject to the same limitations of all self-report measures. The only
way to ensure an individual is adherent is to visually confirm medication usage (e.g., component
2 of the tuberculosis monitoring programs).48 Pill bottle counts, and even blood serum level
measurements involve some error. Individuals may take a pill out of their bottle every day, but
not consume the pill. Serum levels can indicate that a pill is being taken and that it has reached a
therapeutic level, but for many longer-lasting medications it may not confirm if the medication is
being taken at the frequency of time of day as prescribed.49
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Modeling person-centered care for BD
Person-centered care, as described by Davidson et al. (2015), is a patient-centered model
of care in the medical domain recognizing the person and his/her active role beyond the “patient”
status.50 Person-centered care is becoming more prominent in clinical settings as a means to
identify and account for individual differences in responses to treatment for a multitude of
illnesses, including BD.51 All medical interventions, even those benign as aspirin, have some risk
of adverse effects. When prescribing medications, providers routinely weight the benefit versus
risks of those treatments to arrive at a care plan that is net beneficial. Clinical guidelines indicate
that three core aspects, or dimensions, should be considered when balancing these aspects for
treating BD: psychiatric symptoms, adverse effects, and overall functioning.16 These dimensions
are not independent of each other and work synergistically to influence clinical outcomes.
Identifying how groups of individuals differentially experience these three dimensions, and
whether this heterogeneity relates to adherence, can give further insight into improving treatment
regimens for this population.
To conceptualize this intersection we have created a three-dimensional model of Clinical
Net Benefit (CNB). Each dimension of CNB is an axis: (1) psychiatric symptoms; (2) adverse
effects; and (3) overall functioning. The intent of this construct is to model individual
heterogeneity in the experience of treatment for BD along each of these dimensions, grouping
individuals at different coordinates as depicted in Figure 1.2. The relationship between adherence
and CNB is also bi-directional: poor adherence may be a consequence of inability to tolerate
medication adverse effects, for example. Alternatively, when individuals with BD are in
maintenance and feel their condition is well-controlled (e.g., low psychiatric symptoms) they
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may not take their medications as prescribed.39 Therefore the specific coordinates of individuals
will differ, and those coordinates will change over time.
To address the complexity between CNB and medication adherence for BD, this research
will address three core research questions:
1. Can the conceptual model of CNB be identified in a population of individuals with BD?
In addition, is this model externally valid in this population and does it enhance our
understanding of the experiences these individuals have with their medical treatment?
2. Does the association between CNB and adherence remain stable or change over time
while individuals are being closely monitored by treating psychiatrists? In addition, do
the medication regimens differentially affect adherence?
3. Will the results from question 2 hold in a more naturalistic setting where individuals are
not as closely monitored by their treating psychiatrist? That is, will the association
between CNB, medication regimens, and adherence, remain stable or change over time
when individuals do not meet as regularly with their psychiatrists?
These questions are addressed using the Systematic Treatment Enhancement Program for
Bipolar Disorder (STEP-BD), a large, stepped-care randomized clinical trial (RCT) for persons
with BD.
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Methods
Sample
Sachs, et al. (2003) and the ClinicalTrials.gov Systematic Treatment Enhancement
Program for Bipolar Disorder (STEP-BD) website detail STEP-BD study design.52, 53 STEP-BD
was a large (N=4,360) five-year longitudinal RCT designed to test the utility of different
treatment modalities (i.e., psychotropic medications and psychotherapy) for individuals
diagnosed with bipolar spectrum disorders (BD; i.e., meeting DSM-IV criteria for Bipolar I
Disorder, Bipolar II Disorder, Bipolar Disorder Not Otherwise Specified [NOS], Cyclothymic
Disorder, or Schizoaffective Disorder, Bipolar Subtype). The first two years involved active
study participation where participants had regularly scheduled follow up appointments with their
treating psychiatrist, and the last three years of participation involved a naturalistic follow-up
with little oversight beyond usual care. Recruitment began in 1998 and the study ended in 2005.
The goal of the study was to evaluate the efficacy and risk/benefit ratio of different study
psychotropic medications (e.g., the mood stabilizers lithium, valproate and lamotrigine; the
atypical antipsychotic risperidone; the oral supplement inositol [possible antidepressant 54]); and
the antidepressants paroxetine, tranylcypromine and bupropion) and regimens (i.e., taking two or
more different medications concurrently, or polypharmacy) as participants aimed to achieve
successful psychiatric symptom management.
STEP-BD was chosen for this analysis due to its wealth of information regarding
psychotropic medication use, psychological assessments, large sample size, broad age range,
diverse study population and length of follow up. The decision to use a RCT rather than a
nationally-representative observational study was due in part to the fact that observational studies
do not include all of these factors in one study. Nationally-representative samples such as the
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National Health and Nutrition Examination Survey (NHANES) and the Medical Expenditure
Panel Survey (MEPS) generally have detailed information on medications, large sample sizes
and a broad range of ages.55, 56 However, like many population-based surveys, MEPS does not
differentiate between major depressive disorder and BD,57 and these surveys only include
psychological assessments measuring general distress (12-item short-form health survey (SF-12);
Kessler-6 (K6); Center for Epidemiological Studies Depression Scale (CES-D)) 16, 58-60 or that
are not BD specific. Also, longitudinal data is necessary to examine the bi-directional
relationship between CNB and adherence. Moreover, there are numerous strengths to using a
RCT as opposed to an observational study for these research questions. Finally, the STEP-BD
trial had a public-health focused design to simulate the real-world experiences of individuals
being treated for BD, unique for an RCT.52

Inclusion Criteria
In keeping with the “real world” perspective of STEP-BD, multiple locations and types of
outpatient practices were selected as treatment centers for participation in the study across the
United States. These treatment centers had to be actively treating at least 100 individuals with
BD. They included university hospitals and medical centers (Stanford University School of
Medicine; University of Colorado, Colorado Psychiatric Health Clinical Investigation Center;
University of Massachusetts Medical Center; University of Oklahoma Health Sciences Center;
University of Pennsylvania Medical Center; Baylor College of Medicine; University of Texas
Health Science Center at San Antonio), a general hospital (Massachusetts General Hospital), a
Veteran’s Affairs hospital (Portland Veteran’s Administration Medical Center), and two
universities (Case Western Reserve University; University of Pittsburgh).
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In addition, in order for treating psychiatrists or other clinical interviewers to participate
in the study, they underwent an accredited continuing medical education program to learn Model
Practice Procedures for routine care of individuals with BD. The main evaluation tools utilized in
this training were the Affective Disorders Evaluation (ADE)61 and the Clinical Monitoring Form
(CMF).62 Once psychiatrists or other clinical interviewers could demonstrate proficiency using
these tools, they were deemed STEP-BD certified.
Individuals were eligible to participate in the study if they were 15 years of age or older,
could meet with their clinical specialist as scheduled and could complete all study registration
forms within three months of registration. Written assent was given by those aged 15 to 17 years,
with informed consent given by their legal guardians. Those aged 18 years and older gave their
informed consent to participate. Individuals had to meet the criteria for BD to participate in the
study, and all diagnostically eligible individuals were offered STEP-BD enrollment. These
diagnoses were determined after administration of the ADE given by a STEP-BD certified
psychiatrist and the Mini-International Neuropsychiatric Interview administered by a second
certified clinical interviewer (i.e., psychiatrist, psychologist, social worker or psychiatric nurse).
Once consensus was achieved between these two interviewers, the final diagnosis would be
determined. Exclusion criteria for this study included an unwillingness or inability to adhere to
basic study requirements (i.e., completing rating forms or attending scheduled evaluations), and
lacking competence to give informed consent in the opinion of the study investigator. No healthy
volunteers were included in the study.
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STEP-BD Study Design: Standard Care Pathway and Randomized Care Pathways
STEP-BD had two overall treatment pathways: the Standard Care Pathway (SCP) and the
Randomized Care Pathways (RCPs). Upon entrance to the study, individuals were assigned to
the SCP with individuals aged between 15 and 17 years limited to participation in the SCP, but
those aged 18 and over could participate in either pathway. In the SCP individuals could retain
their existing psychiatrists, if they were STEP-BD certified, and could remain on their existing
medications and regimens, in essence treatment as usual. If a certain medication was not found to
be efficacious, the participant’s treating psychiatrist would make the determination as to whether
and what medication changes to make. While individuals participated in STEP-BD, they were
also given a battery of clinician- and self-administered psychological assessments to identify
symptoms of depression and mania, detect comorbid diagnoses, adverse effects experienced by
participates while taking their medications, quality of life, and social and occupational
functioning at multiple time points during study participation (Table 1.1.). Clinicians also
determined participants’ adherence at multiple time points.
There were three RCPs in which some medications and regimen combinations were
randomized and placebo controlled. A participant could enter a RCP if they met criteria for that
pathway, and were blinded to the treatments if that was the protocol for that pathway.
Acute Depression Pathway: This pathway could be entered by individuals who met
criteria for current major depressive episode, who were currently taking or agreed to begin taking
a mood stabilizer, and agreed to taper off non-study antidepressants. This pathway was doubleblinded for up to 24 weeks and included two random assignments: (1) a mood stabilizer plus a
placebo versus a mood stabilizer plus paroxetine and (2) a mood stabilizer plus a placebo versus
a mood stabilizer plus bupropion.
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Refractory Depression Pathway: This treatment resistant pathway, was open (nonblinded) for up to 24 weeks. Individuals could enter this pathway if they failed to respond to
treatment in the first two weeks while in the Acute Depression Pathway. Alternatively, they
could enter this pathway if they failed to respond to two trials of antidepressants during their
current depressive episode. They also needed to meet criteria for a major depressive episode for
eight weeks before they entered the STEP-BD study. To begin this RCP, they needed to be
currently taking or agree to begin a mood stabilizer. The three assignments were: (1) inositol
versus risperidone; (2) risperidone versus lamotrigine; and (3) lamotrigine versus inositol.
Relapse Prevention Pathway: This pathway was double-blinded for up to two years. An
individual could enter this RCP if they had a manic, mixed or hypomanic episode while taking
lithium or valproate. They also had to have normal levels of thyroid stimulating hormone and
creatinine. The assignment for this pathway was one mood stabilizer plus a placebo versus
divalproex plus lithium.
As a stepped-treatment trial, treating psychiatrists’ could discontinue participants’
ineffective treatments and either advance to the next level of randomized treatments until they
achieved effective symptom management, or could prescribe a different medication in the SCP.
Additionally, participants could elect to return to the SCP at any time during their participation in
the RCPs.

Strengths and limitations of STEP-BD
The strengths of STEP-BD include the large number of psychological assessments
administered at multiple time points, explicit details of psychotropic medication use identifying
up to 12 distinct medications an individual could be taking, their dosages and missed doses, the
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large sample size for a clinical trial, and length of follow up that included both an active
participation phase and a naturalistic follow-up. The rigorous design of an RCT is the gold
standard of study design, and the fact that a treatment as usual arm was also included added the
complexity we see in an observational setting.52
Limitations of STEP-BD included missing data on many psychological measures
(Chapter 1, Table 1.1.), which limited the number of measures used in the subsequent analyses.
In addition, participants’ perceptions of their care or medications, including believes about the
necessity of taking medications to maintain remission (i.e., scales like the Beliefs about
Medicines Questionnaire), were not measured.63 This limited our analysis to inference on CNB
to clinical experience, without the added knowledge of participants’ opinions and perceptions of
benefit. Medication usage was determined via clinical interviews with the treating psychiatrist,
which is the best-practice for large and complex trials,47 but was not confirmed by pill counts or
blood serum levels. Finally, although STEP-BD was designed to have a diverse population of
individuals with bipolar spectrum disorders from multiple locations across the United States, the
sample was not nationally representative of persons with BD.

Statement Regarding Human Subjects Research
This dissertation used data from the previously collected, de-identified, limited access
clinical trial STEP-BD. No original data was collected as part of this research. This data was
included in the National Institute of Mental Health Data Repositories, which were accessed after
completion of a Data Use Agreement. On June 30, 2015, the VCU Office of Research found that
the proposed study qualified for HHS Exemption 45 CFR 46.101(b)(4) (Research involving the
collection or study of existing data, documents, records, pathological specimens, or diagnostic
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specimens, if these sources are publicly available or if the information is recorded by the
investigator in such a manner that subjects cannot be identified, directly or through identifiers
linked to the subjects) for Human Subjects Research.

Measures: The Clinical Monitoring Form
The CMF is a clinician administered assessment used at each study visit. It was designed
as a substitute for traditional narrative clinical follow-up notes and consisted of nine sections
including current mood modules, functional assessments and an overall clinical status.

Psychiatric Symptoms
Beck Hopelessness Scale: The self-report 20-item BHS assesses an individual’s negative
expectancies of the future. Each item is scored as true or false, with scores ranging from 0=none
to 20=severe; higher scores indicating higher levels of hopelessness. Internal consistency of total
BHS scores was found to be 0.93 by Beck, et al., (1974) with an inpatient sample of individuals
who made recent suicide attempts.64 Later studies found the reliability to be 0.86 and 0.83 in
psychiatric samples,65 and 0.92 in clinical populations.66, 67 Validity of the scale was based on a
comparison between clinician ratings of hopelessness and the scale scores in both a general
practice outpatient sample, validity of 0.74, and a psychiatric inpatient sample hospitalized for a
recent suicide attempt, validity of 0.62.64
Young Mania Rating Scale: The clinician-administered 11-item YMRS assesses the
severity of mania an individual is experiencing. Items 1, 2, 3, 4, 7, 10, and 11 are on a Likert
scale from 0=absent to 4=severe. Items 5, 6, 8, and 9 are given extra weight as they are more
difficult to gauge in severely impaired individuals, with a Likert scale of 0=absent to 8=severe.
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Scores range from 0=absent to 60=severe, with higher scores indicating greater severity of mania
symptoms. When examining an inpatient sample of manic individuals, the interrater reliability of
the scale was 0.93 when compared between two physicians administering the scale
independently. The concurrent validity when comparing the YMRS to other mania rating scales
(Petterson Scale and Beigel Scale)68, 69was between 0.71 and 0.89.70
Montgomery-Asberg Depression Rating Scale: The clinician administered 10-item
MADRS assesses the severity of depression with particular sensitivity to psychotropic
medication treatment response. It is scored on a Likert scale from 0=no symptoms to 6=severe
symptoms, and scores range from 0=absent to 50=severe, with higher scores indicating greater
severity of the illness. Testing of the reliability and validity of the scale was conducted with a
sample including both Swedish and English individuals with a primary depressive illness.
Reliability between the raters ranged from 0.89 to 0.97. Validity of the scale was compared with
a clinician’s global judgement of an individual’s response to treatment and other scales that also
measure depression severity. MADRS had the highest correlation with the clinician’s judgement
at 0.70.71
Psychiatric Comorbidities
Diagnoses of comorbid psychiatric and substance use conditions were obtained from the
CMF. These included current alcohol abuse (yes or no), current substance abuse or dependence
(yes or no), current panic disorder (yes or no), and current binge purge (yes or no) disorders in
addition to the licit substance use current caffeine cups per day (continuous) and current nicotine
packs per day (continuous).62
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Measures: Adverse effects
Adverse effects from medications were obtained from the CMF. Nine adverse effects
were assessed, each rated on a 4-point Likert Scale ranging from 0=none to 4=severe. The
adverse effects collected on the CMF were: tremor, dry mouth, sedation, constipation, diarrhea,
headache, poor memory, sexual dysfunction, and increase appetite.

Measures: Overall Functioning
Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ): The 16-item QLESQ
is completed by the participant and assesses the degree of enjoyment and satisfaction
experienced in various areas of daily functioning. Example items include: “Taking everything
into consideration, during the past week how satisfied have you been with your physical health?”
Items are scored on a Likert scale from 1=very poor to 5=very good, with the first 14 items
summed for a raw score and items 15 and 16 as stand-alone scores. Scores range from 14 to 70
with higher scores indicating higher satisfaction. In populations with psychiatric illnesses, testretest reliability ranges from 0.63 to 0.89. Internal consistency ranged from 0.90 to 0.96.72
LIFE Range of Impaired Functioning Tool (LRIFT): The LRIFT is a tool that was
originally administered during the Longitudinal Interval Follow-up Evaluation (LIFE) study.73
The LIFE assessed the longitudinal course of psychiatric disorders determining time to recovery,
length of wellness intervals and time to relapse.73 Examples of items from the LRIFT include:
“Which of the following categories best characterizes the degree to which the patient's current
(past week) work activities have been impaired as a result of psychopathology?” Item responses
are on a Likert scale ranging from 1=no impairment to 5=severe impairment. In addition, four
summary scores (work, interpersonal relations, satisfaction, and recreation) are determined: (1)
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Work score is the sum of items 1 – 3; (2) Interpersonal relations score is the sum of items 4 – 6;
(3) Satisfaction is the score from item 7; and Recreation is the score from item 8. These four
scores are summed for a total score ranging from 4-20 with higher scores indicating increased
impairment.74 The validity of the LRIFT was determined in a sample of individuals with mood
disorders. Concurrent validity of the LRIFT compared to the Clinical Global Measures Scale,
another measure of functioning (GAS)75 was 0.56. Reliability across the two-year study period
ranged from 0.81 at six months to 0.83 at 24 months.74
Work Impact Form: The WIF uses a portion of the World Health Organization Disability
Assessment Schedule, or WHODAS-2.76 The portion utilized in STEP-BD included three
questions regarding levels of ability to work or carry out participants’ normal activities over the
past 30 days. For each question, there was a subset of three questions asking participants whether
they were due to mental health or substance use. Scores for the three main questions were counts
of the how many days in the past 30 days they experienced difficulties, and were categorized as
0=0 days, 1=1 day, and 2=greater than 1 day. The three sub-questions were binary scores of yes
or no. Garin, et al., (2010) tested the validity of the full WHODAS-2 (36 items) with a sample of
individuals with different chronic illnesses including individuals with BD.77 When compared
with scores on the YMRS and the Hamilton Depression Rating Scale,78 the Cronbach’s
alpha=0.88 and the Intra-class Correlation Coefficient=0.612 for individuals with BD.
Global Assessment of Functioning (GAF): The GAF score came from the CMF. The GAF
is an overall assessment of psychiatric disturbance and evaluates the psychological, social and
occupational functioning of an individual. It ranges from 1 to 100, with higher scores indicating
higher functioning.79 In a sample of individuals with three consecutive admissions to a
psychiatric hospital and with diagnoses of schizophrenia, schizophreniform or schizoaffective

18

disorders, the reliability of the GAF ranged from 0.89 to 0.95 over 3 time points when
administered by two independent raters. The validity of the score when compared with the Scale
for the Assessment of Negative Symptoms (SANS),80 Scale for the Assessment of Positive
Symptoms (SAPS)81 and Social Behavior Schedule (SBS) 82 ranged from 0.37 to 0.77 over three
time points.79

Primary outcome: Medication Adherence assessed using the CMF
In the CMF the treating psychiatrist indicated both the names of the medications and
prescribed dosages, and dosages missed in the past seven days, as well as an indication of
significant noncompliance (yes vs. no) with a space for a description of the noncompliance if
yes. If an individual missed less than 25% of their medication dosage according to the CMF, they
were identified as adherent. This adherence is consistent with prior analyses using STEP-BD as
well as other analyses of adherence.83

Overview of Analysis
Chapter 2
Can the conceptual model of CNB be identified in a population of individuals with BD?
In addition, is this model externally valid in this population and does it enhance our
understanding of the experiences these individuals have with their medical treatment?

The purpose of the first paper was to create the CNB construct and determine its external
validity using data from the baseline assessment of STEP-BD. This involved two latent variable
methods: Exploratory Factor Analysis (EFA), and Latent Class Analysis (LCA). Latent variable
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techniques are commonly used when identifying concepts that cannot be directly measured, or
can only be measured with error (i.e., situations in which there is no gold standard for
assessment).84-86 For example, there is no gold standard way to measure depression, a complex
symptom cluster of low mood and disturbances in appetite, sleep, cognition, and physical
functioning. Instead various self-report assessments are used to identify different symptoms of
depression and the scores on these scales are summed to determine a probable case of
depression. Another advantage of the latent variable framework is that it does not employ
artificial cut-points of symptom counts to determine “caseness” (e.g., DSM-5 diagnosis of major
depression requires endorsement of 5 of 9 symptom groups, one of which is low mood or
anhedonia). Instead, latent variable techniques like EFA and LCA use the correlations between
variables (e.g., symptoms) to empirically identify distinct subgroups in the data (e.g., high vs.
low depressive symptoms) rather than artificial cutpoints. Unlike regression techniques that aim
to remove collinearity, latent variable techniques identify latent constructs by the strength of the
very correlations between items that are indicating a common construct.87

Determining the indicators of CNB using Exploratory Factor Analysis
The goal of EFA is to reduce the number of measures (e.g., psychometric measures,
adverse effect measures, and functioning measures) to those that are most reliable, common and
with the highest shared variance with the three dimensions of CNB. It is a data reduction
technique used to understand the correlation between a set of observed variables that are believed
to describe a common (unobserved) factor. EFA is often used in the creation or modification of
scales to measure psychological constructs. This method was used to determine the indicators
that best describe the three dimensions of the novel construct of CNB.
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In EFA, multiple techniques can be used to determine the number of factors and
measured indicators that comprise a latent construct. EFA empirically identifies the number of
indicators and factors of a latent construct that provide the best fit to the data, without any prespecifications as is done in Confirmatory Factor Analysis.88 We conducted three EFAs, one for
each of the dimensions of CNB using the measures listed previously to define each latent
construct. Measures for the psychiatric symptoms dimension included not only scales of
symptoms such as the YMRS, but also comorbidities that may be used as self-medication or
behaviors to mitigate psychiatric symptoms such as caffeine cups per day and binge purge
disorders.
EFA uses statistical methods to identify and reduce the number of measured indicators to
only those necessary for each factor of a latent construct. It does this without a priori
assumptions of the number of factors. The resulting latent factor should explain most of the
shared variance seen in the associations between the original measured variables, (i.e., the
correlation among the variables).86 For example, when creating a depression scale, one wants to
be able to use the fewest number of questions (i.e., measured variables) necessary to accurately
capture the latent construct of “depression”. EFA has four main assumptions: (1) measurement
error has a constant variance that is on average approximately 0; (2) there is no association
between the factor and measurement error; (3) there are no associations between error terms; and
(4) given the factor, observed indicators are independent of one another (i.e., there is no
relationship between the measured indicator except through their relationship with the factor).89,
90

EFA can incorporate dichotomous, ordinal and continuous measures in the same analysis,

thereby decreasing error due to transformation of variables into the same format (i.e.,
transforming all measures into dichotomous variables).88 However, EFA is sensitive to missing
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data and outliers, therefore we could only use the measures from STEP-BD with less than 10%
missing data, and missing data was estimated using Full Information Maximum Likelihood
Estimation (FIML).91, 92
To determine the final number of measures and factors from an EFA, the type of rotation
must first be determined to use in the analysis. Rotations are the ways in which to account for the
level of correlation between the measures as identified via the correlation matrix. If the measures
are highly correlated an oblique rotation is used, if correlation is low an orthogonal rotation is
used. Verimax rotation identifies preliminary factor loadings, but to group factor loadings closest
to the two extremes (1 or 0), an additional promax rotation is needed.93 This will identify simple
structure, factor loadings exceeding absolute value of 0.50 with cross loadings of at least 0.15
less than item’s highest factor loading among the factors.94, 95 With factor loadings closest to the
extremes one can be more confident that each factor is distinct from the others, with very low
correlation between the factors.88 Results from an EFA indicate the eigenvalues for the number
of factors up to the highest number of measures used in the analysis (if 15 measures were
initially included, there will be 15 eigenvalues). An eigenvalue of one indicates the number of
factors to include in the final EFA, which can also be visualized with a scree plot.96

Identifying distinct subgroups based on CNB using Latent Class Analysis
LCA is a method used to identify distinct unobserved (latent) subgroups (called classes)
within a given population based on the correlations between a set of observed variables. LCA has
three elements: measurement, characteristics, and grouping. First, as a measurement approach it
evaluates whether an unobserved latent binary variable exists (i.e., do the measured indicators
represent a common construct). Then LCA is used to determine the number of classes (i.e.,
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subgroups) of the latent variable that exist in the sample. Finally, LCA is used to assign
participants to a particular class of the latent variable from their posterior probabilities of
symptom endorsement.97 For example, with LCA one can assess whether a latent binary variable
of depression exists, and then can identify different classes within that latent variable, such as
low, medium and high levels of depression. Participants can then be assigned as belonging to the
different classes of depression (i.e., low, medium and high). LCA has two main assumptions: (1)
exhaustiveness is the assumption that every set of responses to measured indicators is associated
with membership in that particular class, thus participants are provisionally assigned to a
particular class based on their responses to the measured indicators; and (2) local independence
assumes that members of a particular class will have independent responses from those of other
members of the same class.98 Typically, the latent class is a binary measure, therefore ordinal,
continuous and categorical variables must be transformed into binary variables.99
LCA was chosen for this analysis, rather than other methods of clustering individuals into
groups, due to the empirical nature of the analysis. LCA uses a statistical model to derive the
groups of individuals based on their responses to measured indicators 84 rather than a more
arbitrary method of class identification based on apparent groupings such as is used in Cluster
Analysis.93 The measures identified in the EFA that defined each dimension of CNB were then
included as measures of the CNB in the LCA. The scores on each measure of each dimension
defined each class. For example, individuals would be identified by their degree of psychiatric
symptoms (high or moderate), adverse effects (low or high) and overall functioning (moderate or
low). Using these degrees, the classes would be identified by their overall degree of the three
(i.e., individuals with low psychiatric symptoms, low adverse effects, and high overall
functioning would be identified as the High CNB Class).
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To determine the number of classes that best fits the sample, the following measures are
used: Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), Sample-Size
Adjusted BIC (BICN), Bootstrapped Likelihood Ratio Test (BLRT) and Entropy.100 For each of
these indices smaller values, and Entropy values closest to 1, indicate better relative fit.99 With
large sample sizes large numbers of classes may be indicated, therefore measures of model fit,
prevalence of class membership and model interpretability are all used to determine the final
number of classes.101

Chapter 3
Does the association between CNB and adherence remain stable or change over time
while individuals are being closely monitored by treating psychiatrists? In addition, do the
medication regimens differentially affect adherence?

After determining the classes of CNB in STEP-BD, we wanted to test whether these
classes changed over time and whether individuals moved between classes. In addition we
wanted to know whether these changes affected adherence. We conducted this analysis using
data from the active participation phase of STEP-BD, approximately two years. Two main
methods can be used to analyze change over time of latent classes. The Repeated Measures
Latent Class Analysis identifies the arch of change in all time points simultaneously, but does not
give the detail regarding incidence of change between time points. We not only wanted to
determine class membership at each time point, but also the probability of participants changing
class membership (i.e., transitioning) at each consecutive time point. Therefore we chose to
conduct a Latent Transition Analysis.99, 102
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Examining the short-term relationship between CNB and Adherence using Latent Transition
Analysis
LTA is able to determine the probability of an individual in a specific latent class at one
time point transitioning to the same or different class at a subsequent time point. These
probabilities are determined by a multinomial regression of the classes at the subsequent time
point on the classes at the previous time point (i.e., classes at time 3 regressed onto classes at
time 2). This entails two models, a measurement model to identify the latent classes at each time
point, (i.e., an LCA), and a structural model showing how the latent classes related to each
other.102 The first step in conducting the LTA is to determine the best fitting number of latent
classes at each time point using AIC, BIC, BICN, BLRT and Entropy as is done in LCA.
However, when running the LTA, probabilities of movement between classes is also adjusted
for, which cannot be accounted for with an LCA at each time point. This may lead to slightly
different numbers of classes and class memberships. Thus, after determining the best fitting
number of classes from the individual LCAs, an initial LTA should be analyzed to determine the
number of best fitting classes when all time points are in the model.102 Fit indices for the LTA
using AIC, BIC, and BICN can confirm if the number of LCA classes are the best fit for the LTA
classes. For example, if the analysis using LTA will include five time points, an LCA for each
time point should be conducted to determine the number of classes that best fit the data. If four
and five classes fit the data for each time point, then in the LTA the fit of four classes and five
classes should be tested to determine the number of classes that best fit the data using LTA.
Once the best fitting classes are determined for the LTA, the actual LTA can be
conducted. We wanted to determine if the classes themselves changed over time (i.e., values for

25

the MADRS in time two differed from time one) as well as whether participants changed classes
at each subsequent time point. Therefore we did not hold the classes invariant across time.99, 102
In addition, a large number of random starts is preferred to ensure the validity of the LTA results.
However, because we were comparing multiple latent variables, we reduced the number of
random starts as is indicated in the literature.102

Chapter 4
Will the results from question 2 hold in a more naturalistic setting where individuals are
not as closely monitored by their treating psychiatrist? That is, will the association between
CNB, medication regimens, and adherence, remain stable or change over time when individuals
do not meet as regularly with their psychiatrists?

After completing the short term analysis of change in classes and CNB over the
approximately two years of active study participation, we wanted to determine whether these
CNB classes, changes in classes over time, and adherence held during the naturalistic follow-up
in STEP-BD. The final three years of STEP-BD were designed to approximate the treatment
environment in the general population, where individuals have fewer appointments with their
treating psychiatrist leading to much less monitoring.52 The results from the LTA in Paper 2 may
not be fully capturing adherence and CNB in a real world setting. We wanted to determine if less
monitoring would differentially affect both CNB class membership, changes in benefit and
subsequent adherence.
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Examining the long-term relationship between CNB and Adherence using Latent Transition
Analysis
We conducted this analysis from the last time point in paper 2, time 5, until time 8, which
was approximately the end of the three-year naturalistic follow-up. Few individuals completed
the full five years of STEP-BD. Only approximately 200 individuals completed exit interviews,
which is at the extreme low end of sample size with enough power to adequately complete latent
variable modeling. Therefore, we conduct analyses using data through time 8, which gave us a
sample size of approximately 500, considered a “very good” level of power.103
Our analysis used the same methods as in Paper 2. We first conducted LCAs for each
time point to determine the number of classes that best fit the data for those time points using
AIC, BIC, BICN, BLRT and Entropy. We kept the number of classes the same across time points
to more easily identify changes in values of the measures making up the classes of CNB and to
identifying how class membership changed over time. Once the number of classes that best fit
the data were determined, we conducted an LTA to confirm the fit of the number of classes using
AIC, BIC and BICN. Finally, we conducted the LTA for time 5 – 8 to determine transition
between classes from the previous to each subsequent time point.
The characteristics of members of each class, including medication regimens they took,
adherence to their regimens, and membership in SCP or RCPs were determined and compared to
individuals who did not complete the study.

27

Table 1.1. Psychological assessments either clinician- or self-administered to all participants in
STEP-BD. Includes the number of participants that completed these assessments.
Clinician-Administereda
Final Sample Size
Affective Disorders Evaluation
4107
Clinical Monitoring Form
3730
Care Utilization Form
3908
Demographic Form
3867
Family Contacts
3098
Montgomery-Asberg Depression Rating Scale
3931
Hospitalization Form
3073
Range of Impaired Functioning Tool
3904
Mini International Neuropsychiatric Interview
3790
UCLA Social Attainment Scale
381
Work Impact Form
3899
Young Mania Rating Scale
3927
Participant Self-Administered
Beck Depression Inventory Version II
300
Edinbergh Handedness Inventory
2977
Family History
2860
Medication History
2963
NEO Five Factor Inventory
2338
Attributional Style Scale
265
Beck Hopelessness Scale
3179
Care Satisfaction Questionnaire
3377
Dysfunctional Attitudes Scale
285
Helping Alliance Questionnaire
2595
Interpersonal Support Evaluation List
283
Life Experience Survey
3118
Perceived Criticism Scale
1225
Personality Diagnostic Questionnaire – Version 4
2897
Quality of Life Enjoyment and Satisfaction (Short Form) 3371
Religiosity
2574
SF-36 Health Survey
2920
Social Rhythm Metric “Short Form”
31
a. Includes treating psychiatrist, clinical specialist, or other certified rater
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Figure 1.1. Participant flow chart for STEP-BD.
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Figure 1.2. Conceptual diagram of Clinical Net Benefit latent construct.

Caption: Dots represent different hypothetical CNB groups and their relative coordinates of psychiatric symptoms,
adverse medication effects, and overall functioning.
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CHAPTER 2
Identifying Clinical Net Benefit of Psychotropic Medication Use with Latent Variable
Techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD)
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ABSTRACT
Objectives: Adherence to psychotropic medication is poor among individuals with bipolar
disorder (BD). Multiple factors influence the clinical net benefit (CNB) experienced from
treatment, however existing models may fail to capture the complex intersection of psychiatric
symptoms, adverse effects, and functioning. This study empirically quantified a novel construct
of CNB and characterized its relationship with polypharmacy and medication adherence.
Methods: Data come from baseline assessments of individuals aged 18+ from the Systematic
Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Latent class analysis
identified distinct groups based on the intersection of the three factors of CNB: psychiatric
symptoms (i.e., decrease in episodes), adverse effects (e.g., sedation), and functioning (i.e.,
employment, quality of life). Adherence was defined as taking 75% or more of medications as
prescribed. Polypharmacy was categorized as number of medications taken concurrently.
Associations between CNB and adherence were tested using multiple logistic regression
adjusting for sociodemographic characteristics.
Results: Five classes of CNB were identified: High (24%), Moderately high (26%), Moderate
(12%), Moderately low (27%) and Low (12%). Adherence did not differ between classes (71%
to 74%, χ2=1.34, p=0.854). Medication regimens differed by class: 57% of the High CNB were
taking two or fewer medications; 49% of the Low CNB were taking four or more medications.
Conclusions: CNB is substantially heterogeneous in individuals treated for BD. Despite this
variation, and differences in polypharmacy regimens, adherence is similar across classes of
CNB. Understanding why individuals adhere to their regimens, despite suboptimal CNB, may
provide novel insights into important aspects influencing adherence.
Keywords: Adverse Effects, Medication Adherence, Polypharmacy, Bipolar Disorder
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INTRODUCTION
Bipolar disorder (BD) is among the leading causes of disability-adjusted life-years lost
worldwide.13 Effective treatment with psychotropic medication, often in combination with
psychotherapy, can help individuals with BD manage their illness.16, 104
Despite advances in pharmacotherapy, adherence to medication among individuals with
BD has not markedly improved since the 1950’s when medications with serious adverse effects
were the primary treatment modalities.43 Approximately 20-60% of individuals with BD will be
non-adherent to their medication at some point in their treatment;105 medication non-adherence
contributes to elevated relapse, suicidal behavior and greater healthcare costs.106, 107 Poor
adherence is thought to stem from multiple sources, including effects of the illness itself (e.g.,
“lack of insight” about the condition),39, 40 adverse effects of medications (e.g., heart disease,
somnolence),43, 44, 108 and complexity of medication regimens (e.g., multiple pills taken multiple
times per day).39, 42
When considering prescribing medications, practitioners routinely weigh the clinical net
benefit (CNB) of each treatment, seeking a positive balance between expected benefits and risk
of adverse effects.16 However, existing notions of CNB are limited in two important ways. First,
although long-term treatment guidelines identify the importance of preventing relapse and
promoting quality of life and functioning,104 most approaches are unidimensional (i.e., reducing
the benefit-risk ratio to a single quantity like Number Needed to Treat).109 This does not
appropriately capture the complexity of what CNB means for the patient; from the patient’s
perspective, CNB of medications can be conceptualized as the complex intersection between
psychiatric symptom reduction, medication adverse effects, and overall functioning.
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Second, there has been only limited discussion of how CNB relates to medication
adherence for individuals with BD, with focus instead on psychoeducation promoting adherence
42

and the individual’s perception of their providers’ confidence in the medication regimen.110 A

handful of studies explored how perspectives of individuals with BD relate to medication
adherence. Using the Beliefs about Medication Questionnaire 63 Clatworthy, et al. (2009) found
that perceptions of higher concern and lower necessity regarding medication were associated
with lower adherence.43 Using components of the Rating of Medication Influences Scale
(ROMI),111 Adams and Scott (2000) found that participants’ perceived benefits-to-risks for
medications differentiated those who were highly adherent and partially adherent.112 Other
descriptive studies of individuals with BD have identified treatment of depression, improved
functioning, and management of adverse effects as factors most important to CNB, but these
studies did not examine the relationships between these factors and medication adherence.16, 113
These reports were also limited in scope (i.e., small samples, limited to one type of medication)
and relied on self-administered mail-in questionnaires with lower validity relative to clinical
assessments.113-115
The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
overcame many limitations of these prior studies. It was a large (N=4360), 5-year longitudinal
randomized controlled trial (RCT) designed to test the utility of different treatment modalities
(medications and psychotherapy) for individuals with BD. It included stepped-treatment where
participants were allowed to discontinue ineffective treatments and advance to the next level of
randomized treatments until they achieved effective symptom management. Participants were
also given a battery of clinician- and self-administered psychological assessments as well as
clinician determined medication adherence at multiple time points.52
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The objective of this study was to use the baseline assessments of STEP-BD participants
to identify and characterize subgroups of CNB. Due to the complex, multi-dimensional nature of
CNB this project employed two latent variable approaches, exploratory factor analysis (EFA)
and latent class analysis (LCA), to quantify CNB in the context of medical treatment.116 Latent
variable modeling is ideal for quantifying a complex construct such as CNB,117, 118 and can
effectively classify people into discrete subgroups. Classes of CNB were characterized according
to indicators of symptom management, adverse effects, and overall functioning. Further, the
association between these CNB classes with characteristics of medication treatment (i.e., type of
medication, polypharmacy) and medication adherence was assessed. We hypothesized that LCA
will identify unique classes of individuals who systematically differ in characteristics of CNB.
We also hypothesized that these distinct classes will be differentially associated with medication
adherence.
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METHODS
Sample
All eligible participants aged 18 years and older from the STEP-BD trial were included in
the current study, as medications prescribed in STEP-BD were only approved for this population
when the study began.119, 120 The details of the original study design were described elsewhere.52
Briefly, STEP-BD was a 5-year RCT of individuals treated for bipolar spectrum disorders. It was
designed to simulate the “real world” experiences in treatment of individuals with BD. STEP-BD
was not solely a RCT, as eligible participants could choose to enter either the Randomized Care
Pathways (RCPs) or Standardized Care Pathway (SCP). In the RCPs, participants were randomly
assigned to specific medications (i.e., mood stabilizers, antipsychotics, antidepressants or
placebos) to minimize self-selection bias. In the SCP, participants maintained current treatment.
If initial regimens were ineffective, participants moved on to subsequent medications until an
effective regimen was reached. Participants routinely underwent a battery of clinician- and selfadministered psychological assessments, including medication adherence.
Although 4,360 participants enrolled in the original study, this study further excluded 321
participants with incomplete data on the psychological assessments and physical measures with
less than 10% missing data used in this analysis, and 301 individuals who were less than aged 18
years. Missing data <10% was imputed using Full Information Likelihood Estimation.92 The
final analytic sample size was 3,738 (Supplemental Figure 2.1.).
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Outcomes
Clinical Net Benefit
CNB incorporates three main effects of treatment on the individual: (1) symptom
reduction; (2) adverse effects; and (3) overall functioning. CNB can be conceptualized as a 3dimensional construct lying at the intersection of these axes. Individuals differentially experience
these components of treatment, depicted as points in Figure 2.1. These different experiences, or
coordinates, may in turn uniquely relate to medication adherence. To conceptually define and
quantitatively measure these three dimensions of CNB, we used the baseline scores of the
following variables. Three EFAs empirically reduced measures to only those necessary for the
three dimensions of CNB. LCA then grouped participants into distinct subgroups of CNB.
Psychiatric Symptoms
Nine symptom scales and psychiatric diagnoses were explored as potential indicators of
this component of CNB at baseline.16 All symptom indicators were reverse coded such that
higher scores indicated lower symptomology. The treating psychiatrist-administered Clinical
Monitoring Form (CMF),62 indicated binary (yes/no) comorbid DSM-IV diagnoses of alcohol
abuse, substance abuse/dependence, binge/purge, and panic disorder; the number of caffeine
cups per day (mean: 1.83, SD: 2.35) and number of cigarettes per day (mean: 6.04, SD: 10.96)
were transformed into binary variables above and below the sample mean. Mania and depression
were measured using the participant self-reported 20-item Beck Hopelessness Scale (BHS)
(range: 0=none to 20=severe; mean: 11.49, SD: 5.75); the clinician-rated 11-item Young Mania
Rating Scale (YMRS) (range: 0=absent to 60=severe; mean: 32.00, SD: 6.53); and the clinicianrated 10-item Montgomery-Asberg Depression Rating Scale (MADRS) (0=absent to 50=severe;
mean: 33.19, SD: 10.90). Externalizing symptoms (i.e., alcohol abuse, substance
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abuse/dependence, binge/purge, caffeine cups per day, cigarettes per day)117 were combined into
an externalizing count variable.
Adverse Effects
Ten adverse effects from the CMF were explored as potential indicators of CNB at
baseline. Each was scored on a 4-point scale ranging from 0=none to 4=severe. All of these
indicators were reverse coded so that higher scores indicated fewer effects. These included
tremor (mean: 3.77, SD: 0.60); dry mouth (mean: 3.75, SD: 0.63); sedation (mean: 3.70, SD:
0.69); constipation (mean: 3.90, SD: 0.43); diarrhea (mean: 3.88, SD: 0.45); headache (mean:
3.78, SD: 0.60); poor memory (mean: 3.74, SD: 0.64); sexual dysfunction (mean: 3.80, SD:
0.63); increased appetite (mean: 3.80, SD: 0.60); and extrapyramidal symptoms (mean: 3.99, SD:
0.17).
Overall Functioning
Four scales were explored as potential indicators of CNB at baseline. All items were
reverse-coded so higher scores indicated better functioning: (1) participant self-reported 16-item
Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) (mean: 42.53, SD: 10.87);
(2) clinician-rated LIFE Range of Impaired Functioning Tool (LRIFT),74 (mean: 39.88, SD:
6.45); (3) three indicators from the clinician-rated Work Impact Form (WIF), were combined
creating a weighted work impairment score (totally unable to work/carry out normal activities
score X 2; able to work/carry out normal activities but had to cut down score X 1.5; extreme
effort to perform up to usual level of work/normal daily activities score X 1) (ranging from 0=no
impact to 9=high impact; mean: 4.18, SD: 3.11); (4) the CMF Global Assessment of Functioning
(GAF) for the past week (mean: 62.40, SD: 11.07).
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Adherence
The CMF recorded milligrams missed for each medication in the past seven days at
baseline. Adherence was defined as missing 25% or less of participants’ medication regimens in
the past week; participants who missed more than 25% were considered non-adherent. This is
consistent with the definitions used in STEP-BD studies.83
Demographic Characteristics
Demographic characteristics at baseline included age; gender; race (White, Black, and
Other); educational attainment (≤high school, high school diploma or GED, some college,
Bachelor’s degree, and Graduate or professional degree); current marital status (married or living
as though married, divorced or separated, never married, or widowed); whether participants lived
alone; primary residence (private home, group home or something else); income (greater or less
than $50,000); whether participants received disability insurance or welfare; and employment
status (employed, unemployed, disabled or something else). In addition, whether individuals
entered the SCPs or RCPs were noted.
Medication
Medications taken at baseline were listed by name (either generic or brand) on the CMF.
All medications were identified and grouped into six families: (1) antidepressants, (2) mood
stabilizers, (3) antipsychotics, (4) sedatives/hypnotics, (5) stimulants, and (6) other.121 A regimen
count variable was created indicating whether a participant was taking one (monotherapy), two,
three, four or five or more medications (polypharmacy).
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Analytic Approach
Analyses took place in two steps. First, EFAs reduced the number of measures to only
those necessary to comprise each of the three dimensions of CNB (symptoms, adverse effects,
and functioning). Second, LCA grouped the participants into distinct classes (subgroups) of
CNB. We characterized and examined the correlates of those subgroups in terms of demographic
characteristics, medication regimens and medication adherence.
Exploratory Factor Analysis
We conducted three EFAs, (psychiatric symptoms, adverse effects and overall
functioning) using the previously described indicators. Using Equamax rotation,122 eigenvalues >
one indicated the number of factors to retain. We only retained indicators meeting the definition
of simple structure (factor loadings exceeding 0.50 and a cross loading of at least 0.15 less than
the items’ highest factor loading).87, 88, 94-96
Latent Class Analysis
To improve interpretability of the classes, we dichotomized all continuous and ordinal
indicators retained from the EFAs based on the participants’ mean scores,123, 124 with 1=above
the mean (better outcomes). The number of distinct latent classes of CNB were determined by
comparing model fit using the Akaike Information Criterion (AIC), Bayesian Information
Criterion (BIC), Sample-Size Adjusted BIC (BICN), Bootstrapped Likelihood Ratio Test (BLRT)
and Entropy; for each of these indices smaller values, and Entropy values closest to 1, indicate
better relative fit. Measures of model fit, prevalence of class membership and model
interpretability were all used to determine the final number of classes.97, 125 Most likely class
membership for each participant was determined from their posterior probabilities.
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Characterizing the latent classes of CNB
The demographic characteristics, adherence to medication regimens, types of medication
regimens (i.e., monotherapy versus polypharmacy) and makeup of these medication regimens
(i.e., percent antidepressants versus mood stabilizers) of the latent classes of CNB were
compared using ANOVA for continuous measures and Chi-square analyses for categorical
measures.
Descriptive statistics were calculated using SAS version 9.4 (SAS Institute Inc.). EFA
and LCA were conducted using Mplus version 7.91
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RESULTS
Table 2.1. describes the baseline characteristics of the sample. Mean age was 40 years, a
little over half (58%) were female and 91% were non-Hispanic white. Only 1% lived in group
homes, and most lived with at least one other person (73%). Over 15% received Social Security
Disability Insurance. Two medications were the most common regimen, and 72% of participants
were adherent to their medication regimen. Only 5% of the sample entered a RCP.
Exploratory Factor Analysis
Table 2.2. provides factor loadings for the three EFAs. Eigenvalues for the psychiatric
symptoms EFA indicated one factor (first factor: 1.981, and second factor: 0.950). Although the
factor loading for YMRS was less than 0.50 (0.312), BHS and MADRS only measure depressive
states, therefore YMRS was retained to account for mania. The final psychiatric symptoms EFA
retained one factor with three indicators: MADRS, BHS and YMRS. The overall functioning
EFA eigenvalues indicated a one factor model (first factor: 2.090 and second factor: 0.704),
therefore the final overall functioning EFA retained one factor with four indicators: QLESQ,
LRIFT, GAF and Work Impairment. Although the eigenvalues for the adverse effects EFA
indicated a two factor model (first factor: 4.179 and second factor: 1.123), the second factor had
only one measure. Therefore, the one factor model was retained, and the final adverse effects
EFA included: memory difficulties, dry mouth, sexual dysfunction, headache, constipation,
sedation, diarrhea, and tremor.
Latent Class Analysis
Model fit statistics indicated that both the five and six class models had comparable fit
(Supplementary Table 2.1.). However, the smallest class in the five class model consisted of
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N=432 (12%) of the participants, whereas the smallest class in the six class model consisted of
only N=259 (7%) of the participants. Thus, the five class model was chosen due to the best
balance of interpretability and model fit.
Results for the five class model of CNB defined by their responses on the three
dimensions of CNB (psychiatric symptoms, overall functioning, and adverse effects) are in
Figure 2.2. and Supplementary Table 2.2. The five classes were: (1) high benefit (low symptoms,
low adverse effects and high functioning; class prevalence: 24%); (2) moderately high benefit
(moderate symptoms, low adverse effects and moderate functioning; class prevalence 26%); (3)
moderate benefit (moderate symptoms, moderate adverse effects and moderate functioning; class
prevalence 12%); (4) moderately low benefit (high symptoms, low adverse effects and low
functioning; class prevalence 27%); and (5) low benefit (high symptoms, moderate adverse
effects, and low functioning; class prevalence 12%).
Characterizing the classes
The results of both the ANOVA and Chi-square tests between the classes are indicated as
P-values in Table 2.1. Classes differed in all characteristics except in terms of age (F=2.01;
p=0.09), race (χ2=5.51, p=0.70) and primary residence (χ2=8.33, p=0.40). The high benefit class
had the highest proportion with graduate education (N=189, 24%), employment (N=467, 57%)
and the lowest percentage entering the RCP (N=5, 0.61%), while the low benefit class had the
highest proportion unemployed (N=117, 28%), receiving social security disability insurance
(N=87, 21%) and entering the RCP (N=42, 10%).
Medication adherence did not differ across the classes (χ2=1.34, p=0.854), ranging
between 71% and 74%. This held true after adjusting for all significantly different between class
demographic characteristics including medication regimens (i.e., monotherapy versus taking five
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or more medications; see bottom of Table 2.1.). However, medication regimens did differ
between classes (χ2=167.39, p<0.001; see Figure 2.3.). In the high benefit class over 50% were
taking two or fewer medications. In contrast, in the low benefit class almost 50% were taking
four or more medications. Only the monotherapy regimens (i.e., proportions of antidepressants,
mood stabilizers, etc.) differed between the classes (Supplementary Table 2.3. and
Supplementary Figure 2.2.; χ2=39.8, p<0.001). As the number of medications increased (i.e., two
medications to three medications) the percent mood stabilizers decreased and other medications
taken increased in all classes (i.e., 84% to 28% and 2% to 34% respectively in the high benefit
class).
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DISCUSSION
The primary finding from this study is that the notion of CNB from medical intervention
can be expanded beyond traditional metrics using latent variable techniques. We empirically
identified subgroups of individuals with distinctly intersecting clinical characteristics of
psychiatric symptoms, adverse effects and overall functioning using a novel three dimensional
model. Supporting our hypothesis and the external validity of these classes of CNB, the five
subgroups of high, moderately high, moderate, moderately low and low benefit also differed in
terms of sociodemographic characteristics such as education, employment, disability status, and
entry into the Randomized versus Standard Care Pathways in STEP-BD.
Importantly, contrary to our hypothesis, although classes differed in the three CNB
dimensions, they did not differ in medication adherence. Approximately 70% were adherent,
which is typical for BD populations.42 These results suggest that factors associated with
adherence identified by prior work (e.g., effects of the illness itself, adverse effects from
medications, and complex regimens) are only part of the complex interplay of experiences
individuals have of their illness and its treatment. Future work should examine whether the
relationship between CNB and adherence changes over time.
Strengths and Limitations
Strengths of this study include use of a large RCT with rigorous and extensive
assessments. STEP-BD was a more heterogeneous sample than most RCTs in that it enrolled
individuals with comorbidities, already taking medications, at different stages of illness, from a
wide age range, and from the full spectrum of BD; this increases generalizability of the results.
By using latent variable techniques we empirically identified the indicators of CNB rather than
relying solely on theoretical conceptualizations. Finally, detailed information on medications
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allowed us to examine components of complex medication regimens commonly used to treat
individuals with BD and their relationship with adherence.
Limitations included the lack of measures of participants’ perceptions of their illness or
of medications used to treat it, or of their individual preferences. Medication usage was not
confirmed by pill counts or blood serum levels; however, the clinical interview used here is bestpractice for large, complex trials like STEP-BD. Missing data limited the number of measures
used to describe the CNB construct.
Conclusions
Our findings support the importance of collaborative, person-centered, shared decisionmaking approaches to treatment to identify targets for supporting medication adherence. Our
results are broadly consistent with previous studies of the experience of individuals with BD that
highlight the importance of perceived necessity of medication versus concerns about adverse
effects; if perceptions of necessity outweigh concerns, individuals may continue taking their
medications even if symptom management and functioning is suboptimal. This may contribute to
the unexpected finding of high adherence across these groups that differed substantially in CNB.
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Table 2.1. Demographic Characteristics of the Full Sample, and by LCA Class. Includes logistic regression results testing association of classes with adherence*.

N (%)
Age (Mean, SD)
Female – no./total no. (%)
Race – no./total no. (%)
White
Black
Other
Education – no./total no. (%)
Less than high school diploma
High school diploma or GED
Some college
College diploma (Bachelor’s degree)
Graduate or professional degree
Marital Status – no./total no. (%)
Married/Living as married
Divorced/Separated
Never married
Widowed
Lives alone – no./total no. (%)
Primary residence – no./total no. (%)
Private home
Group home/assisted living facility
Other
Income – no./total no. (%)
$50,000 or less
More than $50,000
Other sources of income
SSDI – no./total no. (%)
Welfare – no./total no. (%)
Employment – no./total no. (%)
Employed
Unemployed
Disabled

Full Sample

Class 1
High Benefit

Class 3
Moderate Benefit

889 (23.78)
41.13 (14.33)
N=837
445/837 (53.17)

Class 2
Moderately High
Benefit
961 (25.71)
39.54 (12.93)
N=930
530/929 (57.05)

Class 5
Low Benefit

432 (11.56)
41.04 (13.18)
N=417
266/417 (63.79)

Class 4
Moderately Low
Benefit
1010 (27.02)
40.50 (11.39)
N=958
553/955 (57.91)

3738
40.45 (12.78)
N=3568
2054/3563 (57.65)
2531/2789 (90.75)
162/2789 (5.81)
96/2789 (3.44)

565/621 (90.98)
33/621 (5.31)
23/621 (3.70)

656/724 (90.61)
45/724 (6.22)
23/724 (3.18)

281/305 (92.13)
12/305 (3.93)
12/305 (3.93)

722/798 (90.48)
53/798 (6.64)
23/798 (2.88)

307/341 (90.03)
19/341 (5.57)
15/341 (4.40)

105/3448 (3.05)
521/3448 (15.11)
1296/3448 (37.59)
911/3448 (26.42)
615/3448 (17.84)

16/800 (2.00)
100/800 (12.50)
256/800 (32.00)
239/800 (29.88)
189/800 (23.63)

29/907 (3.20)
127/907 (14.00)
335/907 (36.93)
265/907 (29.22)
151/907 (16.65)

6/401 (1.50)
42/401 (10.47)
143/401 (35.66)
118/401 (29.43)
92/401 (22.94)

44/926 (4.75)
168/926 (18.14)
390/926 (42.12)
197/926 (21.27)
127/926 (13.71)

10/414 (2.42)
84/414 (20.29)
172/414 (41.55)
92/414 (22.22)
56/414 (13.53)

1300/3531 (36.82)
888/3531 (25.15)
1285/3531 (36.39)
58/3531 (1.64)
956/3526 (27.11)

305/829 (36.79)
171/829 (20.63)
341/829 (41.13)
12/829 (1.45)
232/828 (28.02)

336/923 (36.40)
214/923 (23.19)
357/923 (38.68)
16/923 (1.73)
226/922 (24.51)

174/414 (42.03)
98/414 (23.67)
137/414 (33.09)
5/414 (1.21)
113/414 (27.29)

313/942 (33.23)
298/942 (31.63)
317/942 (33.65)
14/942 (1.49)
287/940 (30.53)

172/423 (40.66)
107/423 (25.30)
133/423 (31.44)
11/423 (2.60)
98/422 (23.22)

3310/3459 (95.69)
37/3459 (1.07)
112/3459 (3.24)

767/801 (95.76)
8/801 (1.00)
26/801 (3.25)

869/910 (95.49)
9/910 (0.99)
32/910 (3.52)

375/400 (93.75)
4/400 (1.00)
21/400 (5.25)

898/932 (96.35)
11/932 (1.18)
23/932 (2.47)

401/416 (96.39)
5/416 (1.20)
10/416 (2.40)

1968/3261 (60.35)
1293/3261 (39.65)

413/760 (54.34)
347/760 (45.66)

505/851 (59.34)
346/851 (40.66)

201/382 (52.62)
181/382 (47.38)

603/873 (69.07)
270/873 (30.93)

246/395 (62.28)
149/395 (37.72)

523/3405 (15.36)
65/3405 (1.91)

78/786 (9.92)
5/786 (0.64)

119/894 (13.31)
7/894 (0.78)

55/395 (13.92)
8/395 (2.03)

184/921 (19.98)
30/921 (3.26)

87/409 (21.27)
15/409 (3.67)

1623/3504 (46.32)
816/3504 (23.29)
629/3504 (17.95)

467/818 (57.09)
157/818 (19.19)
74/818 (9.05)

432/917 (47.11)
229/917 (24.97)
138/917 (15.05)

202/414 (48.79)
87/414 (21.01)
62/414 (14.98)

372/934 (39.83)
226/934 (24.20)
250/934 (26.77)

150/421 (35.63)
117/421 (27.79)
105/421 (24.94)

P-values

446 (11.93)
40.46 (11.65)
N=426
260/425 (61.18)

0.091
0.004
0.702

<0.001

<0.001

0.015
0.402

<0.001

<0.001
<0.001
<0.001
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Other
Medication Regimens – no./total no. (%)
Monotherapy
Two Medications
Three Medications
Four Medications
Five or More Medications
Adhere – no./total no. (%)
Pathway
Standardized Care
Randomized Care

436/3504 (12.44)

120/818 (14.67)

118/917 (12.87)

63/414 (15.22)

86/934 (9.21)

49/421 (11.64)

620/3393 (18.27)
863/3393 (25.43)
738/3393 (21.75)
504/3393 (14.85)
668/3393 (19.69)
2423/3347 (72.39)

202/785 (25.73)
244/785 (31.08)
145/785 (18.47)
85/785 (10.83)
109/785 (13.89)
557/769 (72.43)

150/869 (17.26)
249/869 (28.65)
203/869 (23.36)
130/869 (14.96)
137/869 (15.77)
626/862 (72.62)

57/429 (13.29)
85/429 (19.81)
87/429 (20.28)
69/429 (16.08)
131/429 (30.54)
315/424 (74.29)

158/875 (18.06)
208/875 (23.77)
210/875 (24.00)
145/875 (16.57)
154/875 (17.60)
620/862 (71.93)

53/435 (12.18)
77/435 (17.70)
93/435 (21.38)
75/435 (17.24)
137/435 (31.49)
305/430 (70.93)

3344/3537 (94.54)
193/3537 (5.46)

816/821 (99.39)
5/821 (0.61)

869/918 (94.66)
49/918 (5.34)

416/431 (96.52)
15/431 (3.48)

844/926 (91.14)
82/926 (8.86)

399/441 (90.48)
42/441 (9.52)

<0.001

0.854
<0.001

Predicting
Adherence
OR (95% CI)
Classes (Ref=High Benefit)
Moderately High Benefit
0.95 (0.74-1.21)
Moderate Benefit
0.89 (0.65-1.20)
Moderately Low Benefit
1.03 (0.81-1.32)
Low Benefit
1.09 (0.81-1.47)
* Adjusted for medication regimens, gender, education, marital status, lives alone, income, social security disability insurance, welfare, and employment
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Table 2.2. Results from Exploratory Factor Analysis. Factor loadings are in order of importance.
Measures
Factor Loadings
Psychiatric Symptoms
0.808
MADRS
0.652
BHS
Panic
0.404
0.312
YMRS
Externalizing Disorders*
-0.199
Adverse Events
0.804
Memory Difficulties
0.733
Dry Mouth
0.678
Sexual Dysfunction
0.644
Headache
0.601
Constipation
0.600
Sedation
0.537
Diarrhea
0.535
Tremor
Appetite Increase
0.487
EPS
0.230
Functioning
0.703
QLESQ
0.629
LRIFT
0.557
GAF Past Week
0.523
Work Impact Score**
Bold=Kept in model
*Count that combined: Alcohol Abuse (Y/N); Current
Substance Abuse or Dependence (Y/N); Binge Purge
(Y/N); Caffeine Cups Per Day (cont.); Nicotine Packs
Per Day (cont.)
**Weighted combination: Unable to work or carry out
normal activities; Had to cut down on what you did;
Extreme effort to perform usual level of normal
activities
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Supplemental Table 2.1. Fit Statistics from five and six class Latent Class Analyses.
Class
AIC
BIC
BICN
BLRT
Entropy
51734.203
52226.081
51975.057
181.755, p<0.001a 0.710
Five Classes
51692.095
52283.594
51981.730
74.108, p<0.001b
0.687
Six Classes
For each of these indices smaller values, and Entropy values closest to 1, indicate better
relative fit.
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; BIC N: SampleSize Adjusted BIC; BLRT: Bootstrapped Likelihood Ratio Test
a
BLRT for 4-class versus 5-class model
b
BLRT for 5-class versus 6-class model

50

Supplemental Table 2.2. Overall five-class model from Latent Class Analysis, N=3,738. Higher scores indicate better outcomes.
Clinical Net Benefit

Class 1
Class 2
Class 3
Class 4
Class 5
High Benefit
Moderately High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit
Predicted Probabilities of Symptom Endorsement
Psychiatric Symptoms
BHS
0.922
0.688
0.782
0.138
0.165
YMRS
0.825
0.607
0.698
0.516
0.522
MADRS
1.000
0.545
0.817
0.084
0.131
Adverse Effects
Tremor
0.921
0.927
0.612
0.907
0.592
Dry Mouth
0.957
0.973
0.477
0.942
0.390
Sedation
0.924
0.910
0.467
0.911
0.487
Constipation
0.981
0.987
0.793
0.983
0.742
Diarrhea
0.968
0.976
0.775
0.967
0.743
Headache
0.955
0.958
0.635
0.943
0.477
Memory Difficulties
0.976
0.969
0.488
0.976
0.311
Sexual Dysfunction
0.982
0.976
0.690
0.969
0.577
Overall Functioning
QLESQ
0.913
0.557
0.796
0.105
0.134
LRIFT
0.916
0.585
0.779
0.195
0.291
GAF Past Week
0.845
0.490
0.603
0.204
0.189
Work Impact Score
0.789
0.349
0.546
0.218
0.190
BHS: Beck Hopelessness Scale; YMRS: Young Mania Rating Scale; MADRS: Montgomery-Asberg Depression Rating Scale;
QLESQ: Quality of Life Enjoyment and Satisfaction Questionnaire; LRIFT: Life Range of Impaired Functioning; GAF: Global
Assessment of Functioning
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Supplemental Table 2.3. Medication Types in each Regimen by Class.
Antidepressant
Mood Stabilizer
Class 1 High Benefit
Monotherapy (N=202)*
13 (6.44)
169 (83.66)
Two Medications (N=244)
93 (19.06)
255 (52.25)
Three Medications (N=145)
80 (18.39)
178 (40.92)
Four Medications (N=85)
54 (15.88)
120 (35.29)
Five + Medications (N=109)
85 (15.60)
155 (28.44)
Class 2 Moderately High Benefit
Monotherapy (N=150)
11 (7.33)
119 (79.33)
Two Medications (N=249)
103 (20.68)
262 (52.61)
Three Medications (N=203)
135 (22.17)
268 (44.01)
Four Medications (N=130)
81 (15.58)
191 (36.73)
Five + Medications (N=137)
100 (14.53)
221 (32.12)
Class 3 Moderate Benefit
Monotherapy (N=57)
6 (10.53)
42 (73.68)
Two Medications (N=85)
31 (18.24)
83 (48.82)
Three Medications (N=86)
44 (17.05)
106 (41.09)
Four Medications (N=70)
64 (22.86)
95 (33.93)
Five + Medications (N=131)
106 (15.87)
195 (29.19)
Class 4 Moderately Low Benefit
Monotherapy (N=158)
12 (7.59)
122 (77.22)
Two Medications (N=208)
93 (22.36)
207 (49.76)
Three Medications (N=210)
128 (20.32)
255 (40.48)
Four Medications (N=145)
107 (18.45)
212 (36.55)
Five + Medications (N=154)
126 (16.20)
228 (29.31)
Class 5 Low Benefit
Monotherapy (N=53)
10 (18.87)
25 (47.17)
Two Medications (N=77)
28 (18.18)
69 (44.81)
Three Medications (N=93)
74 (26.52)
102 (36.56)
Four Medications (N=75)
58 (19.33)
98 (32.67)
Five + Medications (N=137)
142 (20.11)
187 (26.49)
*Monotherapy regimens are different between Classes (χ2=39.8, p<0.001)

Antipsychotic

Sedative/Hypnotic

Stimulant

Other

15 (7.43)
72 (14.75)
61 (14.02)
44 (12.94)
54 (9.91)

-17 (3.48)
38 (8.74)
34 (10.00)
57 (10.46)

-2 (0.41)
4 (0.92)
2 (0.59)
8 (1.47)

5 (2.48)
49 (10.04)
74 (17.01)
86 (25.29)
186 (34.13)

13 (8.67)
66 (13.25)
85 (13.96)
58 (11.15)
82 (11.92)

3 (2.00)
21 (4.22)
60 (9.85)
54 (10.38)
86 (12.50)

-5 (1.00)
7 (1.15)
8 (1.54)
8 (1.16)

4 (2.67)
41 (8.23)
54 (8.87
128 (24.62)
191 (27.76)

6 (10.53)
30 (17.65)
41 (15.89)
39 (13.93)
78 (11.68)

-13 (7.65)
21 (8.14)
31 (11.07)
61 (9.13)

--1 (0.39)
2 (0.71)
3 (0.45)

3 (5.26)
13 (7.65)
45 (17.44)
49 (17.50)
225 (33.68)

16 (10.13)
50 (12.02)
95 (15.08)
69 (11.90)
96 (12.33)

4 (2.53)
26 (6.25)
74 (11.75)
92 (15.86)
126 (16.20)

-1 (0.24)
3 (0.48)
7 (1.21)
10 (1.29)

4 (2.53)
39 (9.38)
75 (11.90)
93 (16.03)
192 (24.68)

10 (18.87)
19 (12.34)
31 (11.11)
40 (13.33)
88 (12.46)

3 (5.66)
13 (8.44)
35 (12.54)
42 (14.00)
106 (15.01)

-1 (0.65)
-2 (0.67
6 (0.85)

5 (9.43)
24 (15.58)
37 (13.26
60 (20.00)
177 (25.07)
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Figure 2.1. Conceptual diagram of Clinical Net Benefit latent construct.

Caption: Dots represent different hypothetical CNB groups and their relative coordinates of psychiatric symptoms,
adverse medication effects, and overall functioning.
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Figure 2.2. Results of the Latent Class Analysis depicting the five classes of CNB.
1

Predicted Probability of Symptom Endorsement
0=Poor to 1=Better Outcomes

0.9
0.8
0.7
0.6

0.5
0.4
0.3
0.2
0.1
0

Components of Clinical Net Benefit
Class 1 (23.78%)

Class 2 (25.71%)

Class 3 (11.56%)

Class 4 (27.02%)

Class 5 (11.93%)

Caption: BHS, YMRS and MADRS are the Psychiatric Symptoms dimension. Tremor through Sex are the Adverse Effects dimension. QLESQ, LRIFT, GAF
and Work Impairment are the Overall Functioning dimension.
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Figure 2.3. Psychotropic Regimens by Class.
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Supplemental Figure 2.1. Flowchart from original sample to current analytical sample.

4,360 Enrolled in
STEP-BD
321 did not complete
psychological
assessment at baseline
4,039 completed at
least one psychological
assessment at baseline
301 < 18 years of age
at baseline
3,738 18+ years of age
at baseline

56

Supplemental Figure 2.2. Make up of Psychotropic Medication regimens by Class and Regimen Type.
Monotherapy
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Class 4
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Class 2
Class 1
2 Medications
Class 5
Class 4
Class 3
Class 2
Class 1
Antidepressants

3 Medications
Class 5
Class 4
Class 3
Class 2
Class 1

Mood Stabilizers
Antipsychotics
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Stimulants
Other

4 Medications
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Class 4
Class 3
Class 2
Class 1
5+ Medications
Class 5
Class 4
Class 3
Class 2
Class 1
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20%

40%

60%
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CHAPTER 3
The Bi-directional Relationship between Clinical Net Benefit and Medication Adherence Over
Time in Bipolar Disorder: A Latent Transition Analysis
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ABSTRACT
Objectives: Poor adherence to psychotropic medication is a significant problem for individuals
with bipolar disorder (BD), despite effective therapies. Clinicians report individuals who benefit
from treatment over time become less adherent possibly due to perceptions that treatment is no
longer necessary. Clinical net benefit (CNB) models the experiences individuals have while
being treated for BD. We aimed to test whether transitions between classes of benefit occur over
time and whether these changes are associated with adherence.
Methods: Data come from the Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD), including two years of follow up (Time 1 through 5) of participants aged
18+ years. Latent class analysis identified distinct groups based on the intersection of the three
factors of CNB: psychiatric symptoms (i.e., decrease in episodes), adverse effects (e.g.,
sedation), and functioning (i.e., employment, quality of life). Transitions between classes across
the five time points was determined using latent transition analysis. Adherence was defined as
taking 75% or more of medications as prescribed. Polypharmacy was categorized as number of
medications taken concurrently. Associations between CNB classes, medication regimens,
changes in both over time, and adherence were tested using multiple logistic regression adjusting
for sociodemographic characteristics.
Results: Five classes of CNB were identified at each time point: High, Moderately high,
Moderate, Moderately low and Low. The lower benefit classes transitioned to higher benefit
classes by Time 5 (probability of low benefit at Time 4 to moderate benefit at Time 5=0.86),
while the higher benefit classes transitioned to lower benefit classes by Time 5 (probability of
high benefit at Time 4 to moderately low benefit at Time 5=0.96), but transitioning was not
associated with adherence. Relative to monotherapy, taking less complex regimens (three or
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fewer) while in the higher benefit classes, were associated with lower adherence (e.g., high
benefit at Time 2 taking two medications: OR=0.40; 95% CI: 0.20-0.81), and more complex
regimens (four or more) in the lower benefit classes were associated with higher adherence (e.g.,
moderately low benefit at Time 2 taking five + medications: OR=1.98; 95% CI: 1.05-3.76).
Medication regimens were nonlinearly associated with adherence; taking 3 or fewer medications
were associated with lower adherence (e.g., three medications at Time 2: OR=0.62; 95% CI:
0.46-0.83), taking 4 or more were associated with higher adherence (e.g., five + medications at
Time 2: OR=1.60; 95% CI: 1.12-2.27). Adherence did not differ across classes at each time
point.
Conclusions: Individuals initially experiencing low CNB from their medications transitioned to
higher CNB classes over time, with few participants in the low benefit class by Time 5.
However, individuals receiving high benefit early in the study transitioned to the lower benefit
classes by Time 5. This supports reports from clinicians treating individuals with BD and
suggests psychotherapeutic methods such as psychoeducation are possible ways to increase
adherence in individuals who are experiencing high benefit from their medications.
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INTRODUCTION
Bipolar disorder (BD) is a psychiatric condition characterized by cyclical periods of
mania and depression that affects 1-4% of the United States population.19, 126 It is one of the
leading causes of disability adjusted life years lost in the U.S.12, 14 Due to the debilitating, chronic
and cyclical nature of this illness, symptomatic individuals often experience high levels of
unemployment, disability, in-patient care, medical comorbidities, and increased mortality.16, 127
Psychotropic medications can successfully treat symptoms of BD; for example, among
individuals who are adherent to treatment, only 37% relapse into a depression after one year,126
and lithium monotherapy symptom recurrence rates are 40% in long term follow-up studies.30
These individuals can be treated on an outpatient basis and remain fully functioning members of
the general population. However, between 20 and 60% of individuals with BD are non-adherent
over long term treatment, defined as greater than one year.36 Improving medical management of
BD is key to reducing these negative consequences.
To identify determinants of non-adherence, the perspective of health care providers and
individuals with BD themselves have been examined. Health care providers have identified
aspects of the illness itself, such as feeling well or missing the highs experienced in mania,22, 39, 40
as well as adverse effects 44, 108 and complex regimens of multiple psychotropic medications
taken concurrently (i.e., polypharmacy)127 as predictors of non-adherence. Predictors of nonadherence include negative attitudes toward medication in individuals with BD, for example with
the notion that taking medication for their illness is not normal.47 As individuals achieve
remission, non-adherence may increase because individuals may incorrectly believe that they are
cured or that they did not actually have BD.39
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Providers weigh the benefits versus risks of specific medications when selecting a
treatment regimen for individuals with BD, with symptom remission as the primary goal during
acute episodes.32 As individuals with BD achieve remission, they then enter the maintenance
phase of treatment.16 Guidelines indicate that effective treatments in the acute phase should be
continued in the maintenance phase, with medication adjuncts as other symptoms arise (e.g.,
addition of an antipsychotic or antidepressant if symptoms of depression persist).128 BD is a
chronic disorder and thus adherence to treatment must be maintained indefinitely.32 However, if
during maintenance individuals with BD poorly adhere to their medications, this will lead to
relapse and possible hospitalization.19 It has been found that multiple relapses leads to not only
more episodes, but more severe symptoms during those episodes.33
Three main factors are in play when considering the benefit of a particular medication or
medication regimen for managing BD: psychiatric symptom reduction, low levels of adverse
effects, and high functioning.16 These factors work synergistically, and we have developed a
novel construct of Clinical Net Benefit (CNB) to empirical model these elements, detailed
previously.129
To fully explore the associations between the CNB of medication and adherence,
individuals must be followed over time to test the stability of these associations. Using the fiveyear longitudinal Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD),
and the latent construct of CNB identified in our previous analysis, there are three goals for the
current study: (1) to determine if membership in the CNB classes changes over time, (2) to
determine if there is an association between the classes of CNB and adherence over time, and (3)
to determine if the complexity of medication regimens are associated with adherence over time.
The primary hypothesis is that individuals who initially experience high CNB during treatment
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will become less adherent over time, and that this change in adherence will in turn reduce CNB.
The secondary hypothesis is that as the complexity of medication regimens increases, adherence
to those regimens will decrease over time, regardless of CNB.
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METHODS
Sample
Data come from the STEP-BD study analysis. Eligibility criteria for STEP-BD included
diagnoses of bipolar spectrum disorders (meeting DSM-IV criteria for Bipolar I Disorder,
Bipolar II Disorder, Bipolar Not Otherwise Specified, Cyclothymic Disorder, or Schizoaffective
Disorder Bipolar Subtype), currently in outpatient treatment for BD at a STEP-BD treatment
center, could meet with their clinicians as scheduled for the study and could complete all study
registration forms within three months of registration. STEP-BD was a 5-year randomized
clinical trial (RCT) of individuals treated for bipolar spectrum disorders. It was designed to
simulate the “real world” experiences of treatment for individuals with BD. STEP-BD was not
solely an RCT, as eligible participants could choose to enter either the Randomized Care
Pathways (RCPs) or Standardized Care Pathway (SCP; i.e., treatment as usual). In the RCPs,
participants were randomly assignment to specific medications (i.e., mood stabilizers,
antipsychotics, antidepressants or placebos) to minimize self-selection bias. If initial regimens
were ineffective, participants moved on to subsequent medications, either randomized or
determined by the treating physician, until an effective regimen was reached. Participants
routinely underwent a battery of clinician- and self-administered psychological assessments. In
addition, at each meeting the treating clinicians assessed participants using the Clinical
Monitoring Form (CMF). This form is used as a comprehensive tool for clinicians to use during
follow-up assessments with participants and includes information on mood episodes, medication
use, adverse events, mental status as well as medication adherence.62 Additional details of the
original study design are described elsewhere.52
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STEP-BD enrolled 4,360 participants that met these eligibility criteria for the study. This
analysis excluded 321 participants with less than five STEP-BD assessments (approximately two
years of active study participation), as well as those missing data on all of the components of
CNB, the main exposure for this analysis. In addition 399 participants were excluded who were
less than age 18 at Time 1 and all follow-ups. The final analytic sample size was 3,996
(Supplemental Figure 3.1.). For those with incomplete data, missing values were imputed using
Full Information Maximum Likelihood Estimation.92
Measures
Clinical Net Benefit
CNB incorporates three main effects of treatment on the individual: (1) psychiatric
symptom reduction; (2) adverse effects; and (3) overall functioning. As we indicated in Chapter
1, CNB can be conceptualized as a 3-dimensional construct lying at the intersection of these
axes. Individuals differentially experience these components of treatment, depicted as points in
Figure 1.1. from Chapter 1. Our prior work in Chapter 2 used latent class analysis to empirically
define and quantitatively measure these three dimensions of CNB, using baseline data from
STEP-BD.
In the current study the psychiatric symptoms dimension consisted of the MontgomeryAsberg Depression Rating Scale (MADRS)71 and the Young Mania Rating Scale (YMRS).70
However, due to the small sample size of the Beck Hopelessness Scale relative to the other
measures by Time 5, we removed this assessment from the psychiatric symptoms dimension. The
adverse effects dimension included the measures of memory difficulties, dry mouth, sexual
dysfunction, headache, constipation, sedation, diarrhea, and tremor from the CMF.62 Finally, the
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overall functioning dimension included the Quality of Life Enjoyment and Satisfaction
Questionnaire (QLESQ),72 LIFE Range of Impaired Functioning Tool (LRIFT)73 three indicators
from the Work Impact Form (WIF),52 and past week Global Assessment of Functioning (GAF)79
score from the CMF.
Medication
Supplemental Table 2.3. from Chapter 2 indicates the psychotropic medication families
making up the different regimens that participants were taking at their baseline assessment in
STEP-BD stratified by CNB class. These medications were listed by name (either generic or
brand) on the CMF and were recorded at each of the five assessments. All medications were
identified and grouped into six families: (1) antidepressants, (2) mood stabilizers, (3)
antipsychotics, (4) sedatives/hypnotics, (5) stimulants, and (6) other using the U.S. Food & Drug
Administration National Drug Code Directory.121 Next, a medication count variable was created
indicating whether a participant was taking one (monotherapy), two, three, four or five or more
medications (polypharmacy).
Adherence
The CMF recorded both the milligrams prescribed as well as milligrams missed for each
medication a participant was taking in the past seven days. We calculated adherence by first
identifying whether participants were taking each of their medications as prescribed. Then they
were defined as adherent if 75% or more of their regimens were taken as prescribed. For
example, if individuals were prescribed four medications in their regimens, and if they were fully
adherent to three of the four medications then they would be defined as adherent. Participants
who missed more than 25% of the milligrams prescribed for one or more of the medications in
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their regimens were defined as non-adherent. Adherence defined as missing less than 25% of an
individual’s regimen is consistent with definitions used in STEP-BD studies.83
Standard Care or Randomized Care Pathways
Identification of treatment pathway was also included. STEP-BD was designed to have
both a SCP and three RCPs. The SCP was subsequently categorized into 15 distinct pathways
and the RCP added an additional pathway.62 Approximately 5% (N=195) of participants entered
RCPs at Time 1, therefore we categorized entry into any SCP as one category and any RCP as
the second category.
Demographic Characteristics
Demographic characteristics included age (in years); gender; race (White, Black, and
Other); educational attainment (≤high school, high school diploma or General Education
Development (GED), some college, Bachelor’s degree, and Graduate or professional degree);
current marital status (married or living as though married, divorced or separated, never married,
or widowed); whether participants lived alone; primary residence (private home, group home or
something else); income (greater or less than $50,000); whether participants received Social
Security Disability Insurance (SSDI) and welfare; and employment status (employed,
unemployed, disabled or retired/not in the labor force).
Analytic Approach
Analyses took place in two steps. First, five latent class analyses (LCAs) were conducted,
one at each STEP-BD time point, to determine the number of classes that best fit the sample at
each time point and the predicted probabilities of participant membership in each class at each of
these time points. Second, a Latent Transition Analysis (LTA) was conducted to confirm fit for
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the number of classes at each time point, and to identify participants’ movement between classes
at each time point.
Latent Class Analysis
As described in Chapter 2, the values of the measured indicators for CNB, whether
ordinal or continuous, were dichotomized at all time-points based on the participants’ mean
scores at those time points, with 1=above the mean (better outcomes). Then the number of
distinct latent classes of CNB were determined by conducting the LCA with these measures at
each time point. To determine model fit, we compared the Akaike Information Criterion (AIC),
Bayesian Information Criterion (BIC), Sample-Size Adjusted BIC (BICN), Bootstrapped
Likelihood Ratio Test (BLRT) and Entropy; for each of these indices smaller values, and
Entropy values closest to 1, indicate better relative fit.100 Measures of model fit, prevalence of
class membership and model interpretability were all used to determine the final number of
classes for each time point.125 Finally, most likely class membership at each time point for each
participant was determined from their posterior probabilities identified in these LCAs.97
Latent Transition Analysis
The goal of LTA is to determine whether individuals in one latent class at a particular
time point remain in the same class or transition to another latent class at a subsequent time
point.99 The goal of this analysis is to determine if the CNB classes are static or change over
time; for example, whether individuals in the low benefit class stay in that class over time or
move to higher benefit classes over the course of the trial.
The primary outcome of LTAs are transition probabilities, which are akin to posterior
probabilities of individuals’ class membership generated from an LCA. However, in this case,
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the transition probabilities quantify the likelihood of moving from one class to another across
two time points.99 LTA was used to quantify three aspects of CNB change over time: (1) the best
fitting number of latent classes, (2) the change in values of the measured indicators for each
class, and (3) the probability of participant class membership change at each time point. LCA is a
cross sectional analysis that determines the best fit of the number of classes at each time point.
However, it lacks the additional information regarding probability of participants’ changing
classes over time.99 This can result in different numbers or characteristics of classes. Therefore,
the LCA fit for each time point was confirmed when conducting the LTA using the AIC, BIC,
and BICN.
We also wanted to allow for changes in values in each of the measured indicators at each
time point in addition to participant class membership change. Therefore we did not impose
parameter restrictions to hold the item-response probabilities equal across each time point, which
is often done but not necessary for an LTA.99, 102 For example, a parameter restriction would hold
the MADRS scores in the high benefit class constant over time, and would not give us the
additional insight into whether and which direction MADRS scores changed for the high benefit
class at subsequent time points.
LTA is preferable to other analytical approaches for examining change over time (such as
Repeated Measures Latent Class Analysis) because we not only wanted to determine class
membership at each time point, but also the probability of participants changing class
membership (i.e., transitioning) at each consecutive time point. This additional measure of
transitioning probabilities can most effectively be determined in LTA.99, 102
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Characterizing the Latent Classes of CNB
The demographic characteristics, adherence to medication regimens, types of medication
regimens (i.e., monotherapy versus polypharmacy) and membership in the SCPs or RCPs of the
Time 1 latent classes of CNB were compared using ANOVA for continuous measures and Chisquare analyses for categorical measures.
Predictors of Adherence
To determine predictors of adherence, multiple logistic regression analyses, adjusted for
demographic characteristics, were conducted at each of the five time points. The primary
predictors of adherence were: (1) CNB class membership at each time point from the LCAs, and
(2) number of medications in participants’ regimens at each time point. An additional predictor
was changes in medication regimens from the previous time point.
Descriptive statistics and regressions were calculated using SAS version 9.4 (SAS
Institute Inc.). LCA and LTA were conducted using Mplus version 7.91
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RESULTS
Table 3.1. describes the characteristics of the analytic sample at Time 1. The mean age
was 40 years, 58% were female, and 91% were non-Hispanic white. The majority had an income
less than $50,000, 15% had income from SSDI, and 23% were unemployed. Most participants
lived with at least one other person (73%), and only 1% lived in group homes. Three out of ten
participants took five or more medications. Three quarters of participants were adherent to their
medication regimen at the Time 1 assessment.
Fitting the Latent Class Analysis for Clinical Net Benefit
Model fit statistics indicated that both the four- and five-class models of CNB had
comparable fit across the five time points (Supplemental Table 3.1.). At Time 1 and 4, the AIC,
BICN and BLRT indicated better fit for the five-class model, however, at Time 2 and 3 the BIC,
BICN and Entropy indicated better fit for the four-class model. At Time 5 , both the four- and
five-class models had equivalent fit, although the smallest class prevalence at Time 5 for the
four-class model was 12% (N=322) compared with the smallest class in the five-class model of
only 2% (N=47). The best fitting model when confirmed via the LTA, was the five-class model
at each time point with an AIC, BIC, BICN greater than the four-class model (Supplementary
Table 3.1.). In addition, keeping the number of classes the same at each time point in the LTA
aided the interpretability of class membership change. For example, if prevalence of a class
reduced in size at each time point, and a greater percentage of individuals moved from that class
to a higher benefit class, this may support the notion that over time participants’ CNB increased.
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Characteristics of the Classes of Clinical Net Benefit
Characteristics for the five-class model of CNB are shown in Figure 3.1. The five classes
of CNB were: (1) high benefit (characterized by low psychiatric symptoms, low adverse effects,
and high functioning); (2) moderately high benefit (moderate psychiatric symptoms, low adverse
effects and moderate functioning); (3) moderate benefit (moderate psychiatric symptoms,
moderate adverse effects and moderate functioning); (4) moderately low benefit (high psychiatric
symptoms, low adverse effects and low functioning); and (5) low benefit (high psychiatric
symptoms, moderate adverse effects, and low functioning). Finally, participation in the SCPs
versus the RCPs differed across CNB classes at Time 1. Consistent with the notion that
individuals deriving the most benefit from their current medication regimens would choose to
stay with their current treatment, almost all (99%) of those in the high benefit class elected to
stay in the SCPs; in contrast, 10% of the low benefit class elected to enter an RCP.
Table 3.2. describes the CNB class prevalence and medication adherence for each CNB
class across the five time points as well as the differences in adherence across classes at each
time point. This table illustrates three key points: First, the high benefit class grows substantially
over the 2-year follow up period, from 19% to 36%. These findings are consistent with the fact
that these data are derived from a stepped treatment trial, and it is expected that providers and
participants will make treatment changes to improve the outcomes if participants do not appear
to be benefiting from their current medication regimens.52 Second, they are also consistent with
the notion that individuals who are not deriving much benefit from their medications are more
likely to drop out of the trial. At Time 1, when compared to participants who stayed through
Time 5, those who ever dropped out during the study were less likely to have at least a
Bachelor’s degree (N=258, 24%), less likely to have an income of $50,000 or greater (N=333,
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33%), more likely to be unemployed (N=291, 27%), and more likely to live in a group home
(N=17, 2%). In addition, adherence was less in individuals who ever dropped out of the study
(71% versus 76%) and almost 42% were taking five or more medications compared with 25%
who stayed in the study (Table 3.3.). Medication adherence ranged from 72% to 80% across
classes and time points, and did not differ across classes at each time point, with the exception of
Time 2 (Table 3.2.).
Clinical Net Benefit, Medication Regimens, and Medication Adherence at Time 1
On average, participants were taking 3 (range 1 – 12) medications at Time 1. Medication
adherence did not differ across the classes (χ2=2.96, p=0.57) at Time 1, ranging between 72%
and 77%. However, medication regimens did differ between classes (χ2=75.18, p<0.001). In the
high benefit class over 60% were taking three or fewer medications. In contrast, in the low
benefit class almost 50% were taking four or more medications.
Latent Transition Analysis: Changes in Clinical Net Benefit over Time
Characteristics of the different measured indicators of CNB are also in Figure 3.1. In
general the scores for the three dimensions of CNB remained consistent across time, with the
greatest variability seen in the psychiatric symptoms dimension and the overall functioning
dimension. The values on the three dimensions remained relatively stable for the high benefit, the
moderate benefit and the low benefit classes. The moderately high benefit class saw a decrease in
symptoms over time, while the other two dimensions remained consistent. The moderately low
benefit class saw decreased symptoms and increased functioning over time.
Latent Transition Analysis: Movement between Classes of Clinical Net Benefit over Time
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Table 3.4. illustrates the latent transition probabilities of moving between classes at each
consecutive time point. Each column and each row sum to a probability of 1.0.99 For example,
the transitions between Time 1 and 2 illustrate that most of the movement between classes
occurred among the moderate, moderately high and high benefit classes. For example, there was
an 80% probability of moving from the moderate to the moderately high benefit class, and an
85% probability of moving from the moderately high to the high benefit class. In contrast, the
moderately low and low benefit classes were generally stable, with about a 75% probability of
remaining in these classes. Somewhat unexpected, the high benefit class had a 79% probability
of transitioning to the moderate benefit class; this represents the precariousness of ideal
outcomes for this population.
From Time 2 to 3, most of the movement between classes happened with the moderately
high to moderately low benefit classes. The probability of moving to a lower benefit class ranged
from 81% to 86% for these three classes. The high benefit class remained stable with a 93%
probability of remaining in this class. The low benefit class was the only class that had an
increase in benefit, with a probability of 84% moving to the moderately high benefit class.
Movement from Time 3 to 4 was most notable for the increase in benefit of the two lower
benefit classes, with an 85% probability of the low benefit class moving to the high benefit class,
and an 88% probability of the moderately low benefit class moving up to the moderate benefit
class. The three highest classes had probabilities of between 84% and 89% movement to a lower
benefit class.
Finally, from Time 4 to 5 the three lowest benefit classes had probabilities between 86%
and 92% of moving to higher benefit classes However, the two highest benefit classes at Time 4
had probabilities of moving to lower benefit classes at Time 5; the high benefit class had a 96%
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probability of moving to the moderately low benefit class and the moderately high benefit class
had a 92% probability of moving to the low benefit class.
Additionally, change in a participant’s regimen was associated with movement between
classes at Time 4 and 5 with 34% odds of moving to a lower benefit class at Time 4, and a 28%
odds of moving to a lower class at Time 5. In addition, a regimen change was associated with
32% odds of moving to a higher benefit class at Time 5 (Figure 3.2.).
Changes in Clinical Net Benefit, Medication Regimens, and Medication Adherence
Table 3.5. shows the relative odds of adherence across the five CNB classes over time. At
Time 1, class membership was not associated with adherence. Over time, however, several
patterns emerged in the relationship between CNB and adherence. Relative to the high benefit
class, most classes had lower adherence over time. For example, compared to the high benefit
class, the low and moderately low benefit classes had approximately 30% lower odds of
adherence at Time 2, a trend that continued to Time 4. At Time 5, the moderately high benefit
class had 24% lower odds of adherence when compared with the high benefit class.
Across all time points, there was a non-linear relationship between polypharmacy and
adherence. Compared to monotherapy, taking three or fewer medications was associated with
lower adherence, however taking four or more medications was associated with higher
adherence. At Time 2, 3 and 5 taking two or three medications was associated with lower
adherence as compared to monotherapy. However, changing medication regimens, including
adding, removing or changing a medication, was not associated with adherence over time (Time
2: OR=0.86; 95% CI: 0.72-1.03; Time 3: OR=0.95; 95% CI: 0.78-1.16; Time 4: OR=1.07; 95%
CI: 0.87-1.32; Time 5: OR=0.84; 95% CI: 0.68-1.04).
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Post-hoc analysis
Medication regimens were significantly different between the classes at Time 1,
participants in the low benefit class were the most likely to be taking complex polypharmacy
(four or more medications). Additionally, at Time 1 adherence across all classes of benefit did
not differ. Therefore to further examine the association between classes of CNB and their
medication regimens with adherence, a post hoc analysis of the association between medication
regimens and adherence stratified by class was conducted (Table 3.6.). The post hoc analysis
revealed that the high benefit class had a trend of lower odds of adherence over time, reaching
significance at Time 2, 3 and 5, when prescribed less complex regimens (three medications or
less). The low benefit class had a trend of higher odds of adherence over time, with the odds
reaching significance at Time 1 to 3 with more complex regimens of 4 or more medications.
Due to the high rates of dropout by Time 5, we also compared the demographic
characteristics at Time 1 of participants who stayed in the study through Time 5 to those who
ever dropped out of the study before Time 5. Those who dropped out of the study were different
from those who stayed in almost all demographic and study characteristics. In addition to the
differences noted above, individuals who dropped out of the study were also less adherent, taking
more medications concurrently, were less likely to be in a RCP, but were actually more likely to
be in a higher benefit class (Table 3.6.).
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DISCUSSION
The primary finding from this study is that membership in the classes of CNB changes
over time even in this sample of BD patients being actively treated. On a positive note,
participants who were receiving less benefit from their medications at the start of the trial
transitioned to classes of increased benefit over time. This is anticipated, as the purpose of a
stepped-treatment trial is to increase the benefit participants are receiving from their treatment.52
However, the initial higher benefit classes transitioned to lower benefit classes over time. The
relationship between changes in CNB and changes in adherence is complex even during this
relatively short 2-year period. Finally, toward the conclusion of the trial, changes to medication
regimens were associated with both positive and negative changes to CNB. These findings
broadly support clinicians’ reported experiences while working with individuals with BD. The
individuals who benefit from their treatment become less adherent over the long term, leading to
less benefit from their medications, likely due to their belief that they have been cured, or never
had BD.130
Medication regimens were associated with adherence across time, as expected, although
this relationship was bi-directional. Our post hoc analysis of the association between medication
regimens and adherence stratified by class revealed that the high benefit class had lower odds of
adherence over time. This provides further support that individuals with higher benefit over time
become less adherent, leading to less benefit from their treatment.41
A notable finding was that the low benefit class had a trend of higher odds of adherence
over time in participants who were taking more complex regimens of 4 or more medications. It is
highly likely that only when it was absolutely necessary did participants’ treating psychiatrists
prescribe complex polypharmacy, taking into account that under-dosing has been associated with
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higher non-adherence.16 This may also be due to differential drop out, because individuals who
dropped out of the study were taking more complex polypharmacy regimens than those who
remained. Nevertheless, this finding adds support to previous analyses suggesting that adherence
likely results in better outcomes because these medications are effective treatments of BD.30, 126
Overall adherence across classes slightly increased over time although at each time point
adherence across classes was not different, with the exception of Time 2. This indicates that
individuals who are receiving low benefit of their medication had the same prevalence of
adherence as those with high benefit from their medication. This lends support to the theory of
the association between adherence and individuals’ perspectives of necessity versus concerns of
their treatment.43 Although participants are not greatly benefiting from their medications at Time
1, their high levels of adherence are likely associated with their movement to higher benefit
classes.
Strengths and Limitations of the Study
Strengths of this study include the use of a randomized controlled trial that was large and
actively followed individuals at multiple time points over two years. In addition to the
randomized pathways, treatment as usual was also allowed which more closely replicated the
circumstances in naturalistic studies. The wealth of rigorous psychological assessments allowed
for detailed LCAs at each time point. Detailed information on psychotropic medications gathered
at each time point allowed us to determine the number and make up of medication regimens
prescribed to participants in the study. The inclusion criteria allowing for bipolar spectrum
disorders, comorbidities, different stages of the illness, and continuation of current medications
increased the generalizability of the results. Finally, the use of both LCA to identify the
indicators of CNB, and LTA to quantify the likelihood of moving from one class to another
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across time points gave us empirical results rather than a reliance on theoretical
conceptualizations.
These results must be tempered by the limitations of this study. The primary limitation is
that nearly one in three participants dropped out of the trial by Time 5, and this attrition was
differential based on medication regimen and Time 1 adherence. These individuals were less
educated, had lower socioeconomic status, and were taking more complex medication regimens
than individuals who remained in the study. However, this is a comparable rate of retention with
other longitudinal RCTs.131, 132 Despite the dropout rates, by Time 5 the sample size was almost
2,800, which indicates a very high level of power for conducting latent analysis techniques.103
Additionally, indications of adherence by the treating clinician were not confirmed by pill bottle
counts or blood serum levels.38 In large clinical trials, this is a common measurement of
adherence, which makes comparison between studies easier.47 Finally, participant perceptions of
their illness, medication treatment, and their preferences for treatment were not assessed in this
study (e.g. Beliefs about Medicines Questionnaire).63 Therefore we can only infer participants’
perceptions of the benefit they are receiving from their medications by their symptom and
functional outcomes used in the psychological assessments.
Conclusions
Our findings support continued collaborative, person-centered care to optimize adherence
for individuals with BD. Consistent with practitioners’ experiences, we found that individuals
who initially benefit from their medication are likely to become less adherent over time, possibly
due in part to remission and the concept of being cured.46 This also suggests that becoming well
is not as difficult as staying well. This is surprising to find in a study such as STEP-BD which is
designed as the “best-case” scenario with regards to support, and in which participants agreed
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upon participation. Our findings were also consistent with the reported experiences of individual
being treated for BD that necessity versus concerns are associated with adherence.43 Individuals
were adherent despite low benefit from their medications, and if they maintained adherence were
likely to experience an increase in benefit from their medications over time. Education regarding
the course of BD as well as psychotherapy with a focus on shared decision making and positive
alliances between individuals and their practitioners have been suggested as a way to support
adherence in populations with BD.45, 133 However, this may need to play a greater role in helping
individuals who are successfully recovering from BD symptoms and benefiting from their
medications as well. Further insight into whether adherence and CNB is maintained in a
naturalistic setting can add to our results, which may be limited due to active study participation.
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Table 3.1. Time 1 Demographic Characteristics of the full sample and by clinical net benefit class. Includes between group significant differences using ANOVA
or chi-square analyses.

N (%)
Age (M, SD)
Female - no./total no. (%)
Race - no./total no. (%)
White
African American
Other
Education - no./total no. (%)
Less than High School
High School/GED
Some College
Bachelor’s Degree
Graduate Degree
Marital Status - no./total no. (%)
Currently Married
Previously Married
Never Married
Widowed
Lives Alone - no./total no. (%)
Income - no./total no. (%)
<$50,000
$50,000 +
SSDI - no./total no. (%)
Welfare - no./total no. (%)
Employment - no./total no. (%)
Employed
Unemployed
Disabled
Other
Type of Residence - no./total no. (%)
Private Home
Group Home
Other
Adhere - no./total no. (%)

Full Sample

High Benefit

Moderate Benefit

744 (18.62)
41.99 (14.37)
363/710 (51.13)

Moderately High
Benefit
940 (23.52)
39.01 (13.58)
508/895 (56.76)

Low Benefit

410 (10.26)
40.99 (13.04)
250/397 (62.97)

Moderately Low
Benefit
1,450 (36.29)
39.84 (11.54)
818/1383 (59.15)

3,996
40.25 (12.82)
2,206/3814 (57.84)
2725/3008 (90.59)
176/3008 (5.85)
107/3008 (3.56)

456/510 (89.41)
32/510 (6.27)
22/510 (4.31)

113/3692 (3.06)
553/3692 (14.98)
1398/3692 (37.87)
979/3692 (26.52)
649/3692 (17.58)

P value

659/718 (91.78)
37/718 (5.15)
22/718 (3.06)

277/299 (92.64)
10/299 (3.34)
12/299 (4.01)

1028/1144 (89.86)
79/1144 (6.91)
37/1144 (3.23)

305/337 (90.50)
18/337 (5.34)
14/337 (4.15)

16/677 (2.36)
85/677 (12.56)
196/677 (28.95)
206/677 (30.43)
174/677 (25.70)

22/873 (2.52)
114/873 (13.06)
343/873 (39.29)
251/873 (28.75)
143/873 (16.38)

5/383 (1.31)
45/383 (11.75)
132/383 (34.46)
113/383 (29.50)
88/383 (22.98)

59/1343 (4.39)
232/1343 (17.27)
550/1343 (40.95)
318/1343 (23.68)
184/1343 (13.70)

11/416 (2.64)
77/416 (18.51)
177/416 (42.55)
91/416 (21.88)
60/416 (14.42)

1381/3780 (36.53)
954/3780 (25.24)
1385/3780 (36.64)
60/3780 (1.59)
1008/3775 (26.70)

279/707 (39.46)
145/707 (20.51)
275/707 (38.90)
8/707 (1.13)
175/707 (24.75)

288/886 (32.51)
204/886 (23.02)
374/886 (42.21)
20/886 (2.26)
254/885 (28.70)

163/393 (41.48)
93/393 (23.66)
134/393 (34.10)
3/393 (0.76)
108/394 (27.41)

472/1368 (34.50)
410/1368 (29.97)
469/1368 (34.28)
17/1368 (1.24)
370/1364 (27.13)

179/426 (42.02)
102/426 (23.94)
133/426 (31.22)
12/426 (2.82)
101/425 (23.76)

2108/3484 (60.51)
1376/3484 (39.49)
554/3642 (15.21)
67/3642 (1.84)

346/648 (53.40)
302/648 (46.60)
69/668 (10.33)
6/668 (0.90)

499/816 (61.15)
317/816 (38.85)
110/859 (12.81)
4/859 (0.47)

193/363 (53.17)
170/363 (46.83)
54/377 (14.32)
7/377 (1.86)

829/1261 (65.74)
432/1261 (34.26)
238/1325 (17.96)
36/1325 (2.72)

241/396 (60.86)
155/396 (39.14)
83/413 (20.10)
14/413 (3.39)

1747/3754 (46.54)
874/3754 (23.28)
665/3754 (17.71)
468/3754 (12.47)

412/697 (59.11)
119/697 (17.07)
63/697 (9.04)
103/697 (14.78)

427/880 (48.52)
211/880 (23.98)
126/880 (14.32)
116/880 (13.18)

190/395 (48.10)
81/395 (20.51)
63/395 (15.95)
61/395 (15.44)

567/1358 (41.75)
340/1358 (25.04)
313/1358 (23.05)
138/1358 (10.16)

151/424 (35.61)
123/424 (29.01)
100/424 (23.58)
50/424 (11.79)

3543/3705 (95.63)
40/3705 (1.08)
122/3705 (3.29)
2,468/3282 (75.20)

650/680 (95.59)
3/680 (0.44)
27/680 (3.97)
456/597 (76.38)

829/875 (94.74)
15/875 (1.71)
31/875 (3.54)
555/734 (75.61)

357/382 (93.46)
5/382 (1.31)
20/382 (5.24)
297/387 (76.74)

1304/1350 (96.59)
13/1350 (0.96)
33/1350 (2.44)
857/1145 (74.85)

403/418 (96.41)
4/418 (0.96)
11/418 (2.63)
303/419 (72.32)

452 (11.31)
40.55 (11.87)
267/429 (62.24)

<0.001
<0.001
0.356

<0.001

<0.001

0.260
<0.001

<0.001
<0.001
<0.001

0.047
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0.565

Medication Regimens - no./total no. (%)
Monotherapy
Two Medications
Three Medications
Four Medications
Five + Medications
Pathway - no./total no. (%)
Standardized Care
Randomized Care

<0.001
631/3977 (15.87)
875/3977 (22.00)
760/3977 (19.11)
519/3977 (13.05)
1,192/3977 (29.97)

173/744 (23.25)
191/744 (25.67)
115/744 (15.46)
71/744 (9.54)
194/744 (26.08)

136/938 (14.50)
210/938 (22.39)
180/938 (19.19)
118/938 (12.58)
294/938 (31.34)

51/406 (12.56)
96/406 (23.65)
78/406 (19.21)
67/406 (16.50)
114/406 (28.08)

214/1445 (14.81)
309/1445 (21.38)
288/1445 (19.93)
194/1445 (13.43)
440/1445 (30.45)

57/444 (12.84)
69/444 (15.54)
99/444 (22.30)
69/444 (15.54)
150/444 (33.78)

3418/3613 (94.60)
195/3613 (5.40)

650/658 (98.78)
8/658 (1.22)

810/830 (97.59)
20/830 (2.41)

397/408 (97.30)
11/408 (2.70)

1156/1269 (91.10)
113/1269 (8.90)

405/448 (90.40)
43/448 (9.60)
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<0.001

Table 3.2. Class prevalence and prevalence of adherence at each time point, with indications of differences in
adherence across classes at each time point from chi-square analyses.

N (%)
Class (N, %)
High Benefit Class
Adherence
Moderately High Benefit
Adherence
Moderate Benefit
Adherence
Moderately Low Benefit
Adherence
Low Benefit
Adherence
P-value

Time 1
3996

Time 2
3530

Time 3
3240

Time 4
2988

Time 5
2785

744 (18.62)
456 (76.38)
940 (23.52)
555 (75.61)
410 (10.26)
297 (76.74)
1450 (36.29)
857 (74.85)
452 (11.31)
303 (72.32)
0.565

590 (16.71)
429 (80.94)
1204 (34.11)
813 (77.06)
367 (10.40)
260 (76.02)
934 (26.46)
606 (73.54)
435 (12.32)
308 (74.04)
0.023*

776 (23.95)
535 (78.45)
433 (13.36)
323 (80.55)
443 (13.67)
324 (76.24)
1277 (39.41)
871 (75.35)
311 (9.60)
225 (75.76)
0.213

1174 (39.29)
848 (79.55)
767 (25.67)
538 (76.42)
311 (10.41)
236 (78.15)
496 (16.60)
337 (74.56)
240 (8.03)
175 (76.42)
0.239

1003 (36.01)
723 (79.54)
1033 (37.09)
731 (76.23)
372 (13.36)
272 (77.49)
332 (11.92)
244 (76.25)
45 (1.62)
34 (79.07)
0.493
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Table 3.3. Characteristics at Time 1 of individuals who remained in the trial for at least five time points compared
with those who ever dropped out before Time 5. Includes between group significance using ANOVA and chi-square
analyses.

Time 1
N, %
Age (M, SD)
Female - no./total no. (%)
Race - no./total no. (%)
White
African American
Other
Education - no./total no. (%)
Less than High School
High School/GED
Some College
Bachelor’s Degree
Graduate Degree
Marital Status - no./total no. (%)
Currently Married
Previously Married
Never Married
Widowed
Lives Alone - no./total no. (%)
Income - no./total no. (%)
<$50,000
>=$50,000
SSDI - no./total no. (%)
Welfare - no./total no. (%)
Employment Status - no./total no. (%)
Employed
Unemployed
Disabled
Other
Residence - no./total no. (%)
Private Home
Group Home
Other
Adherence - no./total no. (%)
Pathway - no./total no. (%)
Standard Care
Randomized Care
Medication Regimens - no./total no. (%)
Monotherapy
Two Medications
Three Medications
Four Medications
Five + Medications

Time 5
Ever Dropped out Stayed
1211 (30.31)
2785 (69.69)
38.51 (12.95)
40.95 (12.71)
628/1104 (56.88)
1578/2710 (58.23)
950/1066 (89.12)
81/1066 (7.60)
35/1066 (3.28)

P-value
<0.001
0.446
0.009

1775/1942 (91.40)
95/1942 (4.89)
72/1942 (3.71)
<0.001

52/1079 (4.82)
173/1079 (16.03)
443/1079 (41.06)
258/1079 (23.91)
153/1079 (14.18)

61/2613 (2.33)
380/2613 (14.54)
955/2613 (36.55)
721/2613 (27.59)
496/2613 (18.98)

340/1089 (31.22)
304/1089 (27.92)
426/1089 (39.12)
19/1089 (1.74)
283/1086 (26.06)

1041/2691 (38.68)
650/2691 (24.15)
959/2691 (35.64)
41/2691 (1.52)
725/2689 (26.96)

666/999 (66.67)
333/999 (33.33)
143/1061 (13.48)
25/1061 (2.36)

1442/2485 (58.03)
1043/2485 (41.97)
411/2581 (15.92)
42/2581 (1.63)

476/1079 (44.11)
291/1079 (26.97)
181/1079 (16.77)
131/1079 (12.14)

1271/2675 (47.51)
583/2675 (21.79)
484/2675 (18.09)
337/2675 (12.60)

1022/1083 (94.37)
17/1083 (1.57)
44/1083 (4.06)
546/768 (71.09)

2521/2622 (96.15)
23/2622 (0.88)
78/2622 (2.97)
1922/2514 (76.45)

871/881 (98.86)
10/881 (1.14)

2547/2732 (93.23)
185/2732 (6.77)

203/1211 (16.76)
234/1211 (19.32)
166/1211 (13.71)
106/1211 (8.75)
502/1211 (41.45)

428/2766 (15.47)
641/2766 (23.17)
594/2766 (21.48)
413/2766 (14.93)
690/2766 (24.95)

<0.001

0.570
<0.001

0.062
0.137
0.009

0.041

0.003
<0.001

<0.001
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Classes - no./total no. (%)
High Benefit
Moderately High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

<0.001
258/1211 (21.30)
316/1211 (26.09)
84/1211 (6.94)
471/1211 (38.89)
82/1211 (6.77)

486/2785 (17.45)
624/2785 (22.41)
326/2785 (11.71)
979/2785 (35.15)
370/2785 (13.29)
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Table 3.4. a-d. Probabilities of transitions between latent classes of CNB for each pair of time points. Bold indicates
highest probability of movement to subsequent class.
a.

Time 2

Time 1
High Benefit
Moderately High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

High Benefit
0.087
0.849
0.005
0.009
0.064

b.
Time 2
High Benefit
Moderately High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

Time 3

c.
Time 3
High Benefit
Moderately High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

Time 4

d.
Time 4
High Benefit
Moderately High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

Time 5

0.932
0.000
0.058
0.000
0.080

0.007
0.003
0.079
0.039
0.850

0.026
0.000
0.000
0.874
0.011

Moderately
High Benefit
0.000
0.000
0.805
0.027
0.086

Moderate
Benefit
0.788
0.108
0.016
0.206
0.025

Moderately
Low Benefit
0.084
0.000
0.062
0.721
0.049

Low Benefit
0.041
0.043
0.112
0.038
0.776

0.025
0.100
0.026
0.015
0.840

0.003
0.812
0.001
0.036
0.017

0.040
0.000
0.849
0.093
0.000

0.000
0.087
0.066
0.855
0.062

0.894
0.033
0.000
0.113
0.000

0.088
0.044
0.000
0.835
0.100

0.000
0.050
0.880
0.000
0.025

0.012
0.871
0.041
0.014
0.025

0.006
0.038
0.918
0.000
0.045

0.003
0.038
0.019
0.078
0.863

0.957
0.000
0.063
0.048
0.052

0.008
0.924
0.000
0.000
0.030
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Table 3.5. Results from logistic regression analyses with class membership, medication regimens and medication regimen change predicting adherence at each
time point.

Predicting Adherence at

Time 1
(OR, 95% CI)

Time 2
(OR, 95% CI)

Time 3
(OR, 95% CI)

Time 4
(OR, 95% CI)

Time 5
(OR, 95% CI)

Class (ref=High Benefit
Class)
Moderately High Benefit
0.99 (0.74-1.31)
0.81 (0.61-1.09)
1.08 (0.77-1.52)
0.84 (0.65-1.09)
0.76 (0.59-0.97)*
Moderate Benefit
1.16 (0.83-1.64)
0.77 (0.54-1.12)
0.95 (0.68-1.32)
0.92 (0.65-1.31)
0.79 (0.57-1.10)
Moderately Low Benefit
0.91 (0.70-1.19)
0.80 (0.62-1.03)‡
0.79 (0.59-1.06)
0.77 (0.55-1.09)
0.69 (0.51-0.93)*
Low Benefit
0.87 (0.63-1.21)
0.75 (0.52-1.08)
0.70 (0.48-1.01)‡
0.87 (0.37-2.05)
0.71 (0.50-0.99)*
Medication Regimen (ref=1)
Two Medications
0.86 (0.65-1.12)
0.94 (0.67-1.31)
0.69 (0.51-0.91)** 0.51 (0.37-0.71)**
0.58 (0.40-0.85)**
Three Medications
0.63 (0.48-0.82)**
0.62 (0.46-0.83)** 0.53 (0.38-0.74)**
0.71 (0.50-0.99)*
0.49 (0.34-0.72)**
Four Medications
1.24 (0.83-1.84)
1.17 (0.76-1.80)
1.41 (1.01-1.96)*
1.45 (1.01-2.09)*
1.43 (0.97-2.11)‡
Five + Medications
1.28 (0.93-1.75)
1.04 (0.69-1.57)
1.60 (1.12-2.27)** 0.88 (0.61-1.27)
1.44 (0.99-2.09)‡
0.86 (0.72-1.03)
0.95 (0.78-1.16)
1.07 (0.87-1.32)
0.84 (0.68-1.04)
Regimen Change (ref=No)
Values are adjusted for care pathway, age, gender, education, marital status, income, SSDI, Welfare, Employment, Residence
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Table 3.6. Post-hoc analysis results: Odds of adherence predicted by medication regimens stratified by class for each time point.

Predicting Adherence at

Time 1
(OR, 95% CI)

Time 2
(OR, 95% CI)

Time 3
(OR, 95% CI)

Time 4
(OR, 95% CI)

Time 5
(OR, 95% CI)

High Benefit
Regimen (ref=Monotherapy)
Two medications
0.70 (0.39-1.24)
0.91 (0.56-1.49)
0.40 (0.20-0.81)*
0.31 (0.16-0.59)**
0.61 (0.34-1.08)‡
Three medications
0.63 (0.33-1.23)
0.70 (0.42-1.17)
0.36 (0.16-0.80)*
0.35 (0.17-0.70)**
0.46 (0.25-0.85)*
Four Medications
1.30 (0.55-3.10)
0.85 (0.32-2.28)
0.70 (0.29-1.67)
1.30 (0.68-2.48)
0.94 (0.44-2.01)
Five + Medications
1.05 (0.47-2.34)
1.37 (0.44-4.26)
1.68 (0.52-5.47)
1.15 (0.61-2.19)
0.71 (0.35-1.42)
Moderately High Benefit
Regimen (ref=Monotherapy)
Two medications
1.01 (0.58-1.77)
0.67 (0.25-1.81)
0.71 (0.36-1.41)
0.92 (0.50-1.67)
0.56 (0.35-0.89)*
Three medications
0.76 (0.43-1.35)
0.70 (0.43-1.15)
0.51 (0.19-1.40)
0.80 (0.40-1.60)
0.76 (0.42-1.37)
Four Medications
1.37 (0.69-2.71)
1.41 (0.76-2.63)
0.78 (0.25-2.46)
1.28 (0.61-2.73)
2.71 (1.31-5.62)**
Five + Medications
0.42 (0.14-1.26)
1.52 (0.77-3.00)
2.30 (1.08-4.88)*
2.47 (1.15-5.33)*
2.09 (0.90-4.86)‡
Moderate Benefit
Regimen (ref=Monotherapy)
Two medications
0.94 (0.36-2.47)
0.73 (0.23-2.28)
0.52 (0.17-1.55)
1.31 (0.33-5.27)
0.37 (0.10-1.32)
Three medications
0.87 (0.31-2.39)
0.39 (0.12-1.27)
0.51 (0.17-1.51)
0.65 (0.16-2.63)
0.64 (0.18-2.35)
Four Medications
1.44 (0.46-4.48)
2.33 (0.61-8.98)
0.90 (0.28-2.91)
2.23 (0.47-10.65)
0.82 (0.21-3.17)
Five + Medications
1.14 (0.41-3.14)
1.11 (0.33-3.74)
1.38 (0.45-4.27)
1.38 (0.36-5.30)
1.23 (0.32-4.65)
Moderately Low Benefit
Regimen (ref=Monotherapy)
Two medications
0.80 (0.50-1.27)
1.08 (0.61-1.91)
1.59 (0.62-4.12)
-0.55 (0.33-0.91)*
Three medications
0.84 (0.48-1.47)
0.78 (0.31-1.96)
-0.54 (0.34-0.85)**
0.58 (0.34-0.98)*
Four Medications
-1.67 (0.94-2.94)‡
2.62 (1.28-5.35)** 2.02 (1.06-3.84)*
2.48 (0.87-7.06)‡
Five + Medications
0.85 (0.49-1.46)
0.96 (0.54-1.70)
2.16 (0.80-5.86)
-1.98 (1.05-3.76)*
Low Benefit
Regimen (ref=Monotherapy)
Two medications
1.12 (0.42-2.99)
1.30 (0.45-3.77)
1.25 (0.30-5.09)
1.93 (0.25-15.23)
-Three medications
0.61 (0.25-1.51)
0.77 (0.27-2.18)
2.23 (0.56-8.87)
1.09 (0.17-7.12)
-Four Medications
1.43 (0.52-3.92)
1.34 (0.44-4.10)
2.71 (0.42-17.66)
-3.67 (0.88-15.39)‡
Five + Medications
2.53 (0.70-9.10)
4.27 (0.69-26.40)
-2.35 (0.91-6.08)‡
2.60 (0.89-7.64)‡
Values are adjusted for care pathway, age, gender, education, marital status, income, SSDI, Welfare, Employment, Residence
-- Sample size too small for analysis
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Supplemental Table 3.1. Fit statistics for 4 and 5 class LCAs and 4 and 5 class LTA.
AIC

BIC

BICN

BLRT

Entropy

Smallest Class
(%)

Time 1
4 classes
48234.41
48605.7
48418.23
408.883
0.728
11.7
5 classes
48156.63
48622.32
48387.18
107.781
0.646
12.3
Time 2
4 classes
41246.95
41610.94
41423.47
305.253
0.689
12
5 classes
41180.28
41636.81
41401.68
96.668
0.611
12.4
Time 3
4 classes
36059.46
36418.38
36230.91
323.342
0.676
11
5 classes
36044.69
36494.85
36259.72
44.776
0.602
10.6
Time 4
4 classes
31421.84
31775.98
31588.51
288.119
0.65
11.5
5 classes
31376.04
31820.21
31585.09
75.799
0.593
8.2
Time 5
4 classes
28224.47
28574.46
28387
172.43
0.598
11.6
5 classes
28175.8
28614.77
28379.64
78.677
0.624
1.7
LTA
4 classes
175454.4
177537.5
176485.8
---5 classes
174223.6
176954.9
175575.8
---AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; BICN: Sample-Size Adjusted
BIC; BLRT: Bootstrapped Likelihood Ratio Test
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Figure 3.1. Classes of CNB over the course of the study. From left to right, Time 1 (a), 2 (b), 3 (c), 4 (d) and 5 (e) at the bottom.
Predicted Probability of Symptom
Endorsement
0=Poor to 1=Better Outcomes

a

b

1
0.8

0.8

0.6

0.6

0.4

0.4

0.2

0.2

0

0

High (18.6%)

Moderately High (23.5%)

Moderately Low (36.3%)

Low (11.3%)

Moderate (10.3%)

c

High (16.7%)

Moderately High (34.1%)

Moderately Low (26.5%)

Low (12.3%)

High (39.3%)

Moderately High (25.7%)

Moderately Low (16.6%)

Low (8.0%)

Moderate (10.4%)

d
1

1

0.8

0.8

0.6

0.6

0.4

0.4

0.2

0.2

0

0

High (24.0%)

Moderately High (13.4%)

Moderately Low (39.4%)

Low (9.6%)

e
Predicted Probability of Symptom
Endorsement
0=Poor to 1=Better Outcomes

Predicted Probability of Symptom
Endorsement
0=Poor to 1=Better Outcomes

1

Moderate (13.7%)

Moderate (10.4%)

1
0.8
0.6
0.4
0.2
0

High (36.0%)

Moderately High (37.1%)

Moderately Low (11.9%)

Low (1.6%)

Moderate (13.4%)
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Figure 3.2. Medication regimen change and the subsequent odds of changing to an increased or decreased
CNB class at each time point.
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Supplemental Figure 3.1. Flowchart from original sample to current analytical sample.

4,360 enrolled in
STEP-BD
321 did not complete
psychiatric assessment
at Time 1
4,039 completed at
least one psychiatric
assessment at Time 1
399 < 18 years of age
at Time 1 and followups
3,996 18+ years of age
at Time 1
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CHAPTER 4
The Bi-directional Relationship between Clinical Net Benefit and Medication Adherence Long
Term in Bipolar Disorder: A Latent Transition Analysis
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ABSTRACT
Objectives: Treatment for bipolar disorder (BD) is chronic, yet medication adherence is poor.
Research into the long-term efficacy of psychotropic medication treatment of BD largely focuses
on remission or relapse rather than adherence. Long-term studies rarely follow individuals more
than two years, which does not accurately represent treatment of BD that may extend 20 years.
Using the empirically quantified latent construct of clinical net benefit (CNB) and a three-year
naturalistic follow-up, or treatment as usual, of individuals with BD, we tested whether classes of
CNB changed over time and were associated with adherence to the same extent as occurred
during two years of the active participation.
Methods: Data come from the Systematic Treatment Enhancement Program for Bipolar
Disorder’s (STEP-BD) 3-year naturalistic follow up (Time 5 to 8) of participants aged 18+ years,
following two years of active participation. Latent class analysis identified distinct groups based
on the intersection of the three factors of CNB: psychiatric symptoms (i.e., decrease in episodes),
adverse effects (e.g., sedation), and functioning (i.e., employment, quality of life). Transitions
between classes across the four time points was determined using latent transition analysis.
Adherence was defined as taking 75% or more of medications as prescribed. Polypharmacy was
categorized as number of medications taken concurrently. Associations between CNB classes,
medication regimens, changes in both over time, and adherence were tested using multiple
logistic regression adjusting for sociodemographic characteristics.
Results: Four classes of CNB were identified at each time point: High, Moderate, Moderately
low and Low. The lower benefit classes transitioned to higher benefit classes at each time point
(e.g., probability of low benefit at Time 5 to moderate benefit at Time 6=0.93), while the higher
benefit classes transitioned to lower benefit classes by Time 8 (e.g., probability of high benefit at
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Time 7 to moderately low benefit at Time 8=0.79). Medication regimens were associated with
both positive and negative changes in class (e.g., Time 7 taking 5+ medications predicted Time 8
higher class: OR=3.75; 95% CI: 1.07-13.17). Neither the CNB classes, nor transitioning between
them were associated with adherence, and adherence did not differ across classes at each time
point. Relative to monotherapy, taking less complex regimens (three or fewer) was associated
with lower adherence across Time 5 to 7 (e.g., Time 5 taking two medications: OR=0.32; 95%
CI: 0.14-0.74).
Conclusions: Individuals experiencing low CNB from their medications at Time 5 transitioned
to higher CNB classes over time, while individuals receiving high benefit transitioned to the
lower benefit classes by Time 8. This is consistent with our findings from the active participation
phase of STEP-BD. However, class membership was not associated with adherence, and
adherence was equivalent across classes and time points. This suggests that although CNB does
represent experiences people are having during treatment, it does not explain why individuals
adhere to their medications. Using CNB, individuals with low benefit from treatment can be
identified by their clinicians and focus together on changing their treatment to increase their
benefit, with high probability of success due to their adherence.
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INTRODUCTION
Bipolar disorder (BD) only affects 4% of adults,126 but is one of the leading causes of
disability adjusted life years lost in the U.S.12 The first line treatment for individuals
experiencing onset or acute episodes of BD is psychotropic medication.16 Due the chronic and
cyclical nature of BD, medication adherence is not only necessary but must often be maintained
indefinitely. However, medication adherence to treatment is a continuing problem for individuals
with BD, ranging from 20-70% during long term treatment (i.e., greater than one year).36, 37 Nonadherence is associated with increasing numbers and severity of episodes leading to increased
health care costs, disability and mortality.134, 135
There are multiple factors believed to influence medication non-adherence for individuals
with BD. One factor is adverse effects from medications (e.g., sedation, sexual dysfunction).43, 44
However, the prevalence of adherence has remained relatively consistent even with the advent of
newer generation medications (i.e., atypical antipsychotics, selective serotonin reuptake
inhibitors, and antiepileptics) with fewer severe adverse effects, compared with older
medications (i.e., monoamine oxidase inhibitors and typical antipsychotics).43 Another factor
concerns the complexity of medication regimens (taking more than one medication concurrently
or polypharmacy). Baldessarini, et al. (2008), found that 40% of individuals with BD covered by
a large commercial health care plan were prescribed polypharmacy (defined as two or more
psychotropic medications concurrently) between the years of 2001 and 2005.127 Finally, aspects
of the illness itself (“feeling well”, “missing highs”) have also been identified as possibly
associated with lower levels of adherence.22 Specifically, individuals with BD indicate that nonadherence is related to their need to find balance between necessity of treatment versus concerns
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about medications.43 In sum, non-adherence has multiple, intersecting determinants, and novel
methodological approaches are needed to examine this complex relationship.
While the imperative of clinical trials is to demonstrate the efficacy of medications,
studies of “long term” use of medications used to treat BD (e.g., mood stabilizers or atypical
antipsychotics) have an average length of 6 months to two years.30, 136, 137 Additionally, nonadherence is generally not the primary end point of interest for these studies. Instead they focus
on time to relapse/recurrence (i.e., rehospitalization rates, time to any mood episode, total
number of relapses) or remission (i.e., first stabilized with active drug after mood episode,
duration of neutral mood).128, 136, 137 The studies that have identified non-adherence use multiple
definitions of non-adherence (i.e., time to premature discontinuation for any clinical reason,
treatment discontinuation), making comparisons difficult.49
Individuals with BD are often diagnosed in their early twenties,15 and thus most
individuals will be taking medications for many decades as they age.14 Rather than evaluating
efficacy for a relatively short period of time, to fully understand the outcomes of a typical
treatment regimen for individuals with BD it is necessary to follow them for multiple years. The
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) trial was designed
to fill this gap. STEP-BD followed participants for five years. The active participation phase
occurred during the first two years, followed by a naturalistic follow-up for three years with
treatment-as-usual to simulate experiences by individuals with BD being treated in the general
population.52
In addition to medication efficacy, providers weigh the benefits versus risks of any
medication they prescribe to individuals they treat. This follows the treatment guidelines for
individuals with BD,16 which identifies three overarching goals of treatment: psychiatric
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symptom reduction, low levels of adverse effects, and improved functioning. As detailed in
Chapter 2, we have created a novel model of these aspects of treatment for BD as three
intersecting dimensions of a latent variable we call Clinical Net Benefit (CNB). Each of these
dimensions work synergistically and reflect the heterogeneity in benefit (and harm) experienced
by individuals undergoing treatment for BD.
From our previous analyses (Chapter 3), we identified that while a substantial proportion
of STEP-BD participants attained a high level of CNB at some point during the trial, most
individuals did not maintain this status consistently over time. We also identified that for
individuals with low initial levels of CNB, those who maintained adherence to their medications
experienced an increase in their CNB over time. However, our previous study only followed
individuals during the active-trial component of STEP-BD, over approximately two years. To
add to the knowledge gained in our previous work, we extended this to the naturalistic follow-up
during the final three years of STEP-BD. The overarching aims for this study are to determine if,
during the naturalistic follow-up of STEP-BD, (1) membership in classes of CNB change over
time, (2) the CNB classes are associated with adherence over time, and (3) the complexity of the
medication regimens are associated with adherence over time.
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METHODS
Sample
Data come from the STEP-BD study. Eligibility criteria for STEP-BD included diagnoses
of bipolar spectrum disorders (meeting DSM-IV criteria for Bipolar I Disorder, Bipolar II
Disorder, Bipolar Not Otherwise Specified, Cyclothymic Disorder, or Schizoaffective Disorder
Bipolar Subtype), receiving outpatient treatment for BD at a STEP-BD treatment center at the
time of study entrance, participants’ ability to meet with their clinicians as scheduled for the
study and their ability to complete all study registration forms within three months of
registration. STEP-BD was a 5-year RCT designed to simulate the “real world” experiences of
treatment for individuals with BD. The first two years of study participation included active
monitoring and regular meetings occurring approximately every three months. The last three
years of the study were designed to be a naturalistic follow up, with at least one appointment per
year during those subsequent years. Eligible participants could choose to enter either the
Randomized Care Pathways (RCPs) where participants were randomly assignment to specific
medications (i.e., mood stabilizers, antipsychotics, antidepressants or placebos) or Standardized
Care Pathways (SCPs; i.e., treatment as usual). If initial regimens were ineffective, participants
moved on to subsequent medications, either randomized or determined by their treating
physicians, until an effective regimen was reached. Participants underwent a battery of clinicianand self-administered psychological assessments at each scheduled meeting that included the
Clinical Monitoring Form (CMF). In addition to tracking psychiatric symptoms and functioning,
this form also included clinicians’ indications of participants’ medication adherence.62
Additional details of the original study design are described elsewhere.52
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This study used data from the naturalistic follow up, starting with the final active
participation assessment and three follow ups during the last three years. STEP-BD enrolled
4,360 participants that met eligibility criteria for the study. This analysis excluded 1,555
participants with less than five STEP-BD assessments, and missing data on all the components of
CNB, the main exposure for this analysis. In addition, 1,234 participants were excluded because
they were less than 18 years of age at all time points. The final analytic sample size was 1,571
(Supplemental Figure 4.1.). For those with incomplete data on some variables, missing values
were imputed using Full Information Maximum Likelihood Estimation.92
Measures
Clinical Net Benefit
As detailed in Chapter 2, CNB incorporates three main effects of treatment on the
individual: (1) psychiatric symptoms; (2) adverse effects; and (3) overall functioning. CNB can
be conceptualized as a 3-dimensional construct lying at the intersection of these axes. Individuals
differentially experience these components of treatment and our prior work used latent class
analysis to empirically define and quantitatively measure these three dimensions of CNB using
baseline data from the STEP-BD.129
The psychiatric symptoms dimension consisted of the Montgomery-Asberg Depression
Rating Scale (MADRS)71 and the Young Mania Rating Scale (YMRS).70 The adverse effects
dimension included the measures of memory difficulties, dry mouth, sexual dysfunction,
headache, constipation, sedation, diarrhea, and tremor from the CMF.62 Finally, the overall
functioning dimension included the LIFE Range of Impaired Functioning Tool (LRIFT)73 three
indicators from the Work Impact Form (WIF) and past week Global Assessment of Functioning
(GAF)79 score. However, due to the small sample size of the Quality of Life Enjoyment and
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Satisfaction Questionnaire (QLESQ)72 relative to the other measures by the eighth time point, we
removed this assessment from the overall functioning dimension.
Medication
Psychotropic medications were listed by name (either generic or brand) on the CMF and
were recorded at each of the assessments. All medications were identified and grouped into six
families: (1) antidepressants, (2) mood stabilizers, (3) antipsychotics, (4) sedatives/hypnotics, (5)
stimulants, and (6) other using the U.S. Food & Drug Administration’s National Drug Code
Directory. 121 Next, a medication count variable was created indicating whether a participant was
taking one (monotherapy), two, three, four or five or more medications (polypharmacy).
Adherence
The CMF was completed by the study psychiatrist at each assessment. The CMF
recorded both the milligrams prescribed as well as milligrams missed for each medication a
participant was taking in the past seven days.62 We calculated adherence by first identifying
whether participants were taking each of their medications as prescribed. Then they were defined
as adherent if less than 25% of their regimens were not taken as prescribed. For example, if an
individual was prescribed four medications in his/her regimen, if s/he was fully adherent to four
of the five medications then she would be defined as adherent. Participants who missed more
than 25% of the milligrams prescribed for one or more of the medications in their regimens were
defined as non-adherent. Adherence defined as missing less than 25% of an individual’s regimen
is consistent with definitions used in STEP-BD studies.83
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Demographic Characteristics
Demographic characteristics included age (in years); gender; race (White, Black, and
Other); educational attainment (≤high school, high school diploma or GED, some college,
Bachelor’s degree, and Graduate or professional degree); current marital status (married or living
as though married, divorced or separated, never married, or widowed); whether participants lived
alone; primary residence (private home, group home or something else); income (greater or less
than $50,000); whether participants received Social Security Disability Insurance (SSDI) and
welfare; and employment status (employed, unemployed, disabled or retired/not in the labor
force).
Standardized Care or Randomized Care Pathways
Individuals could choose to enter the SCPs or RCPs if they met inclusion criteria. As we
previously found in Chapters 2 and 3, individuals who chose these different pathways were
characteristically different. Therefore, we combined all of the RCPs into one category and all of
the SCPs into a second category and indicated membership in either of these categories across
the classes and time points.
Analytic Approach
Analyses were similar to those conducted in Chapter 3 and took place in two steps. First,
latent class analyses (LCAs) were conducted, one for each time point, to determine the number
of classes that best fit the sample at each time point and the predicted probabilities of participant
membership in each class. Second, a Latent Transition Analysis (LTA) was conducted to
confirm fit for the number of classes at each time point, and to identify participants’ movement
between classes across adjacent time points.
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Latent Class Analysis
We used the same process to create the binary indicators of CNB for the LCAs as
detailed in Chapter 2. LCA is an empirical method to determine the number of subgroups, or
classes, of a latent variable (i.e., CNB) that exist in a sample of participants. The LCA also
assigns individuals’ membership in these classes according to their posterior probabilities of
symptom endorsement for each of the measures.97 To determine the number of classes that best
fit the model at each time point, we compared the Akaike Information Criterion (AIC), Bayesian
Information Criterion (BIC), Sample-Size Adjusted BIC (BICN), Bootstrapped Likelihood Ratio
Test (BLRT) and Entropy;100 for each of these indices smaller values, and Entropy values closest
to 1, indicate better relative fit. Measures of model fit, prevalence of class membership and
model interpretability were all used to determine the final number of classes for each time
point.97, 125
Latent Transition Analysis
Following the methods described in Chapter 3, we conducted the LTA to determine
whether individuals in one latent class at each time point transition to the same class or another
latent class at a subsequent time point. Primary outcomes of an LTA are transition probabilities,
akin to posterior probabilities of the LCAs. These transition probabilities quantify the likelihood
of moving from one class to another class across time points.99 The time span for this analysis is
over a 3-year period, covering visits 5 through 8 which occurred approximately 6-12 months
apart.52 LTA quantified three aspects of CNB change over time: (1) confirmation of the best
fitting number of latent classes, (2) the change in values of the measured indicators for each
class, and (3) the probability of participant class membership change at each time point.
Confirmation of the number of classes found in the LCAs that best fit the sample, taking

103

transition between classes into account, was determined via the LTA using the AIC, BIC, and
BICN. We allowed for changes in values in each of the measured indicators at each time point by
not imposing parameter restrictions to hold the item-response probabilities equal across each
time point,99, 102 as detailed in Chapter 3.
Characterizing the latent classes of CNB
The demographic characteristics, adherence to medication regimens, types of medication
regimens (i.e., monotherapy versus polypharmacy), and whether participants were in the SCPs or
RCPs of the latent classes of CNB at Time 5 were compared using ANOVA for continuous
measures and Chi-square analyses for categorical measures.
Predictors of Adherence
To determine predictors of adherence, multiple logistic regression analyses, adjusted for
demographic characteristics, were conducted at each of the four time points. The primary
predictors of adherence were: (1) CNB class membership at each time point from the LCAs, and
(2) the number of medications in participants’ regimens at each time point. Additional predictors
were: (3) change in CNB class membership from the previous time point, and (4) changes in
medication regimens from the prior time point.
Descriptive statistics and regressions were calculated using SAS version 9.4 (SAS
Institute Inc.). LCA and LTA were conducted using Mplus version 7.91
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RESULTS
Table 4.1. describes the characteristics of the analytic sample at Time 5 of STEP-BD, the
end of active study participation. The mean age of participants was 43 years, 58% were female,
and 94% were non-Hispanic white. The majority had an income less than $50,000 (56%), 17%
had income from SSDI, and 19% were unemployed. Most participants lived with at least one
other person (74%), and less than 1% lived in group homes (0.88%). Three out of ten
participants took five or more medications. Over three quarters of participants were adherent to
their medication regimen at Time 5 (78%).
Fitting the Latent Class Analysis for Clinical Net Benefit
Model fit statistics indicated that the four-class models of CNB had better fit than the
five-class models across Times 6-8, although fit was comparable between the four- and five-class
models at Time 5 (Supplemental Table 4.1.). Additionally, the smallest class prevalence at Times
5-7 were larger for the four-class model than the five-class model (9.3% versus 2.3% at Time 5;
10.6% versus 6% at Time 6; and 9.4% versus 6.4% at Time 7). Class prevalence at Time 8 was
the same for both the four- and five-class models (4.2%). However, the best fitting model when
confirmed via the LTA, was the five-class model at each time point with an AIC, BIC, BICN
greater than the four-class model (Supplementary Table 4.1.). Due to better interpretability of the
four-class model because of higher class prevalence, and the utility of keeping the number of
classes the same at each time point in the LTA to more easily identify class membership change,
we decided to use the four-class model for the LTA.
Characteristics of the Classes of Clinical Net Benefit
Characteristics for the four-class model of CNB are shown in Figure 4.1. In following
with our nomenclature from Chapters 2 and 3, the four classes of CNB were: (1) high benefit
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(characterized by low psychiatric symptoms, low adverse effects, and high functioning); (2)
moderate benefit (characterized by moderate psychiatric symptoms, moderate adverse effects
and moderate functioning); (3) moderately low benefit (characterized by high psychiatric
symptoms, low adverse effects and low functioning); and (4) low benefit (characterized by high
psychiatric symptoms, moderate adverse effects, and low functioning). Finally, participation in
the SCPs versus the RCPs differed across CNB classes at Time 5. As we found in Chapter 3,
individuals deriving the most benefit from their current medication regimens would choose to
stay with their current treatment, over 90% of those in the high benefit class elected to remain in
the SCPs; in contrast, 18% of the moderately low benefit class elected to enter an RCP.
Table 4.2. describes the CNB class prevalence and medication adherence for each CNB
class across the four time points as well as the differences in adherence across classes at each
time point. This table illustrates two key points: First, the high benefit class grew in size over the
3-year naturalistic follow up, going from 35% to almost half (49%) of participants. These
findings are consistent with the trajectories seen in Chapter 3, and are expected even during this
naturalistic follow up because clinicians and participants were continuing to make treatment
changes to improve the outcomes if participants did not appear to be benefiting from their
medications. Second, we also see that the low benefit class is greatly reduced by Time 8, which
suggests that individuals who are deriving less benefit from their medications may be modifying
their regimens and seeing increased benefit from their regimens. This may also indicate that
individuals who are not deriving benefit are dropping out of the trial, since only 33% remained in
the trial from Time 5 through Time 8. However, there were no differences between the group
that dropped out and those who remained except for their pathway membership at Time 5 (Table
4.3.). Although overall adherence remained high across all time points and classes (between 75%
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and 85%), we did see a great reduction in adherence in the low benefit class, ranging from 80%
at Time 5 to 53% at Time 8. This corresponded with a great reduction in membership in this
class, with only 10 people in this class at Time 8, supporting the notion that people who do not
adhere do not derive benefit from their medications and thus remain in the low benefit class.
Clinical Net Benefit, Medication Regimens, and Medication Adherence at Baseline
On average, participants were taking 3.4 (range 1 – 8) medications at Time 5. Medication
adherence did not differ across the classes (χ2=2.35, p=0.50) at Time 5, ranging between 76%
and 80%. However, medication regimens did differ between classes (χ2=111.37, p<0.001). In the
high benefit class 52% were taking three or fewer medications. In contrast, in the low benefit
class over 50% were taking five or more medications.
Latent Transition Analysis: Changes in Clinical Net Benefit over Time
Characteristics of the different measured indicators of CNB are in Figure 4.1. In general,
scores for the three dimensions of CNB remained consistent across time, with the greatest
variability seen in the adverse effects dimension and to a lesser degree in the overall functioning
dimension. The values on the three dimensions remained relatively stable for the high benefit, the
moderately low benefit and the low benefit classes. The low benefit class saw an increase in
adverse effects over time, while the other two dimensions remained relatively consistent. The
moderate benefit class saw the greatest change, with decreased adverse effects and decreased
psychiatric symptoms by Time 8.
Latent Transition Analysis: Movement between Classes of Clinical Net Benefit over Time
Table 4.4. illustrates the latent transition probabilities of moving between classes at each
consecutive time point. Each column and each row sum to a probability of 1.0. Overall, at each
time point individuals in the low benefit class had a high probability of moving to the moderate
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benefit class, and by Time 8 those in the moderately low benefit class had a high probability of
moving to the high benefit class. By Time 8, individuals in both of the higher benefit classes had
a high probability of moving to the lower benefit classes.
Between Times 5 and 6 participants in the moderate and moderately low benefit classes
had high probabilities of moving to lower benefit classes; 90% from the moderate to moderately
low, and 92% from the moderately low to low benefit classes. However, participants in the low
benefit class had a high probability (93%) of moving to the moderate benefit class. Those in the
high benefit class had a 91% probability of staying in that class.
Between Time 6 and Time 7, movement of the high and low benefit classes were the
same as the previous time point; 91% of those in the high benefit class stayed in that class and
92% of those in the low benefit class moved to the moderate benefit class. Those in the moderate
benefit class at Time 6 again had a high probability of moving to a lower benefit class; however,
the probability of remaining in the moderately low benefit class was 87%.
Finally, between Times 7 and 8, members of the low benefit and the moderately low
benefit class had a high probability of moving to a higher benefit class; 87% moving from the
moderately low to the high benefit class and 97% moving from low to moderate benefit class.
Both the high and moderate benefit classes had high probabilities of moving to lower benefit
classes.
Changes in Clinical Net Benefit, Medication Regimens, and Medication Adherence
Table 4.5. shows the relative odds of adherence across the four CNB classes over time. In
general, class membership was not associated with adherence, with the exception of the low
benefit class at Time 7 which had lower odds of adherence when compared to the high benefit
class (OR=0.32; 95% CI: 0.15-0.68). Also, changing to a lower benefit class from Time 6 to

108

Time 7 was also associated with lower adherence (OR=0.49; 95% CI: 0.26-0.91). At Time 5, 6
and 7 taking 2 or 3 medications was associated with lower adherence compared with
monotherapy. However, regimen change was only significantly associated with lower adherence
at Time 7 (OR=0.64; 95% CI: 0.44-0.93).
Post-hoc analysis
The probabilities of movement between the classes was not explained by changing
medication regimens. However, medication regimens were significantly different between the
classes at Time 5; participants in the low benefit class were the most likely to be taking complex
polypharmacy (five or more medications). Additionally, less complex medication regimens were
associated with lower adherence. Therefore, to further explore the drivers associated with
transitions between classes, we conducted a post hoc analysis testing whether medication
regimens taken at each time point were associated with moving to a higher or lower benefit class
at a subsequent time point. This post hoc analysis revealed that at Time 5 having a regimen of
three medications and at Time 6 of five or more medications was associated with changes to a
subsequently lower benefit class. However, at Time 7, having a medication regimen of 4 or more
medications was associated with movement to a higher benefit class at Time 8 (Table 4.6.).
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DISCUSSION
The primary finding from this study is that there is heterogeneity in CNB change over
time during this three-year naturalistic follow-up of STEP-BD participants. The number of
individuals in the high benefit class increased at each time point, and the prevalence of the low
benefit class declined substantially over time. In many ways this was expected, since the goal of
a treatment is to modify medication regimens if symptoms are not improving or adverse effects
are not tolerable over time. However, we also observed that at the conclusion of follow-up
individuals in the two highest benefit classes had moved to lower benefit classes, with the
moderate benefit class moving to lower benefit classes at each time point. This suggests that
even when a person achieves high benefit from their medical treatment, this benefit can decline
over time.41 Finally, number of medications taken concurrently (i.e., polypharmacy) explained
some of the transition between classes, with more complex regimens (3 or more medications)
predicting change to either a higher or lower benefit class.
In general, changes in CNB classes were not associated with adherence during this phase
of the study, contrary to our primary hypothesis. These results parallel our prior findings in that
individuals with less CNB have the same level of adherence as individuals with high CNB
(Chapter 2 and 3). Lower numbers of medications taken concurrently (two or three medications)
were associated with lower adherence relative to monotherapy at Times 5, 6 and 7. However,
changes in medication regimen (i.e., adding a medication, removing a medication or changing
from one medication to another) was not associated with adherence.
These findings suggest that this metric of CNB, while informed by guidelines for
treatment of BD, do not directly drive individual differences in adherence. While this may be
seen as a weakness of the CNB concept, there is good external validity of the CNB construct
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(described in detail in Chapter 2); for example, individuals in the low benefit class have the
highest prevalence of Social Security Disability Insurance (SSDI; 22%), lowest prevalence of
employment (32%), and lowest prevalence of a Bachelor’s or graduate degree (40%). This
suggests that individual level factors we were unable to assess in this study, such as individuals’
attitudes and perspectives toward treatment,43, 112 social support of family and friends,47
psychotherapy support,45 and patient-clinician relationship,47 may have more direct impact on
medication adherence for individuals with BD, as has been suggested in other work.
Strengths and Limitations
Strengths of this study include not only the use of a randomized clinical trial, but also the
length of time people were followed during this trial. Individuals were followed for close to the
three years during the naturalistic follow-up. The wealth of objective information from the
psychological assessments helped us create a robust model of CNB. In addition, information on
medication prescriptions and adherence were recorded by clinicians using standardized
assessments. Unlike more traditional randomized clinical trials, the inclusion criteria were very
broad (bipolar spectrum disorders, any comorbidities, any age over 15), with numerous sites
across the U.S., leading to greater generalizability of the results. Using LCA to identify classes
of CNB experienced by participants in the trial and LTA to quantify the likelihood of changing
to different classes of benefit over time, helped us rely on empirical results rather than theoretical
conceptualizations.
However, there were limitations to this study that cannot be overlooked. The greatest
limitation is the high levels of participant drop out. By the end of this analysis only 500
participants remained, from an initial sample at Time 5 of almost 1,600. Although this is not
uncommon for clinical trials,131, 132 this is poor when compared with observational cohort studies

111

such as the Health and Retirement Study (N=20,000, response rate=85% to 95%).138 However,
according to the most cited guidelines 500 participants gave us enough power to complete the
LCAs and LTA analyses which require a minimum sample size of 200.103 In addition, those who
remained in the study from Time 5 to Time 8 did not differ when compared to those who
dropped out of the study, therefore the findings for this cohort are not strongly influenced by
differential loss to follow-up. This level of dropout, and missing data from the QLESQ, restricted
the measures we could use for the LCA. Finally, participants’ perspectives of their medications
were not analyzed in this study. We can only infer that they are receiving benefit or lack thereof,
but do not know if they perceive they are subjectively doing “better”, and whether they associate
that with their treatment.
Conclusions
Our findings suggest more research into person-centered factors will likely shed light on
aspects of adherence not easily measured through psychological assessments. Other studies have
suggested additional factors such as personality, locus of control, perceptions of one’s illness and
treatment, and rapport between clinicians and individuals they treat may play a significant role in
driving adherence.47 This is most obvious in our findings that individuals who are experiencing
low benefit from their medications are adherent to the same extent as individuals experiencing
high benefit. Subjective reports from individuals achieving different levels of benefit from their
medications would be a highly valuable next step. Further examination into the drivers of
adherence in individuals who are not benefiting from their treatment will inform future treatment
strategies improving the experiences of outcomes of these individuals.
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Table 4.1. Demographic characteristics of the sample at Time 5 and by clinical net benefit class, at the end of active monitoring. Includes between group
differences from ANOVA and chi-square analyses at P-values

N (%)
Age (M, SD)
Female - no./total no. (%)
Race - no./total no. (%)
White
African American
Other
Education - no./total no. (%)
Less than High School
High School/GED
Some College
Bachelor’s Degree
Graduate Degree
Marital Status - no./total no. (%)
Currently Married
Previously Married
Never Married
Widowed
Lives Alone - no./total no. (%)
Income - no./total no. (%)
<$50,000
$50,000 +
SSDI - no./total no. (%)
Welfare - no./total no. (%)
Employment - no./total no. (%)
Employed
Unemployed
Disabled
Other
Type of Residence - no./total no. (%)
Private Home
Group Home
Other
Adhere - no./total no. (%)

Full Sample

High Benefit

Moderate Benefit

Low Benefit

134 (8.53)
44.28 (12.93)
77/132 (58.33)

Moderately Low
Benefit
681 (43.35)
42.20 (11.92)
378/676 (55.92)

1571
42.60 (12.29)
901/1556 (57.90)

549 (34.95)
42.42 (13.06)
315/544 (57.90)

871/928 (93.86)
31/928 (3.34)
26/928 (2.80)

265/288 (92.01)
12/288 (4.17)
11/288 (3.82)

65/70 (92.86)
1/70 (1.43)
4/70 (5.71)

430/449 (95.77)
13/449 (2.90)
6/449 (1.34)

111/121 (91.74)
5/121 (4.13)
5/121 (4.13)

24/1481 (1.62)
213/1481 (14.38)
505/1481 (34.10)
427/1481 (28.83)
312/1481 (21.07)

7/519 (1.35)
59/519 (11.37)
156/519 (30.06)
164/519 (31.60)
133/519 (25.63)

2/120 (1.67)
15/120 (12.50)
33/120 (27.50)
40/120 (33.33)
30/120 (25.00)

10/646 (1.55)
105/646 (16.25)
237/646 (36.69)
180/646 (27.86)
114/646 (17.65)

5/196 (2.55)
34/196 (17.35)
79/196 (40.31)
43/196 (21.94)
35/196 (17.86)

643/1551 (41.46)
377/1551 (24.31)
505/1551 (32.56)
26/1551 (1.68)
407/1551 (26.24)

228/543 (41.99)
122/543 (22.47)
181/543 (33.33)
12/543 (2.21)
144/543 (26.52)

65/131 (49.62)
28/131 (21.37)
36/131 (27.48)
2/131 (1.53)
27/131 (20.61)

252/673 (37.44)
173/673 (25.71)
239/673 (35.51)
9/673 (1.34)
188/674 (27.89)

98/204 (48.04)
54/204 (26.47)
49/204 (24.02)
3/204 (1.47)
48/203 (23.65)

808/1435 (56.31)
627/1435 (43.69)
251/1465 (17.13)
23/1465 (1.57)

242/503 (48.11)
261/503 (51.89)
49/508 (9.65)
1/508 (0.20)

60/124 (48.39)
64/124 (51.61)
18/120 (15.00)
2/120 (1.67)

398/619 (64.30)
221/619 (35.70)
140/641 (21.84)
14/641 (2.18)

108/189 (57.14)
81/189 (42.86)
44/196 (22.45)
6/196 (3.06)

754/1543 (48.87)
293/1543 (18.99)
279/1543 (18.08)
217/1543 (14.06)

326/541 (60.26)
95/541 (17.56)
38/541 (7.02)
82/541 (15.16)

76/129 (58.91)
16/129 (12.40)
20/129 (15.50)
17/129 (13.18)

287/671 (42.77)
138/671 (20.57)
156/671 (23.25)
90/671 (13.41)

65/202 (32.18)
44/202 (21.78)
65/202 (32.18)
28/202 (13.86)

1437/1485 (96.77)
13/1485 (0.88)
35/1485 (2.36)
1115/1432 (77.86)

501/519 (96.53)
2/519 (0.39)
16/519 (3.08)
392/493 (79.51)

116/121 (95.87)
0
5/121 (4.13)
99/129 (76.74)

630/649 (97.07)
7/649 (1.08)
12/649 (1.85)
466/612 (76.14)

190/196 (96.94)
4/196 (2.04)
2/196 (1.02)
158/198 (79.80)

207 (13.18)
43.35 (10.84)
131/204 (64.22)

P value

0.255
0.218
0.143

0.002

0.035

0.281
<0.001

<0.001
0.014
<0.001

0.0940

0.503
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Medication Regimens - no./total no. (%)
Monotherapy
Two Medications
Three Medications
Four Medications
Five + Medications
Pathway - no./total no. (%)
Standardized Care
Randomized Care

<0.001
137/1550 (8.84)
338/1550 (21.81)
331/1550 (21.35)
280/1550 (18.06)
464/1550 (29.94)

73/546 (13.37)
162/546 (29.67)
106/546 (19.41)
77/546 (14.10)
128/546 (23.44)

7/131 (5.34)
19/131 (14.50)
30/131 (22.90)
30/131 (22.90)
45/131 (34.35)

45/670 (34.35)
137/670 (20.45)
167/670 (24.93)
133/670 (19.85)
187/670 (27.91)

11/203 (5.42)
20/203 (9.85)
28/203 (13.79)
40/203 (19.70)
104/203 (51.23)

1299/1503 (86.43)
204/1503 (13.57)

474/521 (90.98)
47/521 (9.02)

119/133 (89.47)
14/133 (10.53)

525/642 (81.78)
117/642 (18.22)

181/207 (87.44)
26/207 (12.56)

<0.001
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Table 4.2. Class prevalence and prevalence of adherence at each time point, with significance of differences in
adherence across classes at each time point.

N (%)
Class (N, %)
High Benefit
Adherence
Moderate Benefit
Adherence
Moderately Low Benefit
Adherence
Low Benefit
Adherence
P-value

Time 5
1571

Time 6
1152

Time 7
802

Time 8
515

549 (34.95)
392 (79.51)
134 (8.53)
99 (76.74)
681 (43.35)
466 (76.14)
207 (13.18)
158 (79.80)
0.503

483 (41.93)
351 (80.69)
104 (9.03)
79 (79.00)
448 (38.89)
320 (79.01)
117 (10.16)
94 (82.46)
0.833

366 (45.64)
274 (84.57)
64 (7.98)
50 (80.65)
248 (30.92)
185 (79.06)
124 (15.46)
81 (69.23)
0.005*

253 (49.13)
173 (75.22)
88 (17.09)
66 (79.52)
153 (29.71)
109 (74.66)
21 (4.08)
10 (52.63)
0.113
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Table 4.3. Characteristics of individuals who remained in the trial for at least eight time points compared with those
who ever dropped out after Time 5. Between group differences from ANOVA and chi-square analyses are indicated
as P-values.

Time 5
N, %
Age (M, SD)
Female - no./total no. (%)
Race - no./total no. (%)
White
African American
Other

Time 8
Dropped out
Stayed
1056 (67.22)
515 (32.78)
42.18 (12.42)
43.45 (11.98)
595/1044 (56.99)
306/512 (59.77)
550/585 (94.02)
20/585 (3.42)
15/585 (2.56)

0.091
20/1022 (1.96)
150/1022 (14.68)
361/1022 (35.32)
292/1022 (28.57)
199/1022 (19.47)

4/459 (0.87)
63/459 (13.73)
144/459 (31.37)
135/459 (29.41)
113/459 (24.62)

432/1038 (41.62)
252/1038 (24.28)
339/1038 (32.66)
15/1038 (1.45)
280/1038 (26.97)

211/513 (41.13)
125/513 (24.37)
166/513 (32.36)
11/513 (2.14)
127/513 (24.76)

546/959 (56.93)
413/959 (43.07)
172/1010 (17.03)
18/1010 (1.78)

262/476 (55.04)
214/476 (44.96)
79/455 (17.36)
5/455 (1.10)

503/1032 (48.74)
210/1032 (20.35)
185/1032 (17.93)
134/1032 (12.98)

251/511 (49.12)
83/511 (16.24)
94/511 (18.40)
83/511 (16.24)

988/1026 (96.30)
10/1026 (0.97)
28/1026 (2.73)
736/958 (76.83)

449/459 (97.82)
3/459 (0.65)
7/459 (1.53)
379/474 (79.96)

949/999 (94.99)
50/999 (5.01)

350/504 (69.44)
154/504 (30.56)

102/1052 (9.70)
221/1052 (21.01)
219/1052 (20.82)
186/1052 (17.68)
324/1052 (30.80)

35/498 (7.03)
117/498 (23.49)
112/498 (22.49)
94/498 (18.88)
140/498 (28.11)

0.794

Marital Status - no./total no. (%)
Currently Married
Previously Married
Never Married
Widowed

Lives Alone - no./total no. (%)
Income
<$50,000
>=$50,000
SSDI - no./total no. (%)
Welfare - no./total no. (%)
Employment Status - no./total no. (%)
Employed
Unemployed
Disabled
Other

Adherence - no./total no. (%)
Pathway - no./total no. (%)
Standard Care
Randomized Care
Medication Regimens - no./total no. (%)
Monotherapy
Two Medications
Three Medications
Four Medications
Five + Medications

0.350
0.496

0.876
0.330
0.129

0.301

Residence - no./total no. (%)
Private Home
Group Home
Other

0.055
0.298
0.839

321/343 (93.59)
11/343 (3.21)
11/343 (3.21)

Education - no./total no. (%)
Less than High School
High School/GED
Some College
Bachelor’s Degree
Graduate Degree

P-value

0.179
<0.001

0.267
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Classes - no./total no. (%)
High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

0.148
381/1056 (36.08)
98/1056 (9.28)
443/1056 (41.95)
134/1056 (12.69)

168/515 (32.62)
36/515 (6.99)
238/515 (46.21)
73/515 (14.17)
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Table 4.4. a-c. Probabilities of latent transitions between classes of CNB for each pair of time points. Bold indicates
highest probabilities of transitioning.
a.

Time 6

Time 5
High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

High Benefit
0.905
0.052
0.005
0.002

b.
Time 6
High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

Time 7

c.
Time 7
High Benefit
Moderate Benefit
Moderately Low Benefit
Low Benefit

Time 8

0.911
0.029
0.067
0.019

0.173
0.000
0.866
0.016

Moderate
Benefit
0.000
0.051
0.079
0.928

Moderately
Low Benefit
0.000
0.897
0.000
0.024

Low Benefit
0.095
0.000
0.916
0.046

0.062
0.056
0.005
0.918

0.000
0.006
0.872
0.005

0.027
0.908
0.056
0.059

0.023
0.008
0.134
0.966

0.794
0.000
0.000
0.000

0.009
0.992
0.000
0.018
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Table 4.5. Results of logistic regression analyses predicting adherence at each time point. Also shown is prediction of class change when medication regimens
changed (either an increase or decrease in number of medications taken, or a change of medication).

Predicting Adherence at

Time 5
(OR, 95% CI)

Time 6
(OR, 95% CI)

Time 7
(OR, 95% CI)

Time 8
(OR, 95% CI)

Class (ref=High Benefit
Class)
Moderate Benefit
0.63 (0.33-1.21)
0.67 (0.30-1.54)
0.63 (0.23-1.70)
1.41 (0.61-3.29)
Moderately Low Benefit
1.07 (0.70-1.66)
0.86 (0.52-1.43)
0.66 (0.34-1.28)
1.35 (0.71-2.58)
Low Benefit
1.22 (0.65-2.28)
1.14 (0.51-2.54)
0.51 (0.14-1.80)
0.32 (0.15-0.68)**
Change in Class (ref=No)
Higher Benefit
-0.92 (0.53-1.57)
1.42 (0.64-3.16)
0.91 (0.49-1.71)
Lower Benefit
-1.35 (0.67-2.74)
0.75 (0.32-1.75)
0.49 (0.26-0.91)*
Medication Regimen (ref=1)
Two Medications
0.84 (0.36-1.96)
0.68 (0.32-1.44)
0.32 (0.14-0.74)**
0.46 (0.20-1.04)‡
Three Medications
0.54 (0.24-1.23)
0.55 (0.27-1.14)
0.35 (0.15-0.81)*
0.50 (0.22-1.12)‡
Four Medications
1.20 (0.46-3.12)
0.90 (0.37-2.16)
0.95 (0.40-2.23)
1.64 (0.73-3.64)
Five + Medications
0.71 (0.30-1.71)
0.93 (0.39-2.17)
0.82 (0.36-1.86)
0.90 (0.43-1.87)
1.08 (0.28-4.20)
0.87 (0.60-1.25)
Regimen Change (ref=No)
0.64 (0.44-0.93)*
Values are adjusted for care pathway, age, gender, race, education, marital status, income, SSDI, Welfare, Employment,
Residence
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Table 4.6. Results of logistic regression predicting change to a higher or lower benefit class by prior time point medication regimen.
Prior Time Point
Medication Regimen (ref=1)

Time 6

Time 7

Higher
Lower
Higher
Lower
Higher
Two Medications
1.43 (0.51-3.99)
2.33 (0.48-11.38)
1.11 (0.34-3.62)
3.64 (0.42-31.50)
2.47 (0.66-9.33)
Three Medications
1.68 (0.61-4.63)
1.07 (0.34-3.43)
4.42 (0.52-37.28)
2.27 (0.63-8.21)
3.82 (0.82-17.84)‡
Four Medications
1.70 (0.61-4.78)
2.33 (0.47-11.52)
1.62 (0.50-5.21)
4.65 (0.54-40.29)
3.52 (0.94-13.23)‡
Five + Medications
1.79 (0.66-4.88)
2.30 (0.48-10.96)
0.93 (0.29-2.97)
6.75 (0.81-56.20)‡
3.75 (1.07-13.17)*
Values are adjusted for care pathway, age, gender, race, education, marital status, income, SSDI, Welfare, Employment, Residence

Time 8
Lower
2.39 (0.41-14.05)
2.40 (0.43-13.35)
2.19 (0.36-13.30)
2.70 (0.50-14.42)
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Supplemental Table 4.1. Fit statistics for 4 and 5 class LCAs at each time point, and 4 and 5 class LTA.

Time 5
4 classes
5 classes
Time 6
4 classes
5 classes
Time 7
4 classes
5 classes
Time 8
4 classes
5 classes
LTA
4 classes
5 classes

AIC

BIC

BICN

BLRT

Entropy

Smallest Class (%)

18108.410
18073.861

18403.181
18443.664

18228.458
18224.466

69.889
62.550

0.700
0.703

9.30
2.30

13312.03
13303.97

13589.74
13652.37

13415.04
13433.21

90.728
36.058

0.733
0.699

10.60
6.00

9369.76
9355.647

9627.551
9679.058

9452.895
9459.944

49.037
42.113

0.661
0.682

9.40
6.40

5915.012
5919.633

6148.441
6212.481

5973.861
5993.463

42.817
23.379

0.719
0.729

4.20
4.20

44627.21
44393.54

45951.00
46130.01

45166.34
45100.73

---

---

---
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Supplemental Table 4.2. Families of medications making up different regimens taken by each class at Time 5.
High Benefit
Monotherapy (N=73)
Two Medications (N=162)
Three Medications (N=106)
Four Medications (N=77)
Five + Medications (N=98)
Moderate Benefit
Monotherapy (N=7)
Two Medications (N=19)
Three Medications (N=30)
Four Medications (N=30)
Five + Medications (N=45)
Moderately Low Benefit
Monotherapy (N=46)
Two Medications (N=137)
Three Medications (N=167)
Four Medications (N=133)
Five + Medications (N=146)
Low Benefit
Monotherapy (N=11)
Two Medications (N=20)
Three Medications (N=28)
Four Medications (N=40)
Five + Medications (N=104)

Antidepressant

Mood Stabilizer

Antipsychotic

Sedative/Hypnotic

Stimulant

Other

9 (12.33)
54 (16.67)
62 (19.50)
50 (16.13)
64 (13.06)

55 (75.34)
178 (54.94)
139 (43.71)
116 (37.42)
139 (28.37)

4 (5.48)
50 (15.43)
39 (12.26)
46 (14.84)
55 (11.22)

-12 (3.70)
24 (7.55)
33 (10.65)
52 (10.61)

-3 (0.93)
6 (1.89)
2 (0.65)
6 (1.22)

5 (6.85)
27 (8.33)
48 (15.09)
63 (20.32)
186 (34.13)

1 (14.29)
8 (21.05)
12 (13.33)
22 (18.33)
24 (10.67)

6 (85.71)
22 (57.89)
38 (42.22)
44 (36.67)
67 (29.78)

-2 (5.26)
15 (16.67)
8 (6.67)
24 (10.67)

-1 (2.63)
5 (5.56)
12 (10.00)
22 (9.78)

---1 (0.83)
2 (0.89)

-5 (13.16)
20 (22.22)
33 (27.50)
86 (38.22)

2 (4.35)
48 (17.52)
101 (20.16)
108 (20.30)
108 (14.79)

30 (65.22)
157 (57.30)
211 (42.12)
212 (39.85)
225 (30.82)

11 (23.91)
29 (10.58)
81 (16.17)
68 (12.78)
88 (12.05)

1 (2.17)
14 (5.11)
46 (9.18)
54 (10.15)
100 (13.70)

--6 (1.20)
5 (0.94)
4 (0.55)

2 (4.35)
26 (9.49)
56 (11.18)
85 (15.98)
205 (28.08)

-12 (30.00)
16 (19.05)
30 (18.75)
87 (16.73)

8 (72.73)
20 (50.00)
36 (42.86)
59 (36.88)
175 (33.65)

2 (18.18)
2 (5.00)
7 (8.33)
16 (10.00)
68 (13.08)

-5 (12.50)
13 (15.48)
21 (13.13)
67 (12.88)

----3 (0.58)

1 (9.09)
1 (2.50)
12 (14.29)
34 (21.25)
120 (23.08)
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Figure 4.1. a-d. CNB LCAs for Time 5 (a), Time 6 (b), Time 7 (c) and Time 8 (d).

Predicted Probability of Symptom Endorsement
0=Poor to 1=Better Outcomes

a
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High Benefit (35.0%)

Moderate Benefit (8.5%)

High Benefit (41.9%)

Moderate Benefit (9.0%)

Moderately Low Benefit (43.4%)
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Moderately Low Benefit (38.9%)

Low Benefit (10.2%)
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Predicted Probability of Symptom Endorsement
0=Poor to 1=Better Outcomes
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0.1
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1
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0.8
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0.4
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a

a
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Moderate Benefit (8.0%)
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Moderately Low Benefit (29.7%)

Low Benefit (4.1%)
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Supplemental Figure 4.1. Flowchart from original sample to current analytical sample.

4,360 enrolled in
STEP-BD
1,555 did not complete
psychological
assessment at time 5
2,805 completed at
least one psychological
assessment at time 5
1,234 < 18 years of age
at time 5 and
follow-ups
1,571 18+ years of age
at time 5
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CHAPTER 5
Afterword
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This chapter provides a brief overview of the results from each of the three empirical
papers, discusses the clinical and public health implications of these findings, and provides
guidance for next steps in research.

Chapter 2: Identifying clinical net benefit among individuals being treated for bipolar disorder
The objective of this first analysis was to create the Clinical Net Benefit (CNB) construct
and determine its external validity using the baseline data from the Systematic Treatment
Enhancement Program for Bipolar Disorder (STEP-BD). In this analysis we used baseline
measures from STEP-BD to create a latent of the three dimensions of CNB: psychiatric
symptoms, adverse effects and overall functioning. This latent construct of CNB was created
using a two-step procedure. First, exploratory factor analysis (EFA) was used to reduce the
number of measures in the CNB construct to only those necessary to define each of the three
dimensions. Second, latent class analysis (LCA) was used to empirically identify distinct classes
of CNB based on the clustering of responses on these three dimensions. This construct illustrated
the heterogeneity in CNB experienced by individuals being treated for BD, with five classes
(high benefit [N=889, 23.8%], moderately high benefit [N=961, 25.7%], moderate benefit
[N=432, 11.6%], moderately low benefit [N=1010, 27.0%], and low benefit [N=446, 11.93%])
identified as the best fit to the data. These classes appeared externally valid in that individuals
differed in terms of sociodemographic characteristics such as education (high benefit class:
highest level of graduate degree (23.6%); highest employment (57.1%); low benefit class: highest
SSDI (21.3%); highest unemployment (27.8%)). An unexpected finding was that the prevalence
of medication adherence did not differ across the classes at baseline. This indicates that even
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groups of individuals with low apparent CNB are just as likely to adhere to their medications as
people with high apparent CNB.
Chapter 3: Change in clinical net benefit and short-term medication adherence
The objectives of this second analysis were to examine whether the classes of CNB
changed over time, whether individuals transitioned between classes, and whether these changes
affected adherence. In this analysis we used latent transition modeling to estimate change in
CNB over the active treatment phase of STEP-BD (approximately two years). We found that
transitioning between CNB classes was common, and that individuals in the lowest benefit
classes moved to higher benefit classes as the trial progressed. However, by the end of the 2-year
period individuals in the higher benefit classes were transitioning to lower benefit classes. We
also found that as time passed, the higher benefit classes had lower odds of adherence when
taking fewer medications concurrently when compared to monotherapy, and the lower benefit
classes had higher odds of adherence when taking more medications concurrently when
compared to monotherapy. An unexpected finding was that when compared to monotherapy,
individuals taking 4 or more medications had higher odds of adherence than individuals taking
three or fewer medications. Finally, as we saw in Chapter 2, the classes of CNB were similar in
their adherence rates at each time point, contrary to our expectations.
Chapter 4: Change in clinical net benefit and long-term medication adherence
The objective of this third analysis was to determine whether our findings of CNB classes
changing over time, and their association with adherence found in Chapter 3 held during the
naturalistic follow-up in STEP-BD (approximately 3 years). This analysis showed that transitions
between CNB classes were similar in the 3-year naturalistic follow-up period to those in the
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active participation phase of the study. Individuals in the lower benefit classes transitioned to
higher benefit classes by the conclusion of the study. As with the earlier chapters, classes of
CNB were not associated with adherence in a systematic way. Medication regimens were
associated with adherence in much the same manner as in Chapter 3, with individuals taking
three or fewer medications concurrently having lower odds of adherence relative to
monotherapy. Complexity of medication regimens predicted change to higher or lower benefit
classes.

Implications and Limitations
Through the identification, creation, and testing of the CNB construct we have looked
beyond the factors of psychiatric symptoms, adverse effects and overall functioning experienced
by individuals with BD. By integrating these three concepts and applying that construct to a large
sample of participants, we have identified individuals who adhere but are not benefitting from
their treatment. We can postulate that these individuals may perceive they are currently
benefitting from their treatment as compared to previous experiences before entering STEP-BD,
which could be supporting their adherence. These individuals also may not be aware that there
are newer medications with fewer side effects to which they could switch for their quality of life
to increase.
If we want a more person-centered approach to treating individuals with BD that will lead
to a higher quality of life, we need to identify and work with individuals such as these. They
have a wealth of insight to provide clinicians as to why they adhere and what they perceive as
benefits from their treatment. They can inform person-centered treatment that may lead to higher
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levels of adherence and quality of life for a broader range of individuals. Increasing public health
for individuals with BD can start by focusing on what we can learn from these individuals. These
individuals were more likely to be taking 4 or more medications concurrently, which puts them
at high risk for development of chronic conditions such as obesity and cardiovascular disease.
With a focus on the health of these individuals and involving them in their care, we can test and
enhance our understanding and use of person-centered care for individuals with BD.
Latent variable modeling is a flexible analytic approach to quantifying multiple aspects
(i.e., psychiatric symptoms, adverse effects, and overall functioning) of the individual’s
experience while being treated for BD. The latent construct of CNB was informed by clinical
guidelines and research on clinical impressions and patient insights to treatment. This construct
highlights the substantial heterogeneity in CNB for this disorder. Using this novel construct, we
identified a group of individuals who experienced low benefit from their treatment, but were
adherent to the same extent as those with high benefit. This group that may have distinct clinical
needs from others treated for BD, including the need for more attention to medication dosage or
more rapid regimen changes to achieve a clinical response.
As has been suggested by clinicians treating individuals with BD, those who initially
benefitted from their treatment experienced a decrease in CNB over time. This may be due in
part to lower adherence when individuals in the high CNB class were taking fewer medications
concurrently, as was found in Chapter 3, or changes in aspects of CNB itself, such as increases in
adverse effects as can be seen in the lower benefit classes at each time point in Chapter 3 Figure
3.1. However, this decrease in CNB may also be due to decreased effectiveness of the treatment
they are receiving (e.g., tachyphylaxis: developing tolerance to antidepressant medication, or
narrow therapeutic indices that restrict continued titration of the medication to retain
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effectiveness).31, 139 This was suggested during the naturalistic follow up where adherence rates
were the same across classes and time points, there was no association between medication
regimen change and class change, yet individuals in the higher benefit classes moved to lower
benefit classes by the end of this phase.
However, due to the longer time intervals between follow-up assessments during the
naturalistic phase of the trial (i.e., assessments occurred every 12 months instead of every 3
months as during the active phase of the trial), our measure of adherence may have been less
valid for this portion of the analysis. Participants were asked about their medication use for the
past week, which likely overestimated the prevalence of adherence when the time between
appointments was from six and twelve months.
The dropout rates during the active phase of the trial (Time 1 through 5) and the many
differences between individuals who dropped out and individuals who remained also tempers the
conclusions that can be made from our findings. Overall high dropout rates lead to bias toward
the null. However, missingness was not at random. Individuals who dropped out before Time 5
were less likely to be adherent, more likely to be taking 5 + medications concurrently, and more
likely to be in the high benefit class. This biases our results away from the null with regards to
adherence in the overall sample, and away from the null with regards to adherence in the high
benefit class. In addition, relationships between adherence and medication regimens would be
biased away from the null for individuals taking 5 + medications concurrently. There was a high
dropout rate during the naturalistic follow-up (Time 5 through 8) as well, although there were no
demographic differences between participants who stayed and who dropped out during that time
period. This non-differentially biases our results toward the null.
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Finally, despite being theoretically grounded in clinical guidelines for CNB and having
external validity, the construct of CNB was generally not related to medication adherence. This
was contrary to expectations, but even though this core hypothesis was not supported, these null
results do provide important information. Foremost, they suggest that something outside of CNB
is driving adherence, at least in our sample. As discussed previously, there are many aspects of
clinical care that could not be examined in this study, including subjective measures of
participants’ opinions about taking their medications, the relationship between clinicians and
those they treat for BD, and past changes in relative functioning before they began the trial. This
may be particularly true with participants in our analyses who were approximately 40 years of
age. Onset of BD takes place when people are approximately 20 years of age. This suggests that
our sample may have been receiving treatment for BD for 20 years or more before STEP-BD
began, and those care experiences and history may be stronger determinants of contemporary
adherence than concurrent symptoms, adverse effects, and functioning.
Selection bias is also a concern in any RCT. Individuals who participate in clinical trials
are different from those who do not in a myriad of ways, which reduces the generalizability of
the results. In addition, even though this was technically a RCT, the vast majority of participants
elected to remain in the Standard Care Pathways (i.e., treatment as usual); this suggests they
were satisfied with their medication regimens at baseline, since they were unwilling to “roll the
dice” so to speak and make a change. It is also unlikely that individuals who were not adherent
would be receiving regular outpatient care.
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Next Steps
A number of directions could be pursued to further test the utility of the CNB construct
For example, qualitative research of individuals with BD, stratified by CNB class, may provide
important new insight into the patients’ perspective of their treatment, relationships with their
provider, and their perspectives of the benefit versus risks of their treatment. This would lend
support, or suggest there is limited utility, of the subgroups identified by CNB. In addition, other
measures of adherence such as pill bottle counts, blood serum levels, and self-report
questionnaires of adherence (e.g., Medication Adherence Rating Scale) may be more sensitive
measures than the metric of adherence used here.
Additionally, the CNB construct could be tested in different clinical populations, such as
with individuals diagnosed with schizophrenia (e.g., CATIE Schizophrenia trial) or major
depression (e.g., STAR*D trial), to understand the heterogeneity in these dimensions across a
range of psychiatric disorders. These RCTs have similar designs to STEP-BD. If we are able to
identify distinct subgroups of CNB in these populations, this would further support the utility of
the CNB construct in understanding heterogeneity in treated populations with psychiatric
disorders, regardless of whether that heterogeneity predicts adherence. Finally, it would be
important to explore the construct of CNB in observational, rather than clinical trial, data (e.g.,
population surveys such as the Medical Expenditures Panel Survey), which have superior
external validity to RCTs.

132

References

1.

Constitution of WHO: principles. Available from: http://www.who.int/about/mission/en/.
Last accessed March 30, 2017.

2.

Megari K. Quality of Life in Chronic Disease Patients. Health Psychol Res 2013;1:e27.

3.

Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease.
Lancet 2013;382:1525-1533.

4.

Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of
engagement in HIV care and its relevance to test-and-treat strategies for prevention of
HIV infection. Clin Infect Dis 2011;52:793-800.

5.

Standards of Medical Care in Diabetes-2015. Diabetes Care 2015;38:S1-S93.

6.

Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS
2003;17 Suppl 1:S141-148.

7.

de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated
lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug
reaction. PLoS One 2013;8:e63623.

8.

Baynes HW, Tegene B, Gebremichael M, et al. Assessment of the effect of antiretroviral
therapy on renal and liver functions among HIV-infected patients: a retrospective study.
HIV/AIDS - Research and Palliative Care 2017;9:1-7.

9.

Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy.
Antiviral Res 2010;85:201-209.

10.

Schackman BR, Fleishman JA, Su AE, et al. The lifetime medical cost savings from
preventing HIV in the United States. Med Care 2015;53:293-301.

133

11.

Zhuo X, Zhang P, Barker L, et al. The lifetime cost of diabetes and its implications for
diabetes prevention. Diabetes Care 2014;37:2557-2564.

12.

Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291
diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global
Burden of Disease Study 2010. Lancet 2012;380:2197-2223.

13.

Bloom DE, Cafiero ET, Jane-Llopis E, et al. The Global Economic Burden of
Noncommunicable Diseases. Geneva: World Economic Forum, 2011.

14.

Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of
diseases, injuries, and risk factors. JAMA 2013;310:591-608.

15.

Etain B, Lajnef M, Bellivier F, et al. Clinical expression of bipolar disorder type I as a
function of age and polarity at onset: convergent findings in samples from France and the
United States. J Clin Psychiatry 2012;73:e561-566.

16.

Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety
Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD)
collaborative update of CANMAT guidelines for the management of patients with bipolar
disorder: update 2013. Bipolar Disord 2013;15:1-44.

17.

Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the
literature. Health Qual Life Outcomes 2005;3:72.

18.

Treuer T, Tohen M. Predicting the course and outcome of bipolar disorder: a review. Eur
Psychiatry 2010;25:328-333.

19.

Degenhardt EK, Gatz JL, Jacob J, Tohen M. Predictors of relapse or recurrence in bipolar
I disorder. J Affect Disord 2012;136:733-739.

134

20.

Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American
Psychiatric Association, 2013.

21.

Larkin GL, Claassen CA, Emond JA, Pelletier AJ, Camargo CA. Trends in U.S.
emergency department visits for mental health conditions, 1992 to 2001. Psychiatr Serv
2005;56:671-677.

22.

Wright WA, Gorman JM, Odorzynski M, Peterson MJ, Clayton C. Integrated Pharmacies
at Community Mental Health Centers: Medication Adherence and Outcomes. J Manag
Care Spec Pharm 2016;22:1330-1336.

23.

Cicchetti D, ed. Developmental Psychopathology. 3rd ed. Hoboken, New Jersey: John
Wiley & Sons, Inc. 2016.

24.

Judd LL, Schettler PJ, Solomon DA, et al. Psychosocial disability and work role function
compared across the long-term course of bipolar I, bipolar II and unipolar major
depressive disorders. J Affect Disord 2008;108:49-58.

25.

Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the
US population: re-analysis of the ECA database taking into account subthreshold cases. J
Affect Disord 2003;73:123-131.

26.

Albert U, Rosso G, Maina G, Bogetto F. Impact of anxiety disorder comorbidity on
quality of life in euthymic bipolar disorder patients: differences between bipolar I and II
subtypes. J Affect Disord 2008;105:297-303.

27.

Salloum IM, Brown ES. Management of comorbid bipolar disorder and substance use
disorders. Am J Drug Alcohol Abuse 2017. 10.1080/00952990.2017.12922791-11.

135

28.

Liu NH, Daumit GL, Dua T, et al. Excess mortality in persons with severe mental
disorders: a multilevel intervention framework and priorities for clinical practice, policy
and research agendas. World Psychiatry 2017;16:30-40.

29.

Correll CU, Ng-Mak DS, Stafkey-Mailey D, et al. Cardiometabolic comorbidities,
readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Ann
Gen Psychiatry 2017;16:9.

30.

Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy
for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.
Am J Psychiatry 2004;161:217-222.

31.

Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J
Bipolar Disord 2016;4:27.

32.

Peselow ED, Naghdechi L, Pizano D, IsHak WW. Polypharmacy in Maintenance of
Bipolar Disorder. Clin Neuropharmacol 2016;39:132-134.

33.

Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of
lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients
with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400.

34.

Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebocontrolled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J
Clin Psychiatry 2004;65:432-441.

35.

Ketter TA, Miller S, Dell'Osso B, Wang PW. Treatment of bipolar disorder: Review of
evidence regarding quetiapine and lithium. J Affect Disord 2016;191:256-273.

136

36.

Vieta E, Azorin JM, Bauer M, et al. Psychiatrists' perceptions of potential reasons for
non- and partial adherence to medication: results of a survey in bipolar disorder from
eight European countries. J Affect Disord 2012;143:125-130.

37.

Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, et al. Adherence to
Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic
Review. J Clin Psychopharmacol 2016;36:355-371.

38.

Gonzalez-Pinto A, Reed C, Novick D, Bertsch J, Haro JM. Assessment of medication
adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry 2010;43:263270.

39.

Ketter TA. Strategies for monitoring outcomes in patients with bipolar disorder. Prim
Care Companion J Clin Psychiatry 2010;12:10-16.

40.

Crowe M, Wilson L, Inder M. Patients' reports of the factors influencing medication
adherence in bipolar disorder - an integrative review of the literature. Int J Nurs Stud
2011;48:894-903.

41.

Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin
Psychiatry 2002;63:384-390.

42.

Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. J
Clin Psychiatry 2005;66:24-29.

43.

Clatworthy J, Bowskill R, Parham R, et al. Understanding medication non-adherence in
bipolar disorders using a Necessity-Concerns Framework. J Affect Disord 2009;116:5155.

44.

Kemp DE. Managing the side effects associated with commonly used treatments for
bipolar depression. J Affect Disord 2014;169:S34-S44.

137

45.

Gaudiano BA, Weinstock LM, Miller IW. Improving treatment adherence in bipolar
disorder: a review of current psychosocial treatment efficacy and recommendations for
future treatment development. Behav Modif 2008;32:267-301.

46.

Colom F, Vieta E, Tacchi MJ, Sanchez-Moreno J, Scott J. Identifying and improving
non-adherence in bipolar disorders. Bipolar Disord 2005;7 Suppl 5:24-31.

47.

Sajatovic M, Ignacio RV, West JA, et al. Predictors of nonadherence among individuals
with bipolar disorder receiving treatment in a community mental health clinic. Compr
Psychiatry 2009;50:100-107.

48.

Venter W, Moturi E, Ousley JT, Cookson ST. U.S. Centers for Disease Control and
Prevention (CDC). Evaluation Tool for Tuberculosis Programs in Resource-limited,
Refugee and Post-Conflict Settings. Available from:
https://www.cdc.gov/globalhealth/healthprotection/errb/pdf/researchandsurvey/tb_tool_2
013.pdf. Last accessed March 31, 2017.

49.

Jonsdottir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients
with severe mental disorders: relation between self-reports and serum level. J Clin
Psychopharmacol 2010;30:169-175.

50.

Davidson L, Tondora J, Miller R, O'Connell MJ. Chapter 4: Person-centered care. In:
Corrigan PW, ed. Person-Centered Care for Mental Illness: The Evolution of Adherence
and Self-Determination. Washington, DC: American Psychological Association, 2015.
81–102.

51.

Susman JL. Improving outcomes in patients with bipolar disorder through establishing an
effective treatment team. Prim Care Companion J Clin Psychiatry 2010;12:30-34.

138

52.

Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic
treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry
2003;53:1028-1042.

53.

U.S. National Institutes of Health. Systematic Treatment Enhancement Program for
Bipolar Disorder (STEP-BD). Available from:
https://www.clinicaltrials.gov/ct/show/NCT00012558?order=1. Last accessed May 1,
2016.

54.

Chengappa KN, Levine J, Gershon S, et al. Inositol as an add-on treatment for bipolar
depression. Bipolar Disord 2000;2:47-55.

55.

Johnson CL, Dohrmann SM, Burt VL, Mohadier LK. National Health and Nutrition
Examination Survey: Sample design, 2011–2014. Vital Health Stat 2014;2.

56.

Agency for Healthcare Research and Quality. MEPS-HC Sample Design and Collection
Process. Available from:
http://www.meps.ahrq.gov/mepsweb/survey_comp/hc_data_collection.jsp. Last accessed
March 26, 2017.

57.

Machlin S, Soni A, Fang Z. Understanding and Analyzing MEPS Household Component
Medical Condition Data. Available from:
https://meps.ahrq.gov/survey_comp/MEPS_condition_data.shtml. Last accessed March
26, 2017.

58.

Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction
of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.

139

59.

Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population
prevalences and trends in non-specific psychological distress. Psychol Med 2002;32:959976.

60.

Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the
General Population. Applied Psychological Measurement 1977;1:385-401.

61.

Sachs GS. Adjuncts and alternatives to lithium therapy for bipolar affective disorder. J
Clin Psychiatry 1989;50 Suppl:31-39; discussion 45-37.

62.

Sachs GS, Guille C, McMurrich SL. A clinical monitoring form for mood disorders.
Bipolar Disord 2002;4:323-327.

63.

Horne R, Weinman J, Hankins M. The Beliefs About Medicines Questionnaire: The
Development And Evaluation Of A New Method For Assessing The Cognitive
Representation Of Medication. Psychology and Health 1999;14:1-24.

64.

Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the
hopelessness scale. J Consult Clin Psychol 1974;42:861-865.

65.

Durham TW. Norms, reliability, and item analysis of the Hopelessness Scale in general
psychiatric, forensic psychiatric, and college populations. J Clin Psychol 1982;38:597600.

66.

Dyce JA. Factor structure of the Beck Hopelessness Scale. J Clin Psychol 1996;52:555558.

67.

Young MA, Halper IS, Clark DC, Scheftner W, Fawcett J. An Item-Response Theory
Evaluation of the Beck Hopelessness Scale. Cognitive Therapy and Research
1992;16:579-587.

140

68.

Petterson U, Fyro B, Sedvall G. A new scale for the longitudinal rating of manic states.
Acta Psychiatr Scand 1973;49:248-256.

69.

Beigel A, Murphy DL. Assessing clinical characteristics of the manic state. Am J
Psychiatry 1971;128:688-694.

70.

Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability,
validity and sensitivity. Br J Psychiatry 1978;133:429-435.

71.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change.
Br J Psychiatry 1979;134:382-389.

72.

Ritsner M, Kurs R, Kostizky H, Ponizovsky A, Modai I. Subjective quality of life in
severely mentally ill patients: a comparison of two instruments. Qual Life Res
2002;11:553-561.

73.

Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up
Evaluation. A comprehensive method for assessing outcome in prospective longitudinal
studies. Arch Gen Psychiatry 1987;44:540-548.

74.

Leon AC, Solomon DA, Mueller TI, et al. The Range of Impaired Functioning Tool
(LIFE-RIFT): a brief measure of functional impairment. Psychol Med 1999;29:869-878.

75.

Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for
measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766771.

76.

World Health Organization. WHO Disability Assessment Schedule 2.0 (WHODAS 2.0).
Available from: http://www.who.int/classifications/icf/whodasii/en/. Last accessed March
31, 2017.

141

77.

Garin O, Ayuso-Mateos JL, Almansa J, et al. Validation of the "World Health
Organization Disability Assessment Schedule, WHODAS-2" in patients with chronic
diseases. Health Qual Life Outcomes 2010;8:51.

78.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:5662.

79.

Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of
Functioning (GAF). Br J Clin Psychol 2002;41:417-422.

80.

Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS):
conceptual and theoretical foundations. Br J Psychiatry Suppl 1989; 49-58.

81.

Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa:
University of Iowa, 1984.

82.

Wykes T, Sturt E. The measurement of social behaviour in psychiatric patients: an
assessment of the reliability and validity of the SBS schedule. Br J Psychiatry
1986;148:1-11.

83.

Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor
pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin
Psychiatry 2010;71:296-303.

84.

Thomas ML, Lanyon RI, Millsap RE. Validation of diagnostic measures based on latent
class analysis: a step forward in response bias research. Psychol Assess 2009;21:227-230.

85.

Conway JM, Huffcutt AI. A Review and Evaluation of Exploratory Factor Analysis
Practices in Organizational Research. Organizational Research Methods 2003;6:147-168.

86.

Kelloway EK. Structural equation modelling in perspective: Summary. Journal of
Organizational Behavior 1995;16:215-224.

142

87.

Tabachnick BG, Fidell LS. Using Multivariate Statistics. Boston, MA: Pearson, 2007.

88.

Goldberg LR, Velicer WF. Principles of exploratory factor analysis. In: Strack S, ed.
Differentiating normal and abnormal personality. New York, NY: Springer, 2006.

89.

Garrett-Mayer E. Factor Analysis I: Johns Hopkins Bloomberg School of Public Health,
2006.

90.

Flora DB, Labrish C, Chalmers RP. Old and new ideas for data screening and assumption
testing for exploratory and confirmatory factor analysis. Front Psychol 2012;3:55.

91.

Muthen LK, Muthen BO. Mplus User's Guide. Los Angeles, CA: Muthen & Muthen,
1998-2015.

92.

Dong Y, Peng CY. Principled missing data methods for researchers. Springerplus
2013;2:222.

93.

Meyers LS, Gamst G, Guarino AJ. Applied Multivariate Research: Design and
Interpretation. Thousand Oaks, CA: SAGE, 2013.

94.

DeVellis RF. Scale Development: Theory and Applications. Thousand Oaks, CA: Sage,
1991.

95.

Worthington RL, Whittaker TA. Scale Development Research: A Content Analysis and
Recommendations for Best Practices. Counseling Psychologist 2006;34:806-838.

96.

Cattell RB. The Scree Test for the Number of Factors. Multivariate Behavioral Research
1966;1:245-276.

97.

McCutcheon AC. Latent class analysis. Beverly Hills: Sage Publications, 1987.

98.

Thompson DM, Latent Class Analysis in SAS®: Promise, Problems, and Programming,
in SAS Global Forum 2007. 2007.

143

99.

Collins LM, Lanza ST. Latent Class and Latent Transition Analysis with Applications in
the Social, Behavioral, and Health Sciences. Hoboken, New Jersey: John Wiley & Sons,
Inc., 2010.

100.

Hooper D, Coughlan J, Mullen M. Structural equation modelling: guidelines for
determining model fit. Electronic Journal of Business Research Methods 2008;6:53-60.

101.

Nylund KL, Asparouhov T, Muthen BO. Deciding on the Number of Classes in Latent
Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study.
Structural Equation Modeling: A Multidisciplinary Journal 2007;14:535-569.

102.

Muthen B, Asparouhov T. LTA in Mplus: Transition probabilities influenced by
covariates. Mplus Web Notes 2011; 1-30.

103.

Comrey AL, Lee HB. A First Course in Factor Analysis. Hillsdale, NY: Erlbaum, 1992.

104.

Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety
Treatments (CANMAT) guidelines for the management of patients with bipolar disorder:
consensus and controversies. Bipolar Disord 2005;7:5-69.

105.

Kutzelnigg A, Kopeinig M, Chen CK, et al. Compliance as a stable function in the
treatment course of bipolar disorder in patients stabilized on olanzapine: results from a
24-month observational study. Int J Bipolar Disord 2014;2:13.

106.

Velligan D, Sajatovic M, Valenstein M, et al. Methodological challenges in psychiatric
treatment adherence research. Clin Schizophr Relat Psychoses 2010;4:74-91.

107.

Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship
of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-811.

108.

Bates JA, Whitehead R, Bolge SC, Kim E. Correlates of medication adherence among
patients with bipolar disorder: results of the bipolar evaluation of satisfaction and

144

tolerability (BEST) study: a nationwide cross-sectional survey. Prim Care Companion J
Clin Psychiatry 2010;12:pii: PCC.09m00883.
109.

Kraemer HC, Frank E, Kupfer DJ. How to assess the clinical impact of treatments on
patients, rather than the statistical impact of treatments on measures. Int J Methods
Psychiatr Res 2011;20:63-72.

110.

Cochran SD, Gitlin MJ. Attitudinal correlates of lithium compliance in bipolar affective
disorders. J Nerv Ment Dis 1988;176:457-464.

111.

Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in
schizophrenia. Schizophr Bull 1994;20:297-310.

112.

Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta
Psychiatr Scand 2000;101:119-124.

113.

Morselli PL, Elgie R, Europe G. GAMIAN-Europe/BEAM survey I--global analysis of a
patient questionnaire circulated to 3450 members of 12 European advocacy groups
operating in the field of mood disorders. Bipolar Disord 2003;5:265-278.

114.

Bowling A. Mode of questionnaire administration can have serious effects on data
quality. J Public Health (Oxf) 2005;27:281-291.

115.

McIntyre RS. Understanding needs, interactions, treatment, and expectations among
individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J
Clin Psychiatry 2009;70:5-11.

116.

Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: A SAS Procedure for
Latent Class Analysis. Struct Equ Modeling 2007;14:671-694.

145

117.

Krueger RF, Markon KE, Patrick CJ, Benning SD, Kramer MD. Linking antisocial
behavior, substance use, and personality: an integrative quantitative model of the adult
externalizing spectrum. J Abnorm Psychol 2007;116:645-666.

118.

Woolston A, Tu YK, Baxter PD, Gilthorpe MS. A comparison of different approaches to
unravel the latent structure within metabolic syndrome. PLoS One 2012;7:e34410.

119.

Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders
in children and adolescents. Pediatr Clin North Am 2011;58:173-187, xii.

120.

Smarty S, Findling RL. Psychopharmacology of pediatric bipolar disorder: a review.
Psychopharmacology (Berl) 2007;191:39-54.

121.

U.S. Food & Drug Administration. National Drug Code Directory. Available from:
http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm. Last accessed December 31,
2016.

122.

Finch WH. A Comparison of Factor Rotation Methods for Dichotomous Data. Journal of
Modern Applied Statistical Methods 2011;10:549-570.

123.

Arnau RC, Meagher MW, Norris MP, Bramson R. Psychometric evaluation of the Beck
Depression Inventory-II with primary care medical patients. Health Psychol 2001;20:112119.

124.

Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA
and -II in psychiatric outpatients. J Pers Assess 1996;67:588-597.

125.

Mezuk B, Kendler KS. Examining variation in depressive symptoms over the life course:
a latent class analysis. Psychol Med 2012;42:2037-2046.

126.

Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381:1672-1682.

146

127.

Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for
patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr
Serv 2008;59:1175-1183.

128.

Hochman E, Krivoy A, Schaffer A, Weizman A, Valevski A. Antipsychotic adjunctive
therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: A
cohort study. Bipolar Disord 2016;18:684-691.

129.

Bareis N, Lu J, Kirkwood CK, et al. Identifying Clinical Net Benefit of Psychotropic
Medication Use with Latent Variable Techniques: Evidence from Systematic Treatment
Enhancement Program for Bipolar Disorder (STEP-BD). 2017.

130.

Darling CA, Olmstead SB, Lund VE, Fairclough JF. Bipolar disorder: medication
adherence and life contentment. Arch Psychiatr Nurs 2008;22:113-126.

131.

Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised
antipsychotic drug trials. Psychopharmacology (Berl) 2001;155:230-233.

132.

Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in
placebo-controlled and active-control clinical trials of antipsychotic drugs: a metaanalysis. Arch Gen Psychiatry 2005;62:1305-1312.

133.

Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological
therapies compared to usual psychiatric treatment for bipolar disorders. Int J
Neuropsychopharmacol 2007;10:123-129.

134.

Heaton PC, Tundia NL, Luder HR. U.S. emergency departments visits resulting from
poor medication adherence: 2005-07. J Am Pharm Assoc (2003) 2013;53:513-519.

135.

Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring
medication adherence. J Am Pharm Assoc (2003) 2011;51:90-94.

147

136.

Yatham LN, Beaulieu S, Schaffer A, et al. Optimal duration of risperidone or olanzapine
adjunctive therapy to mood stabilizer following remission of a manic episode: A
CANMAT randomized double-blind trial. Mol Psychiatry 2016;21:1050-1056.

137.

Lindstrom L, Lindstrom E, Nilsson M, Hoistad M. Maintenance therapy with second
generation antipsychotics for bipolar disorder - A systematic review and meta-analysis. J
Affect Disord 2017;213:138-150.

138.

Health and Retirement Study: Sample sizes and response rates. Available from:
http://hrsonline.isr.umich.edu/sitedocs/sampleresponse.pdf. Last accessed 10.14, 15.

139.

Amsterdam JD, Shults J. Does tachyphylaxis occur after repeated antidepressant
exposure in patients with Bipolar II major depressive episode? J Affect Disord
2009;115:234-240.

148

Appendix
Diagnostic Criteria for Bipolar I Disorder
For a diagnosis of bipolar I disorder, it is necessary to meet the following criteria for a manic
episode. The manic episode may have been preceded by and may be followed by hypomanic or
major depressive episodes.

Manic Episode
A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood
and abnormally and persistently increased activity or energy, lasting at least 1 week and
present most of the day, nearly every day (or any duration if hospitalization is necessary).
B. During the period of mood disturbance and increased energy or activity, three (or more)
of the following symptoms (four if the mood is only irritable) are present to a significant
degree and represent a noticeable change from usual behavior:
1. Inflated self-esteem or grandiosity.
2. Decreased need for sleep (e.g., feels rested after only 3 hours of sleep).
3. More talkative than usual or pressure to keep talking.
4. Flight of ideas or subjective experience that thoughts are racing.
5. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant
external stimuli), as reported or observed.
6. Increase in goal-directed activity (either socially, at work or school, or
sexually) or psychomotor agitation (i.e., purposeless non-goal-directed
activity).
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7. Excessive involvement in activities that have a high potential for painful
consequences (e.g., engaging in unrestrained buying sprees, sexual
indiscretions, or foolish business investments).
C. The mood disturbance is sufficiently severe to cause marked impairment in social or
occupational functioning or to necessitate hospitalization to prevent harm to self or
others, or there are psychotic features.
D. The episode is not attributable to the physiological effects of a substance (e.g., a drug of
abuse, a medication, other treatment) or another medical condition.
o

Note: A full manic episode that emerges during antidepressant treatment (e.g.,
medication, electroconvulsive therapy) but persists at a fully syndromal level beyond
the physiological effect of that treatment is sufficient evidence for a manic episode
and, therefore, a bipolar I diagnosis.

Note: Criteria A–D constitute a manic episode. At least one lifetime manic episode is required
for the diagnosis of bipolar I disorder.

Hypomanic Episode
A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood
and abnormally and persistently increased activity or energy, lasting at least 4
consecutive days and present most of the day, nearly every day.
B. During the period of mood disturbance and increased energy and activity, three (or more)
of the following symptoms (four if the mood is only irritable) have persisted, represent a
noticeable change from usual behavior, and have been present to a significant degree:
1. Inflated self-esteem or grandiosity.
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2. Decreased need for sleep (e.g., feels rested after only 3 hours of sleep).
3. More talkative than usual or pressure to keep talking.
4. Flight of ideas or subjective experience that thoughts are racing.
5. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant
external stimuli), as reported or observed.
6. Increase in goal-directed activity (either socially, at work or school, or
sexually) or psychomotor agitation.
7. Excessive involvement in activities that have a high potential for painful
consequences (e.g., engaging in unrestrained buying sprees, sexual
indiscretions, or foolish business investments).
C. The episode is associated with an unequivocal change in functioning that is
uncharacteristic of the individual when not symptomatic.
D. The disturbance in mood and the change in functioning are observable by others.
E. The episode is not severe enough to cause marked impairment in social or occupational
functioning or to necessitate hospitalization. If there are psychotic features, the episode
is, by definition, manic.
F. The episode is not attributable to the physiological effects of a substance (e.g., a drug of
abuse, a medication, other treatment) or another medical condition.
o

Note: A full hypomanic episode that emerges during antidepressant treatment (e.g.,
medication, electroconvulsive therapy) but persists at a fully syndromal level beyond
the physiological effect of that treatment is sufficient evidence for a hypomanic
episode diagnosis. However, caution is indicated so that one or two symptoms
(particularly increased irritability, edginess, or agitation following antidepressant use)
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are not taken as sufficient for diagnosis of a hypomanic episode, nor necessarily
indicative of a bipolar diathesis.
Note: Criteria A–F constitute a hypomanic episode. Hypomanic episodes are common in bipolar
I disorder but are not required for the diagnosis of bipolar I disorder.

Major Depressive Episode
A. Five (or more) of the following symptoms have been present during the same 2-week
period and represent a change from previous functioning; at least one of the symptoms is
either (1) depressed mood or (2) loss of interest or pleasure.
o

Note: Do not include symptoms that are clearly attributable to another medical
condition.
1. Depressed mood most of the day, nearly every day, as indicated by either
subjective report (e.g., feels sad, empty, or hopeless) or observation made by
others (e.g., appears tearful). (Note: In children and adolescents, can be
irritable mood.)
2. Markedly diminished interest or pleasure in all, or almost all, activities most
of the day, nearly every day (as indicated by either subjective account or
observation).
3. Significant weight loss when not dieting or weight gain (e.g., a change of
more than 5% of body weight in a month), or decrease or increase in appetite
nearly every day. (Note: In children, consider failure to make expected weight
gain.)
4. Insomnia or hypersomnia nearly every day.
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5. Psychomotor agitation or retardation nearly every day (observable by others;
not merely subjective feelings of restlessness or being slowed down).
6. Fatigue or loss of energy nearly every day.
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be
delusional) nearly every day (not merely self-reproach or guilt about being
sick).
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day
(either by subjective account or as observed by others).
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation
without a specific plan, or a suicide attempt or a specific plan for committing
suicide.
B. The symptoms cause clinically significant distress or impairment in social, occupational,
or other important areas of functioning.
C. The episode is not attributable to the physiological effects of a substance or another
medical condition.
Note: Criteria A–C constitute a major depressive episode. Major depressive episodes are
common in bipolar I disorder but are not required for the diagnosis of bipolar I disorder.
Note: Responses to a significant loss (e.g., bereavement, financial ruin, losses from a natural
disaster, a serious medical illness or disability) may include the feelings of intense sadness,
rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which
may resemble a depressive episode. Although such symptoms may be understandable or
considered appropriate to the loss, the presence of a major depressive episode in addition to the
normal response to a significant loss should also be carefully considered. This decision
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inevitably requires the exercise of clinical judgment based on the individual’s history and the
cultural norms for the expression of distress in the context of loss.
In distinguishing grief from a major depressive episode (MDE), it is useful to consider
that in grief the predominant affect is feelings of emptiness and loss, while in an MDE it is
persistent depressed mood and the inability to anticipate happiness or pleasure. The dysphoria in
grief is likely to decrease in intensity over days to weeks and occurs in waves, the so-called
pangs of grief. These waves tend to be associated with thoughts or reminders of the deceased.
The depressed mood of an MDE is more persistent and not tied to specific thoughts or
preoccupations. The pain of grief may be accompanied by positive emotions and humor that are
uncharacteristic of the pervasive unhappiness and misery characteristic of an MDE. The thought
content associated with grief generally features a preoccupation with thoughts and memories of
the deceased, rather than the self-critical or pessimistic ruminations seen in an MDE. In grief,
self-esteem is generally preserved, whereas in an MDE, feelings of worthlessness and selfloathing are common. If self-derogatory ideation is present in grief, it typically involves
perceived failings vis-à-vis the deceased (e.g., not visiting frequently enough, not telling the
deceased how much he or she was loved). If a bereaved individual thinks about death and dying,
such thoughts are generally focused on the deceased and possibly about “joining” the deceased,
whereas in an MDE such thoughts are focused on ending one’s own life because of feeling
worthless, undeserving of life, or unable to cope with the pain of depression.
Bipolar I Disorder
A. Criteria have been met for at least one manic episode (Criteria A–D under “Manic
Episode” above).
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B. The occurrence of the manic and major depressive episode(s) is not better explained by
schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder,
or other specified or unspecified schizophrenia spectrum and other psychotic disorder.

155

Vita
EDUCATION
Master of Science, Social Work
Advanced Generalist Practice and Programming, Contemporary Social Issues
Columbia University School of Social Work, New York, NY

2011 – 2013

Bachelor of Arts, Psychology – Honors: Cum Laude
Psychology Department, College of Science and Engineering
San Francisco State University, San Francisco, CA

1998 – 2007

AWARDS, PROFESSIONAL MEMBERSHIPS, LICENSURE
School of Medicine Phi Kappa Phi Scholarly Achievement Award, Virginia
Commonwealth University, Richmond, VA

2017

Phi Kappa Phi Susan E. Kennedy Scholarship, Nominee, Virginia
Commonwealth University, Richmond, VA

2017

International Society for Bipolar Disorders, Member, Richmond, VA

2016 – Present

International Society for Affective Disorders, Member, Richmond, VA

2016 – Present

Licensed Master Social Worker
The University of the State of New York, License 091216, New York, NY

2014 – Present

American Public Health Association, Member, Richmond, VA

2013 – Present

Paige E. Cook Jr. Fellowship, Columbia University School of Social Work
Competitive award given on the basis of excellence to a student with
career interests in substance abuse, world of work, men’s issues, and
cross-cultural practice in clinical practice.
National Association of Social Workers, Member, New York, NY

2012 – 2013

2012 – Present

RELEVANT PROFESSIONAL EXPERIENCE AND EMPLOYMENT
Graduate Research Assistant
Division of Epidemiology, Department of Family Medicine and Population
Health, School of Medicine, Virginia Commonwealth University

2013 – Present

Mood and Immune Regulation in Twins Study (K01-MH093642, PI: Mezuk)
Project testing how mood affects the immune system over time
 Conduct in-person 60-minute structured interviews with participants
Richmond Stress and Sugar Study (RSASS) (ADA 1-16-ICTS-082, PI: Mezuk)
Project testing the contribution of stress reactivity to diabetes disparities. .
 Conduct intake and in-person interviews with participants
 Assist with development of survey instruments

156



Participate as confederate in Trier Social Stress Test.

Social Work Intern: Year 2 Placement
Social Intervention Group (SIG), Columbia University School of Social Work

2012 – 2013

Connect ‘N Unite (CNU) (R01-DA030296, PI: Wu)
Couples harm reduction intervention for African American Men who have Sex
with Men to decrease risky behaviors leading to HIV and STI infection.
 Conduct participant screenings, intakes and outreach evaluations.
 Trained to facilitate manualized interventions with couples
HIV Intervention Science Training Program for Underrepresented New
Investigators (HISTP) (R25-MH080665, PIs: El-Bassel and Wu)
Mentorship project to increase the number and success of NIH PIs from
underrepresented groups who are highly-trained HIV scientists.
 Event logistics including marketing, recording, evaluations.
 Maintain internet-based mentorship portal.
Social Work Intern: Year 1 Placement
Bowery Residents Committee (BRC) Reception Center, New York, NY
Shelter serving severely mentally ill, chronically homeless adults as they attain
mental and physical health and apply for permanent supportive housing.
 Submit housing applications to the Human Resources Administration.
 Obtain identification, benefits, and entitlements for clients.
 Training in activities of daily living including laundry, budgeting, and
independent travel to medical and housing appointments.

2011 – 2012

Analyst II
Center for Imaging of Neurodegenerative Diseases (CIND), San Francisco, CA
Magnetic Resonance Imaging (MRI) lab at San Francisco VA Medical Center.
 Proofed and edited grant proposals funded by the NIH, DOD, and VA.
 Proofed and submitted manuscripts to journals and conferences.
 Designed and maintained lab website.
 Trained staff in NIH submission requirements.
 Co-produced Alzheimer’s Disease Neuroimaging Initiative
promotional film.

2006 – 2011

PEER-REVIEWED PUBLICATIONS AND PUBLISHED ABSTRACTS
Bareis N and Mezuk B. (2016). The relationship between childhood poverty, military service, and later
life depression among men: Evidence from the Health and Retirement Study. Journal of Affective
Disorders, 206:1-7. doi: 10.1016/j.jad.2016.07.018.
Bareis N. (2016). Client centered treatment to optimize psychiatric medication adherence. Bipolar
Disorders, 18(Suppl 1): S96-S97. (Poster Abstract)
Bareis N and Mezuk B. (2015). Psychiatric polypharmacy and implications for obesity. Bipolar
Disorders, 17(Suppl 1): 131. (Poster Abstract)

157

Bareis N. (2015). Relationship between childhood poverty and military service on late life depression
among men: A life course perspective. The American Journal of Geriatric Psychiatry, 23(3, Suppl 1):
S75-S76. (Poster Abstract)
Needham BL, Mezuk B, Bareis N, Lin J, Blackburn EH and Epel ES. (2015). Depression, anxiety and
telomere length in young adults: Evidence from the National Health and Nutrition Examination Survey.
Molecular Psychiatry, 20:520-528. doi: 10.1038/mp.2014.89
Bareis N, Needham B, and Mezuk B. (2014). Depression, anxiety, and telomere length: Evidence from
the National Health and Nutrition Examination Survey. Comprehensive Psychiatry, 55(8): e45. (Poster
Abstract)
Bareis N, Sando TA, Mezuk B, and Cohen SA. (In-Preparation). Use of psychotropic medication
polypharmacy is associated with balance impairment among middle-aged adults: Results from the
National Health and Nutrition Examination Survey.
Bareis N, Lu J, Kirkwood CK, Kornstein S, Wu E, and Mezuk B. (Submitted). Identifying Clinical Net
Benefit of Psychotropic Medication Use with Latent Variable Techniques: Evidence from Systematic
Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disorders.
PRESENTATIONS AT SCIENTIFIC MEETINGS
Bareis N and Mezuk B. (May, 2017) The Bi-Directional Relationship Between Clinical Net Benefit
and Medication Adherence Over Time in Bipolar Disorder: A Latent Transition Analysis
19th Annual Conference of the International Society for Bipolar Disorders, Washington, DC (Poster)
Bareis N. (March, 2017). Psychiatric Medication Polypharmacy is Associated with Balance
Impairment in Middle-Aged Adults: Evidence from the National Health and Nutrition Examination
Survey (NHANES).
107th Annual Meeting of the American Psychopathological Association, New York, NY (Poster)
Bareis N. (July, 2016). Client-Centered Treatment to Optimize Psychiatric Medication Adherence.
18th Annual Conference of the International Society for Bipolar Disorders Amsterdam, The
Netherlands (Poster)
Bareis N, Sando TA, and Cohen SA. (October, 2015). Psychiatric medication use is associated with
increased impairments in balance and fall risk. 32nd Daniel T. Watts Research Poster Symposium
Richmond, VA (Poster)
Bareis N and Mezuk B. (June, 2015). Psychiatric polypharmacy and implications for obesity.
International Society for Bipolar Disorders 2015 Annual Conference Toronto, Canada (Poster)
Bareis N and Mezuk B. (March, 2015). Relationship between childhood poverty and military service
on late-life depression among men: A life course perspective.
2015 American Association for Geriatric Psychiatry Annual Meeting New Orleans, LA (Poster)
Bareis N, Mezuk B, and Needham B. (March, 2014). Depression, Anxiety and Telomere Length:
Evidence from the National Health and Nutrition Examination Survey.
American Psychopathological Association 2014 Annual Meeting New York, NY (Poster)

158

LECTURES
Bareis N. (December 7, 2016) Stigma.
Epidemiology of Psychiatric and Substance Use Disorders (VCU EPID 646) Richmond, VA
Bareis N. (September 20, 2016). Clinical Net Benefit of Psychiatric Medication Use and Adherence.
VCU School of Medicine, Department of Family Medicine and Population Health, Epidemiology
Division Seminar Series Richmond, VA
Bareis N. (September 14, 2016). The Role of Data in Public Health.
Introduction to Public Health (VCU DENH 411) Richmond, VA
Bareis N. (February 2, 2016). Psychiatric Medication Use is Associated with Impairments in Balance.
VCU School of Medicine, Department of Family Medicine and Population Health, Epidemiology
Division Seminar Series Richmond, VA
Bareis N. (December 2, 2015) Stigma and the Future of Psychiatric Epidemiology.
Epidemiology of Psychiatric and Substance Use Disorders (VCU EPID 646) Richmond, VA
Bareis N. (September 30, 2014). Does Depression Accelerate Aging? Telomeres May Provide
Answers.
VCU School of Medicine, Department of Family Medicine and Population Health, Epidemiology
Division Seminar Series Richmond, VA
TEACHING
Graduate Teaching Assistant
Division of Epidemiology, Department of Family Medicine and Population
Health, School of Medicine, Virginia Commonwealth University
Epidemiology of Psychiatric And Substance Use Disorders (VCU EPID 646)
 Classification, nosology and operational case definitions of disorders
and measurement techniques for field surveys and risk-factor research.

Fall 2015, Fall 2016

SERVICE
Data Analyst and Moderator Trainer, Datapalooza 2014
Community-based participatory research event to present results from the East
End Residents Community Survey to community members.

2014

PhD Student Representative, Faculty Promotion Committee
Department of Family Medicine and Population Health, School of Medicine,
VCU

2014

Judge, Physical Science
2014 Virginia Junior Academy of Science (VJAS) Research Symposium

2014

PhD Student Representative, Curriculum Committee
Division of Epidemiology, Department of Family Medicine and Population
Health, School of Medicine, Virginia Commonwealth University
CUSSW Student Membership Associate

2013 – Present

2012 – 2013

159

National Association of Social Workers (NASW), New York, NY
Student Representative, Ethics Board
Columbia University School of Social Work, New York, NY

2012 – 2013

Mentor Advocate Peer (MAP) Leader
Columbia University School of Social Work, New York, NY

2012 – 2013

Student Facilitator, Professional Development Self Awareness Orientation
Columbia University School of Social Work, New York, NY

2012

Volunteer Facilitator Removing the Bars: TAKE ACTION Conference
Criminalization of People with Mental Illness Session, New York, NY

2012

160

